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 Role of the α4-containing GABA A receptors in anesthetic and ethanol antagonist 
effects: Insights from a global knockout mouse model 
Sangeetha V. Iyer 
University of Pittsburgh, 2010 
Despite their widespread use, the precise molecular actions of anesthetics and 
alcohol are unknown. Although anesthetics have made surgical intervention palatable, 
anesthetics are not free of alarming side effects such as anesthetic awareness and post-
operative cognitive deficits. While alcohol is consumed for positive effects such as anti-
anxiety, euphoria, and relaxation, alcohol consumption also results in adverse behavioral 
effects such as sedation, motor incoordination, and cognitive impairment. Chronic alcohol 
consumption results in alcohol withdrawal syndrome, tolerance, and dependence. 
Understanding the mechanisms of action of anesthetics and alcohol are critical for 
preventing anesthetic side effects and for developing effective treatments for alcohol abuse 
and alcoholism.  
Many putative targets of anesthetics and alcohol have been identified in brain 
including sodium channels, potassium channels, glutamate receptors, glycine receptors, and 
especially GABA receptors. Phasic and tonic inhibitory currents mediated by GABA type 
A receptors are sensitive to modulation by anesthetics and alcohol.  
α4 subunit-containing GABA A receptors mediate tonic inhibitory currents, are 
highly sensitive to GABA, and are strongly implicated in the effects of volatile, 
intravenous, and neurosteroid anesthetics. Global α4 knockout mice showed reduced tonic 
current that was not potentiated by the volatile anesthetic isoflurane or the neurosteroid 
anesthetic, alphaxalone.  Specific Aim 1 tested the hypothesis that volatile and intravenous 
anesthetic effects are mediated via a4-containing receptors by comparing behavioral 
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 responses to these drugs in wild type and α4 KO mice. Results obtained indicate that while 
α4-containing receptors are required for the amnestic effects of isoflurane, they are not 
required for mediating the effects of volatile and intravenous anesthetics on other 
behavioral endpoints. Interestingly, α4-containing receptors are required for low dose 
alphaxalone-induced locomotor stimulation, but not high dose effects. 
α4-containing receptors, when paired with the δ subunit, have been proposed to 
possess a common binding pocket for ethanol and pharmacologic antagonists of ethanol 
action. Previous studies in the Homanics lab indicated that the ethanol-reversing effects of 
Ro15-4513, an imidazobenzodiazepine ethanol-antagonist, were dramatically reduced in 
α4 KO mice both at the cellular and the behavioral level. Specific Aim 2 tested the 
hypothesis that a4-containing receptors are required for the ethanol antagonistic effects of 
RY023, a derivative of Ro15-4513. α4 KO mice showed differential sensitivity to the 
effects of RY023 in the presence and absence of ethanol on loss of righting reflex and 
locomotor behavior. We conclude that α4 containing receptors are involved in some 
intrinsic effects of RY023 but not in the ethanol-antagonistic effects of RY023.   
This study of α4-containing receptors has advanced our understanding of anesthetic 
action and eliminated the theory of a unitary target for ethanol antagonism.  
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 1.0 Introduction 
1.1 Overview 
 
Millions of people all over the world undergo medical procedures that require the 
use of general anesthetics every day. Each time, these patients are warned about the 
occurance of unpleasant post-operative side effects and the risks that accompany anesthetic 
use. Although it has been 150 years since the advent of anesthetics, there is still a dearth of 
knowledge about the precise mechanism of action of general anesthetics. Gaps in our 
understanding of anesthetic mechanisms preclude the prediction of incidence of side effects 
and consequently, patients are exposed to unpleasant experiences such as anesthetic 
awareness, post-operative cognitive deficits, etc [1, 2]. In addition, our incomplete 
understanding of the molecular basis of anesthetic action limits our ability to rationally 
develop newer, safer anesthetics that have limited side effects.  
Like anesthetics, the use of alcohol has been prevalent in society for several 
centuries. Alcohol enjoys a unique position as a beverage whose use is both accepted and 
criticized in society. Consumption of low to moderate levels of alcohol allows the 
individual to experience euphoria, anxiolysis and disinhibition. It is for these desirable 
effects that repeated alcohol consumption is pursued. However, consumption of higher 
amounts of alcohol causes ill effects such as sedation, impairment of motor abilities, 
memory deficits, etc. Chronic consumption of alcohol eventually leads to tolerance to 
alcohol. Because tolerance to alcohol sets in, greater amounts of alcohol are needed each 
time to achieve the same pleasurable effects of alcohol. In addition, alcohol has great abuse 
potential and hence regular, repeated consumption of alcohol can often cause drinking 
behavior to change from a social habit to alcohol dependence and abuse. Unfortunately, 
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 cessation of chronic alcohol consumption produces equally bad effects of alcohol 
withdrawal such as tremors, irritability, insomnia and seizures [3]. Thus, the cycle of 
alcohol consumption is notoriously difficult to break.  
Although neuroscience research has greatly advanced our understanding of the 
mechanisms of action of alcohol, we are only now beginning to tease apart the molecular 
sites of action of alcohol and processes by which alcohol addiction and withdrawal are 
mediated. A better understanding of these processes will enable the development of agents 
that can be used to combat the ill effects of alcohol consumption and withdrawal.  
While numerous neurotransmitter systems have been implicated in the mechanism of 
action of both anesthetic and alcohol, one common target is the γ-aminobutyric acid type A  
(GABAA) receptor system. Although much is known about the role of GABAA receptors, 
the vast repository of receptor subunits and the widespread regions of expression in brain 
and spinal cord have complicated the delineation of functionality. While γ-aminobutryric 
acid (GABA) is considered the principal ligand for these receptors, it is now known that 
several endogenous and exogenous ligands allosterically modulate these receptors with 
varying potencies. Both anesthetics and alcohol are known to modulate GABAA receptors 
allosterically. Because the GABAA receptor system is largely involved in inhibitory 
neurotransmission, alcohol and anesthetics potentiate inhibitory currents to cause 
depressive effects. Although our understanding of the complexity of the GABAA 
neurotransmitter-receptor system has been advanced over the past several decades, there 
are still large gaps in our understanding of its functions, especially the role this system 
plays in alcohol- and anesthetic-induced behavioral responses. 
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  1.2 Introduction to GABAA receptors 
 
GABAA receptors are responsible for conducting inhibitory neurotransmission in 
the brain. These receptors are pentameric, ligand gated chloride channels. Native functional 
receptors are assembled from 19 different subunits- (α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3) [4].  
GABAA receptors are of two kinds- synaptic and extrasynaptic, primarily based 
on location, and conduct two kinds of current that are subject to modulation by ligands. 
Synaptic and extrasynaptic receptors show differences in their rates of desensitization and 
affinities to GABA with the latter having slower rates of desensitization and higher affinity 
for GABA (see review [5]). Phasic current is mediated by synaptic GABAA receptors, that 
are typically composed of α1-3, β1-3, γ1-3 subunits [6] and respond to transient high 
concentrations of GABA (500uM) [7, 8]. These receptors control fast transient inhibitory 
postsynaptic currents. A persistent tonic current is mediated by extrasynaptic receptors that 
are usually composed on α4/α6 with β and δ subunits [6] In addition, α5, β and γ2 
containing receptors also mediate tonic current [9]. These receptors respond to lower 
concentrations of GABA (0.1-3uM) [10] such as that encountered during spillover from a 
synaptic event, or due to leakage from GABA transporters. This tonic form of inhibition is 
thought to regulate both neuronal excitability and processing of information [11, 12].   
GABAA receptor mediated currents are subject to modulation by anesthetics, 
alcohol, benzodiazepines, neurosteroids and other central nervous system (CNS) drugs. 
These drugs modify GABAergic current by influencing affinity of GABA for the receptor 
and by changing channel kinetics (increased burst frequency, prolongation of decay times, 
etc.). Anesthetics and alcohol allosterically modulate GABAA receptors and ultimately 
cause a combination of behavioral effects - amnesia, anxiolysis, sedation, motor-
incoordination, hypnosis, immobilization and analgesia. It is thought that the spectrum of 
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 effects of GABAergic drugs is a result of action on different subunit-containing GABAA 
receptors. Hence, the underlying hypothesis of the field is that specific subtype-containing 
receptors influence specific behavioral effects [13]. This hypothesis has in turn led to the 
search and development of newer ligands that have specificity and affinity for specific 
subtypes. Indeed, studies with both isolated receptor systems and  genetically engineered 
mouse models have revealed that certain drugs show a high degree of specificity for certain 
GABA receptor subtypes [14-17]. Absence of certain subtypes of GABAA receptors often 
results in changes in native phenotype as well as drug-induced behavior as observed in 
genetically engineered models. Experiences such as these add to our understanding about 
the involvement of GABA in different functions.  
1.3 Diversity of GABAA receptors 
The complexity of the GABAA receptor system is directly related to the different 
subtypes of GABAA receptors possible due to subunit combinations. The GABAA receptor 
family consists of 19 related subunits in mammals that are encoded by different genes – 
α(1-6), β(1-4), γ (1-3), δ (1), ε (1), π (1), ρ (1-3) [4]. Although a large number of subunit 
combinations are theoretically possible, only specific subtypes are encountered in vivo. All 
subunits are polypeptides, approximately 50kd in size each and have four hydrophobic 
transmembrane domains each. In addition to the 19 distinct subunits, alternate splicing of 
pre-mRNA of certain subunits (γ2, α5, β2, β4, β3, α6) also contributes to the complex in 
vivo receptor architecture [18-24]. Of these, α, β, γ, δ, ε are encountered in the CNS 
whereas ρ and π are encountered peripherally [25-27]. It is thought that five subunits 
participate in the formation of a functional receptor. The most frequently encountered 
receptor stoichimetry consists of 2α, 2β and 1γ subunit combination [28, 29]. While most 
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 receptors contain a single α isoform within a receptor, a small minority are composed of 
two different α subunits in combination (α1α2, α1α3, α1α5, α2α3 and α3α5) [30-33]. 
Similarly with the β subunit, two identical β subunits or two different β subunits can be 
combined (β1β3, β2β3) within a receptor [34]. The δ subunit replaces γ in a small 
percentage of receptors in the brain [35]. Immunohistochemical studies indicate that α1, 
β1, β2, β3 and γ2 subunits are found throughout the brain [29] while other subunits are 
confined to specific brain regions - α2 (hippocampus, olfactory bulbs, cortex), α3 (raphe 
nuclei), α4 (dentate gyrus, thalamus, cortex, striatum), α5 (hippocampus), α6 (cerebellum), 
γ1(cental and medial amygdaloid nuclei, pallidal areas, substantia nigra pars reticulata, 
inferior olive) and δ (paired with α4 in thalamus, dentate gyrus of hippocampus, cortex, 
striatum and paired with α6 in the cerebellum) [36-38]. As mentioned earlier, synaptic 
receptors are typically composed of α1-3, β1-3 and γ1-3 subunits, whereas extrasynaptic 
receptors are typically composed of α4/6, β2/3 and δ subunit or α5, β2/3 and γ2 subunits.  
The actions of anesthetics and alcohol are the result of interactions with numerous 
neurotransmitter-receptor systems that are beyond the scope of this study. Because GABAA 
receptors are the major focus of this research study, discussions of the mechanism of action 
of anesthetics, alcohol and associated drugs will focus mainly on GABAA receptors.  
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 1.4 Anesthetics 
1.4.1 History of anesthetic research:  
The first documented use of an anesthetic (ether) in a surgical procedure occured in 
1846 by William Morton. Since then, numerous chemical compounds have been discovered 
that are used to produce anesthetic effects. Although these compounds show considerable 
diversity in structure, the spectrum of effects produced by each of them includes sedation, 
amnesia, hypnosis and immobilization. Fig. 1.1  (reproduced with permission from Wolters 
Kluwer Health, [39]) depicts the structures of commonly used anesthetics.   
 
Figure 1.1 Structures of commonly used anesthetics and the year of introduction.  
Reproduced with permission from Wolters Kluwer Health. Kopp Lugli et al, 'Anaesthetic mechanisms: 
update on the challenge of unraveling the mystery of anaesthesia'. European Journal of Anesthesiology, 
2009, 26 (10): pg 807-20 
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 It has now been more than a century since the formal use of the first anesthetic, 
however, the mechanism of action of anesthetics continues to remain elusive. In the early 
19th century, research into anesthetic targets by Meyer and Overton independently 
suggested that anesthetics act nonspecifically upon the lipid bilayer of cells to disrupt them 
leading to anesthesic effects [40, 41]. This theory was put forth following the observation 
that anesthetics were lipid soluble and that anesthetics of greater potency had higher 
solubility in lipid-based solvents. According to this theory, anesthetics distribute into the 
lipid bilayer thus producing changes in the structure of the membrane. This theory 
predominated into the second half of the 20th century.  
However, subsequent research by several groups pointed out flaws in the lipid 
theory. Seminal work by Franks and Lieb showed that anesthetics were capable of direct 
interaction with proteins. This was demonstrated on purified luciferase protein which in the 
absence of a lipid bilayer was dose-dependently inhibited by anesthetics [42]. In addition, 
Eger and colleagues discovered chemical compunds that were very highly lipophilic but 
had no anesthetic effect, or only partial anesthetic effects (non-immobilizers) in contrast to 
that predicted by the Meyer-Overton correlation [43, 44]. Other groups showed that 
anesthetic action was maintained only with specific stereoisomers of compounds. The (+) 
isomer of isoflurane was more effective than the (-) isomer in eliciting isoflurane-induced 
current in molluscan neurons although both isomers were equally effective at disrupting 
lipid bilayers [45]. This stereospecific activity of isoflurane was confirmed in vivo in rats 
independently by another group [46].  The stereospecifity of anesthetic compounds 
indicated that far from a non-specific effect, anesthetics bring about discrete behavioral 
changes owing to other mechanisms [44, 45]. This marked the beginning of a new era – 
that of protein targets for pharmacological effects.  Modulation of inhibitory and excitatory 
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 neurotransmission garnered interest and with it, the study of GABA, glycine, potassium 
channels, on the one hand, and glutamate, neuronal acetylcholine, adenosine, serotonin 
receptors, on the other, gained momentum.   
Inhibitory neurotransmission is mainly mediated by chloride channels – ligand 
gated GABA and glycine receptors. Clinical concentrations of anesthetics were found to act 
on recombinant receptors, they increased chloride currents and caused hyperpolarization 
[47]. Further, the current potentiation of GABAA receptors correlated with the clinical 
potencies of anesthetics [48]. Thus, most anesthetics are capable of acting as GABAA 
receptor allosteric modulators. Advances in the study of GABAA receptors have revealed a 
vast heterogeneity in GABAA receptors with differing sensitivity to anesthetics. It is 
thought that different combinations of these receptor components serve as targets of 
anesthetics and control discrete anesthetic effects.  
1.4.2 Anesthetic effects: 
Up to the mid 1800's, patients requiring surgical intervention suffered a horrible 
ordeal. With the advent of anesthetics, this situation changed. Anesthetics are used 
clinically for their beneficial effects that render surgical procedures possible. The desired 
profile of anesthetic effect includes amnesia, hypnosis, immobility and analgesia.  
Current anesthetics produce two or more of these effects to varying extents. Hence, 
surgical procedures often require a combination of anesthetics to bring about a desirable 
combination of these effects. For example intravaenous anesthetics, etomidate and propofol 
are used for induction of the anesthetic state. While these agents are good amnestic and 
hypnotic agents, their immobilizing and analgesic potencies are limited. Hence, muscle 
relaxing agents (succinylcholine, pancuronium) and immobilizing agents (isoflurane, 
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 sevoflurane) are also used. Thus, multiple anesthetics are often used in combination to 
obtain a balance of the above attributes desired for surgical procedures. Today, almost 30 
million people in the US alone, annually undergo procedures involving anesthetics [49].   
The use of anesthetics has to be carefully regulated due to the steep dose response 
and narrow therapeutic indices of most anesthetics. In spite of their many desirable effects, 
anesthetics cause side effects that are variable in their intensity in different people. These 
side effects range from minor discomforts such as nausea, vomiting, headaches to more 
serious effects such as autonomic instability, respiratory depression, cardiac dysrhythmias 
and persistant cognitive deficits. The incidence of post-operative nausea and vomiting is 
about 30% in subjects undergoing anesthetic procedures [50]. Hypothermia and post-
operative shivering are observed in 50-60% of patients after volatile anesthetic-induced 
general anesthesia and in 13% of patients after propofol anesthesia. [51, 52]. The more 
disturbing effects involve cognitive dysfunctions. One disturbing side effect is 'anesthetic 
awareness' which is the unexpected, explicit recall of events occuring while under the 
influence of an anesthetic. About 1-2 patients in every 1000 experience this effect and 
evidence indicates that the incidence may be higher in children [2, 53, 54]. These episodes 
are not limited to simple recall but also include reports of mild discomfort to severe pain. 
This effect has been linked to later psychological effects of nightmares, anxiety and 
flashbacks [55].   
Rodent studies also imply that pediatric and geriatric populations may be at higher 
risk for anesthetic-induced side effects. Deleterious effects of anesthetics are observed at 
both the behavioral and the cellular level. Exposure to isoflurane and nitrous oxide 
decreased memory performance in aged rats [56, 57]. In addition, anesthetic exposure in 
rodents within the first postnatal week caused neurodegeneration in the hippocampus [58]. 
21
 This period coincides with the switch of GABAA receptors from an excitatory to an 
inhibitory role [59]. Similarly, in humans, pediatric and geriatric populations are 
particularly at risk for anesthetic-induced side effects. In children, two or more episodes of 
anesthetic exposure within the first two years of life, was shown to impact learning abilities 
later in life [60]. Postoperative cognitive dysfunction has been observed in about 25% of 
geriatric patients a week after anesthetic intervention and in 10% of geriatric patients at 3 
months following prolonged exposure to general anesthetics [61, 62].  
Although newer anesthetics that are considered safer than their predecessors have 
been discovered, the lack of knowledge about the precise mode of action of these drugs 
makes it difficult to predict responses in people and precludes the development of 
intelligent drug discovery in this field. The seriousness of the side effects summarized 
above and the possibility of lasting cognitive effects, especially in vulnerable populations 
such as infants and the elderly, make understanding the mechanism of action of anesthetics 
a very important goal.  
Because anesthetic outcomes involve amnesia, unconsciousness and immobilization 
among other effects, the process of understanding the mechanisms of action began from the 
study of brain regions that were likely to be involved in these effects. Several different 
techniques have been used to study anesthetic effects and results obtained from them have 
contributed to our current understanding of anesthetic mechanisms. The major effects of 
anesthetics and our current understanding about the brain regions involved in these effects 
are discussed below. 
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 1.4.2A Hypnosis and sedation:  
Although these terms are used interchangeably, hypnosis is considered distinct from 
the sedating effect of an anesthetic. Hypnosis, which occurs at high concentrations of 
anesthetics, refers to the state of unconsciousness wherein response to verbal stimuli is lost. 
Sedation, which occurs at lower doses of anesthetics, is considered as the step preceding 
hypnosis where cerebral activity starts to decrease. Cerebral blood flow studies with 
sedating and hypnotic concentrations of the anesthetic have indicated that the former 
involves reduction of cortical activity whereas the latter involves depression of sub-cortical 
structures such as the thalamus, reticular formation and the hypothalamus [63-65].  
The first step of hypnosis is depression of ascending corticothalamic pathways. This 
facilitates depression of the thalamocortical circuitry. At sedative concentrations of the 
volatile anesthetic sevoflurane and the intravenous anesthetic propofol, a decrease in α 
waves was observed concomitant with an increase in β waves [66]. This is consistent with 
transition from wakefulness to drowsiness. As higher hypnotic concentrations were 
achieved, β oscillations were reduced and δ oscillations predominated. This indicated a 
transition of anesthetic effect from cortical towards sub-cortical regions. This correlates 
with transition from drowsiness into deep sleep or unconsciousness. The decrease in 
activity in brain regions was coroborrated by decreases in glucose metabolism [67].  
Imaging studies have noted similarities between the brain during non-rapid eye 
movement (NREM) sleep and the anesthetized brain [68-70]. One important brain region 
implicated in sleep processes is the thalamus. Thalamacortical cells that are thought to 
generate cortical δ rhythms towards normal sleep are thought to be involved in anesthetic-
induced δ waves as well [64]. During anesthesia, thalamic neurons have been shown to 
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 enter a low frequency burst mode giving rise to δ oscillations that are characteristic of deep 
sleep [71]. Thus, anesthetic-induced hypnotic effects overlap with natural sleep pathways. 
The transition from sedation to hypnosis by higher doses of anesthetics is thought to be 
coincident with a disconnect in information processing [72-74].  
GABAergic circuits among other discrete nuclei are also thought to be involved in 
pathways of sleep and arousal. These include ventrolateral perioptic nucleus, median 
preoptic nucleus, magnocellular regions of the basal forebrain and the tuberomammillary 
nucleus [75-79]. Because each of these brain regions bears efferent and afferant nerve 
circuits that encompass histaminergic, cholinergic, serotonergic, dopaminergic and 
GABAergic systems, it is likely that anesthetic effects are the result of cumulative actions 
on these neurotransmitter-receptors systems. 
At the molecular level, specific GABAergic receptors have been identified that are 
thought to be involved in the hypnosis and sedation caused by general anesthetics. 
Genetically engineered mouse models have provided information about the role of specific 
subtypes of GABAA receptors in anesthetic actions. Through the use of genetically 
engineered mice, β3 and β2 subunits have been implicated in the actions of some general 
anesthetics. A β3 global knockout mouse model provided the first report of evidence of 
general anesthetic actions being altered due to deletion of a GABAergic subunit [80]. 
However, this result was confounded by developmental compensation [81]. Because global 
deletion of a gene product can result in compensatory changes by way of upregulation of 
other gene products that restore function, a knockin approach is sometimes used to 
circumvent the problem of compensation. A knockin mutation allows normal response to 
endogenous modulators but selectively alters response to the drug or ligand in question. 
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 Different behavioral assays have been developed to assess clinical endpoints of 
anesthetics and other drugs in rodent models. For example, hypnotic effects of drugs are 
tested in rodents by the loss of righting reflex assay (LORR). This assay involves placing 
mice supine on V-shaped troughs following administration of drugs and recording time 
until they right themselves. Similarly, sedative effects of drugs are assessed by 
measurement of reduced motor abilities of rodents studied in an open field arena or other 
assay involving some motor activity. In this manner, a subsequent β3 knockin mouse study 
implicated β3-containing GABAergic receptors in the hypnotic actions of etomidate and 
propofol [15]. These mice bore mutations in the transmembrane region of the β3 subunit 
(N265M) which rendered them insensitive to etomidate actions. An analogous mutation in 
the β2 subunit resulted in mice that had reduced sedative responses to etomidate but not 
propofol [82]. More recently, mice bearing a double knockin mutation in the α1 subunit 
showed altered sensitivity to sedative-hypnotic effects of volatile anesthetics implicating 
the α1 subunit-containing receptors in anesthetic action. These double knockin mice bore 
an isoflurane- and ethanol-insensitive mutation in their α1 subunits that rendered them 
resistant to the loss of righting reflex (LORR) effects of isoflurane and enflurane but not 
halothane [83]. The LORR parameter is used as a surrogate for anesthetic-induced 
unconsciousness in mouse behavioral assays. Interestingly, a double mutation in the α2 
subunit that conferred insensitivity to isoflurane-induced current potentiation in vitro 
paradoxically increased isoflurane-induced recovery of righting reflex (RORR) in the 
mutant mice [84].  
Thus, the creation of genetically engineered murine models has provided much 
information to the understanding of molecular mechanisms of anesthetics. Hence, it is 
thought that this approach will continue to fill gaps in our knowledge of anesthetic effects. 
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 1.4.2B Immobilization:  
Immobilization is a critical effect of an anesthetic, absolutely required for surgical 
procedures. This attribute of a general anesthesia is best described by the minimum 
alveolar concentration (MAC). MAC is defined as that concentration of an anesthetic at 
which half the subjects have lost their response to a noxious stimulus, i.e., surgical incision 
[85, 86]. It is only in the last 20 years that the primary site of action for this effect was 
identified as the spinal cord. The observation that cortical electrical activity did not 
correlate with the immobility produced by an anesthetic sparked a spate of studies with the 
spinal cord as their focus [87, 88]. Selective delivery of anesthetic to the brain of goats 
revealed that nearly three times the concentration of anesthetic was required in supraspinal 
regions to depress movement compared to anesthetic requirement of the whole body [89]. 
Precollicular decerebration of rats did not affect the immobilizing effect of isoflurane [90]. 
These studies suggested that the immobilizing effect of an anesthetic depends largely on 
the spinal cord and is minimally affected by higher brain structures.  
Within the spinal cord, specific neuronal circuits are thought be affected by 
anesthetics. Anesthetics are thought to perturb descending and ascending neuronal 
influences. In vivo electrophysiologic measurements of spinal cord indicated that 
anesthetics depressed both motor [91] and sensory neurotransmission [91, 92]. Studies with 
intact isolated spinal cord showed that anesthetics depress motor neuron output arising 
from dorsal root stimulation to a small extent (~10-20%) and that the effect on dorsal root 
neurons was not critical to the immobilizing effect [92, 93]. Recent work suggests that 
inhibition of neurons in the ventral spinal cord by anesthetics is more critical to producing 
immobility [94]. Specifically, inhibition of the mesencephalic locomotor region may be key 
to achieving immobility [95]. However, although these studies yielded information about 
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 the circuitry involved in immobilizing effects, the search for a molecular target of 
anesthetics continued. 
Specific study of receptors in the spinal cord suggested that anesthetics potentiated 
inhibitory chloride channels and also depressed excitatory channels thus spelling a role for 
GABA and glycine on the one hand and AMPA and NMDA receptors on the other [48, 96-
99]. Sodium, potassium and other channels that regulate membrane potentials were also 
thought to contribute to the effects of anesthetics in the spinal cord.  
Pharmacologic studies of different receptor subtypes indicated that they contributed 
to the effects of anesthetics differentially. For example, the GABA A antagonist picrotoxin 
increased the MAC of propofol by almost 400% but not of isoflurane [100]. With 
isoflurane and with ketamine, MAC was increased to a lesser extent with picrotoxin and 
with the competitive antagonist, gabazine [100]. This smaller increase in MAC for 
isoflurane and ketamine was attributed to an indirect antagonism of naturally ocurring 
GABA release. These and other studies showed that GABAergic receptors were likely not 
involved in the immobilizing effects of inhaled anesthetics [101, 102].  
With glycinergic receptors, greater increases in MAC were observed upon the 
administration of the glycine antagonist, strychnine [103, 104]. Studies with different 
anesthetics, isoflurane and halothane, on glycinergic receptors indicated that the increase in 
MAC with strychnine administration correlated with the magnitude of action of different 
anesthetics upon glycine receptors [101, 104]. This argued for a direct action of these 
anesthetics on glycinergic receptors as opposed to an indirect effect as observed on 
GABAergic receptors.  
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 Blockade of NMDA receptors decreased MAC for inhaled anesthetics by 
approximately 60%. However, the blockade of NMDA receptor activity did not correlate 
with the extent of functional blockade that anesthetics produce at MAC [105, 106]. Hence, 
it is thought that NMDA receptors contribute only in part to the actions of anesthetics. 
In parallel to pharmacologic studies, genetically engineered murine models were 
studied for anesthetic sensitivity with regard to immobilization. In GABA receptor β3 
knockouts, enflurane and halothane MAC were increased by ~10-25% [80]. Similarly, β3  
knockin mice showed reduced sensitivity to enflurane and halothane by ~15-25% even 
though current potentiation studies showed that normal sensitivity to these anesthetics was 
maintained in vitro [15]. In contrast, the spinal reflexes in β3 knockin mice were not 
depressed at very high concentrations of etomidate and propofol, mirroring the resistance 
observed in  vitro to these anesthetics [15]. These and other studies suggest that GABA A 
receptors are only moderately involved in modulating the effects of inhalational anesthetics 
but are involved to a greater extent in the actions of injectible anesthetics. Mice bearing 
mutations in the glycine receptor system have met with better success. Spastic mice, which 
have reduced glycine receptor expression due to abnormal splicing of glycine β subunit 
(Kingsmore 1994), showed a 30% increase in enflurane MAC but no changes with 
halothane MAC [107]. In contrast, spasmodic mice which bear a knockin mutation in the 
glycine α1 subunit had decreased responses to glycine but normal responses to enflurane 
and halothane [108]. Overall, data indicate that glycine receptors may be involved in the 
effects of inhaled anesthetics. The NMDA receptor ε1 subunit knockout mice did not show 
changes in isoflurane- or sevoflurane-induced loss of righting reflex. Hence, a role for 
NMDA receptor subtypes in anesthetic action is still being evaluated. Further studies are 
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 required to understand the involvement of different NMDA receptor subtypes in anesthetic 
activity. 
Previously, the holy grail for dissection of anesthetic action was dictated by the 
principle 'discrete subunit = discrete effect'. However, at least with immobilization, this 
view is challenged. An overview of research conducted by independent groups regarding 
the spinal cord sites of action of anesthetics suggests that anesthetic actions in the spinal 
cord are not mediated by any one type of receptor but rather by a multitude of receptors 
acting in concert to produce immobility. Studies that looked at the immobilizing effects of 
anesthetics lead us closer to the possibility that no single target can explain inhaled 
anesthetic-induced immobility. Rather a multitude of low affinity targets likely act in 
concert to bring about anesthetic-induced immobilization. This argument against a single 
site of action is discussed extensively in a recent review by Eger and colleagues [109].  
In contrast to inhaled anesthetics, the intravenous anesthetics, etomidate and 
propofol were found to mediate their immobilizing effects through GABA receptors. 
GABA A receptors play a major role in the immobilizing effects of these drugs, given the 
fact that β3 knockin mice are insensitive to the immobilizing effects of etomidate and 
propofol [15].  Thus, GABA A receptors may be critical for the effects of intravenous 
anesthetics such as etomidate and propofol whereas their role in the actions of inhaled 
anesthetics is limited. 
1.4.2C Memory: 
Anesthetic impairment of memory is a critical effect of all anesthetics. Amnestic 
effects of anesthetics are observed at doses well below those causing immobility, typically 
around 0.1-0.4 MAC. In some cases, however, patients do not experience amnestic effects 
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 of the anesthetic leading to recall of unpleasant details of surgical procedures. This is 
termed as anesthetic awareness and occurs in 0.1% of patients [2, 53, 54]. At the other end 
of the spectrum, geriatric patients experience post-operative memory deficits attributable to 
anesthetic intervention [61]. The reasons behind these effects is unknown.  
Memory encoding is a complex process that involves several parts of the brain. 
Memories are built in a stepwise manner involving acquisition, consolidation and retrieval. 
The process of programming memory is dependent on sensory cues parsed by cortical and 
sub-cortical structures followed by transmission to the hippocampus. Exposure to 
anesthetics disrupts working memory and the transfer of information into long term 
memory, indicating that it acts on more than one brain area [110]. Different areas of the 
brain such as the prefrontal cortex, sensory cortex, entorhinal cortex, amygdala, cerebellum 
and hippocampus play a role in these processes [111, 112]. In fact, lesions of the 
hippocampus and amygdala have been known to result in memory deficits [113, 114]. Due 
to the role of the hippocampus in memory processes, GABAergic, cholinergic and 
glutamatergic receptors expressed in this region are thought to be involved in regulation of 
memory.  
Various GABA A receptor subtypes are expressed in the hippocampus. Studies with 
genetically engineered mice and anesthetics have revealed that several subtypes play a role 
in the amnestic responses of anesthetics. Subtypes strongly implicated in this process 
include α1 and α5 -containing receptors. Global deletion of α1 subunits resulted in reduced 
amnestic effects of isoflurane [115]. A forebrain specific α1 knockout mouse (that included 
the hippocampus) also had reduced responses to the amnestic effects of isoflurane [115]. 
However, a subsequent study with a knockin mutation in the α1 subunit engineered to 
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 impart isoflurane insensitivity showed that mutant mice responded normally to the 
amnestic effects of isoflurane [83]. This suggested that α1 subunit-containing receptors 
likely play a marginal role in amnesic effects of isoflurane and that the effects observed in 
the global knockout may have arisen due to compensation. The amnestic effects of 
etomidate and enflurane were dramtically reduced in α5 knockout mice [116]. 
Additionally, these mice had better learning and memory than their wildtype counterparts 
in the absence of any anesthetic [117]. A knockin mutation in the α5 subunit also produced 
similar effects in the absence of anesthetics [118]. These studies suggest that deletion of 
major subunits led to resistance to amnestic effects of anesthetics. In addition, reduction in 
specific GABAergic receptor subtypes led to enhanced memory [117, 118]. Hence, it 
stands to reason that GABA A subtypes may play an important role in regulating memory.     
Understanding the mechanisms by which anesthetics exert their amnesic effects and 
relating them to the incidences of post-operative memory deficits such as retrograde and 
anterograde amnesia will help in the development of safer anesthetics. 
Although significant advances in understanding the mechanisms of anesthetics have 
been made, we are still in the dark about the roles of different receptor systems in 
anesthetic actions. The hope that consensus sites may be identified for the actions of 
anesthetics fuels the field of anesthetic research forward. In this regard, the focus of this 
dissertation is to study the role of a single GABAergic target (the α4 subunit) that has been 
implicated in anesthetic actions. It is expected that such studies will advance our 
knowledge about the involvement of different molecular targets in anesthetic actions. 
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 1.5 GABA A receptor mutant models:  
Genetically engineered mice have been used to elucidate the physiological and 
pharmacological significance of particular receptor containing subunits in the actions of 
anesthetics. These studies have provided a wealth of information about the involvement of 
different subunits in anesthetic effects. The following table (Table 1.1) summarizes the 
findings from different mutant mouse screens. 
 
Subunit Genetic Alteration Behavioral Response References 
α1 KO ↓ pentobarbital (LORR) 
↓ etomidate (LORR) 
↓ midazolam (LORR) 
↑ ketamine (LORR) 
= propofol (LORR) 
↓ isoflurane (amnesia) 
= isoflurane (MAC, LORR) 
↓ halothane (LORR) 
[115, 119] 
α5 KO ↓ etomidate (amnesia) 
= etomidate (sedation, hypnosis, motor ataxia) 
[116] 
α6 KO = halothane (LORR) 
= enflurane (LORR, immobilization) 
= midazolam (LORR) 
= pentobarbital (LORR) 
[120] 
β3 KO ↓ etomidate (LORR) 
↓ midazolam (LORR) 
= pentobarbital (LORR) 
↓ enflurane (immobilization) 
↓ halothane (immobilization) 
= enflurane (LORR) 
= halothane (LORR) 
[80] 
β2 KO ↓ etomidate (LORR) 
= pentobarbital (LORR) 
[121] 
γ2L KO ↑ midazolam (LORR) 
= etomidate (LORR) 
= pentobarbital (LORR) 
[122] 
δ KO = etomidate (LORR) [17] 
Table 1.1 Anesthetic responses in genetically engineered murine models 
Numerous studies have assessed the contribution of different GABA A receptor subunits to 
anesthetics actions. 
KO : Knockout; KI : Knockin; CKO: Conditional Knockout 
= no change with respect to genotype; ↓ decreased in comparison to controls ; ↑ increased in 
comparison to controls 
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 = pentobarbital (LORR) 
= midazolam (LORR) 
= propofol (LORR) 
= ketamine (LORR) 
↓ alphaxalone (LORR) 
= halothane (LORR, immobilization) 
= enflurane (LORR, immobilization) 
α1 
(S270H, 
L277A) 
KI = isoflurane (immobilization, amnesia) 
↓ isoflurane (LORR) 
↓ enflurane (LORR) 
= halothane (LORR, immobilization) 
= desflurane (immobilization) 
[123] 
      α2 
(S270H, 
L277A) 
              KI = isoflurane (LORR, immobilization) 
= halothane (LORR, immobilization) 
↑ isoflurane (RORR) 
	  	  	  	  	  	  	  [84] 
β2 
(N265S) 
KI = etomidate (LORR, immobilization) 
= pentobarbital (LORR, immobilization)) 
= propofol (LORR, immobilization) 
↓ etomidate (sedation, motor ataxia) 
[82] 
β3  
(N265M) 
KI ↓ enflurane (immobilization) 
↓ halothane (immobilization) 
↓ isoflurane (immoblization) 
= isoflurane (amnesia) 
↓ etomidate (LORR, immobilization) 
↓ propofol (immobilization) 
= alphaxalone (LORR, immobilization) 
[15, 124] 
α1 CKO 
(forebrain specific) 
↓ isoflurane (amnesia, immobilization)   
= isoflurane (LORR) 
= desflurane (immobilization) 
= halothane (immobilization, LORR) 
= pentobarbital (LORR) 
[115] 
β3 
 
CKO 
(forebrain specific 
 
↓ etomidate (LORR) 
 
[125] 
β3 CKO 
(paneuronal) 
↓ etomidate (LORR) [125] 
 
 
 
1.6. Alcohol 
 
Another area of research that shares the problems of 'multifarious effects through 
multiple targets' is alcohol (ethanol). The gaps in our understanding of how alcohol 
mediates its effects of motor incoordination, unconsciousness, alcohol addiction and 
withdrawal limit our ability to develop effective therapies for treatment of alcohol abuse. 
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 Sadly, the effects of alcohol abuse are far-reaching and pose both an economic and social 
problem. The following section addresses the need to study the effects of alcohol, advances 
in alcohol research and potential therapeutic targets for combating alcohol effects. 
1.6.1 Alcohol in society:  
Ethanol consumption has been a part of social history from as early as 200 BC [126, 
127]. In small quantities, alcohol produces a sense of well being, relaxation, loss of 
inhibiton and emotional arousal. It is for these effects that repeated indulgence of alcohol 
usually occurs. At slightly higher doses, alcohol produces changes in mood (such as anger, 
aggression, depression, stupor), memory deficits and motor incoordination (changes in gait 
and balance). At much higher doses, ethanol finally produces unconsciousness, respiratory 
depression and even death.   
Alcoholism is a major disease that places significant economic burden on society. 
The indirect cost associated with alcoholism easily surpasses 180 million dollars annually 
in the US [128]. Nearly 40% of all traffic crash fatalities are linked to alcohol [129]. In 
2005, nearly 13,000 people died due to alcohol-related cirrhosis in the United States alone 
[130]. A strong link has been found between alcohol and aggresive or violent behavior, 
with alcohol being a significant factor in >50% murders and violent crimes [131]. In 
addition, a strong correlation between alcohol abuse and incidence of psychiatric problems 
has also been suggested [132]. As if this was not enough, problems such as alcohol related 
crime incidence and domestic violence make this drug of abuse a major social hazard.   
Thus, both acute and chronic alcohol consumption have serious consequences not 
only for the individual but also for society. Understanding how these effects of alcohol are 
mediated would be a definite step towards resolving the negative effects of alcohol. Such 
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 information would give us the ability to design agents that could be used to combat the 
effects of alcohol. In the following sections, the effects of acute and chronic alcohol and the 
involvement of neurotransmitter-receptor systems in these actions will be discussed. 
1.6.1A Effects and consequences of acute and chronic ethanol consumption:  
Acute consumption of large amounts of ethanol cause hangover effects on the 
following day such as headache, nausea, vomiting and dehydration. Binge drinking also 
causes mood changes and memory deficits. In addition, binge drinking is often the cause of 
acute alcohol poisoning, the symptoms of which include mental confusion or stupor, 
vomiting, seizures, slow or irregular breathing and hypothermia. Acute ethanol toxicity 
presents an emergency situation warranting the need of therapeutic agents that can reverse 
the ill effects of ethanol. Commonly used therapeutic agents in the management of alcohol 
toxicity include benzodiazepine antagonists such as flumazenil [127, 133, 134]. However, 
these agents are only moderately effective in the treatment of acute ethanol toxicity. Hence, 
there is a need to discover new agents that may be more effective in antagonizing these 
effects of acute ethanol. 
How does chronic alcohol addiction set in? It is thought that repeated exposure to 
alcohol produces changes in the brain that reinforce the addicting aspects of alcohol. 
Inability to self-regulate consumption results in psychological changes such as irritability, 
anxiety, preoccupation or anticipation of the next exposure to alcohol and withdrawal-
related negative effects. Particularly, the negative withdrawal effects are hypothesized to be 
instrumental in providing the major motivational impetus for compulsive ethanol intake 
[135]. Brain regions associated with addictive mechanisms include the extended amygdala 
comprising of stria terminalis, nucleus accumbens shell, sublenticular substantia 
innominata and the lateral hypothalamus (see review, [136]). Changes in neurotransmitter 
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 functions accompany the reinforcing effects of alcohol (see review [137]). GABAergic, 
opioid peptidergic, dopaminergic, glutamatergic and serotonergic systems have been 
implicated in the neurobiology of addiction (see review, [138]). These changes persuade 
the individual to seek alcohol repeatedly. This leads to addiction and tolerance. Tolerance 
to alcohol is said to occur when after continued drinking, greater amounts of alcohol are 
required to achieve the same effect [139]. Due to these effects, the individual requires 
greater amounts of alcohol each time to experience its pleasurable effects. Failure to imbibe 
alcohol produces withdrawal changes that are severe and debilitating. These include 
hyperexcitability, propensity to seizures, irritability, increased anxiety, insomnia and 
tolerance to typical sleep-aids [3].  
Although, a lot more is known about the effects of alcohol and its addictive 
properties now compared to two decades ago, we are far from deciphering the full spectrum 
of its complex effects. Due to all these reasons, alcohol and its effects are the focus of 
much research. As with anesthetics, the molecular mechanisms of action of alcohol are not 
well elucidated. GABA A, glycine, glutamate and dopaminergic receptors systems are all 
though to contribute to the actions of ethanol. The involvement of GABA A receptors with 
alcohol is discussed below. 
 
1.7 Alcohol and GABA:  
 
A plethora of evidence has linked the GABA A receptor system to ethanol effects. 
Behavioral effects of alcohol were potentiated by GABAergic agonists and reduced by 
GABAergic antagonists [140]. Differences in GABA A receptor function are observed in 
mice that show differential sensitivity to ethanol (long sleep and short sleep mice) [141]. 
GABA A receptor subunit mRNA also are changed in alcohol withdrawal prone and 
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 alcohol withdrawal resistant mice [142]. Further, these mice show changes in upregulation 
and downregulation of GABA A mRNA levels following chronic ethanol treatment [143]. 
Studies on alcohol-prefering (P) and non-prefering (NP) rats have implicated the 
GABAergic system in the nucleus accumbens as critical for initiation of ethanol drinking 
behavior [144, 145]. Additionally, quantitative trait loci studies have suggested that 20% of 
candidate genes related to ethanol withdrawal severity are linked to GABA 
neurotransmission [146].  
Studies of direct interactions of alcohol with GABAergic receptors revealed that 
alcohol potentiated chloride uptake via GABA receptors [147]. When studied with 
muscimol, 20-60 mM ethanol potentiated chloride uptake in cultured spinal neurons  [148], 
mouse cerebellar microsacs [149] and cerebral cortical synaptoneurosomes [150, 151]. 
Antagonists of GABA A receptor function such as bicuculline and picrotoxin blocked such 
effects [150, 152]. Thus, it is now a well known fact that ethanol acts on GABAergic 
receptors to enhance inhibitory chloride neurotransmission. However, GABAergic 
receptors differ in their sensitivity to ethanol depending upon receptor composition.  
A study by Mihic et al., identified a 45- amino acid spanning region within the 
second and third transmembrane domains of α1/2 subunits, that was required for direct 
enhancement by ethanol and anesthetics [14]. Mutation of specific residues in this region 
ablated sensitivity to ethanol in in vitro cell systems [153]. 
Several GABA receptor subtypes have been shown to be responsive to ethanol. In 
vitro studies showed that synaptic GABAergic receptors were activated by ethanol [14, 
154, 155]. However, this potentiation was observed at doses of ethanol ≥ 50 mM. This was 
later attributed to the fact that these studies focused on synaptic receptors alone. Recent 
studies by independent groups have revealed a population of receptors uniquely sensitive to 
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 low doses of ethanol [156, 157]. Ethanol was shown to enhance the inhibition of 
extrasynaptic α4/6βδ-GABA A receptors at concentrations that are physiologically relevant 
(3-30 mM), although this finding is controversial [157-160]. (This aspect is discussed in 
greater detail in Section 1.10.2)  
The legal limit for alcohol intoxication in the US is 0.08% or 17mM. It is 
interesting to note that the concentrations at which α4/6βδ- containing receptors are 
modulated (3-30 mM) is within the range of alcohol intoxication observed in humans. 
Thus, the doses of ethanol that produce intoxicating effects of sedation and motor ataxia are 
more likely to be mediated by δ-containing receptors. Human lethal blood alcohol 
concentrations range from 50 mM-110 mM [161, 162], suggesting that synaptic receptors 
must be responsible for the high dose effects of ethanol.  
In addition to direct actions, ethanol can also mediate post-translational 
modifications on GABA A receptors [163-165]. GABA A receptor subunits possess 
phosphorylation sites that are thought to regulate GABA binding in different regions of the 
brain [166], channel conductance and influence internalization [167]. Deletion of different 
isoforms of protein kinase C (PKC) produced variable ethanol effects. For example, 
deletion of PKC γ and δ led to a reduction of some ethanol effects in KO mice [168, 169], 
while the deletion of the ε isoform caused mice to exhibit increased sensitivity to some 
effects of ethanol [170]. Other phosphorylating enzymes have also been shown to be 
involved in modulating the effects of ethanol [171-174]. Finally, ethanol also increases 
neurosteroid levels and thus increases their actions on GABA A receptors [175]. Thus, 
ethanol affects GABA A receptor function in a variety of ways. 
Distinct changes are observed in GABAergic receptor functions and expression 
profiles following chronic ethanol treatment. Following chronic ethanol exposure, there is a 
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 decrease in chloride flux in the hippocampus of rats subjected to chronic intermittent 
ethanol treatment (CIE) [176]. Similar changes have been observed in spinal cord and 
cortical neurons that were exposed to chronic ethanol treatment [177]. In addition to 
changes in chloride flux, GABA A receptors undergo changes in expression of subunits. 
Post chronic ethanol exposure, a downregulation of synaptic α1 subunits occurs [178]. 
However, α4, α6 and γ2 subunits are increased whereas δ subunits are decreased [178]. 
Electron microscopy studies revealed that during chronic ethanol withdrawal, concomitant 
with the decrease in δ, α4 combines with γ2 subunits within the synapse [179]. The α4β2γ2 
combination carries less current than the corresponding extrasynaptic tonic current when in 
combination with δ subunits [178]. The result of this is decreased charge transfer, that 
possibly contributes to the hyperexcitability seen post-chronic ethanol exposure. 
In keeping with the change in subunit combinations, changes in current potentiation 
by different drugs in hippocampal neurons are observed during withdrawal [180]. During 
withdrawal, a decrease in mIPSC potentiation by zolpidem [181], decrease in tonic current 
potentiation by ethanol [179], increased potentiation of mIPSC for gaboxadol [181] [179], 
increased potentiation of mIPSC by Ro15-4513 [179, 181] was observed.  
The changes occuring biochemically are reflected in behavior as well. For example, 
post-chronic ethanol treatment, the effect of ethanol on LORR was reduced by 92% in CIE-
rats compared to control rats. The decrease in δ also contributed to the tolerance seen with 
ethanol and neurosteroids during chronic ethanol withdrawal [180]. Alphaxalone 
(neurosteroid anesthetic) -induced LORR, diazepam-induced LORR was reduced 
dramatically [180]. In addition, the effects of pentobarbital and gaboxadol (THIP) were 
also reduced [181]. The reduced response to these drugs is a reflection of cross-tolerance or 
decreased GABAergic function induced by chronic ethanol withdrawal.  
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 Although the molecular mechanisms of ethanol have been studied extensively, there 
is much that we do not know. For instance, what mechanisms give rise to the changes in 
receptor expression and combination? Are the changes in the GABA receptor system the 
cause or effect of withdrawal behavior? If receptor expression changes were prevented 
during chronic ethanol withdrawal, could withdrawal behavior be alleviated? Research in 
this area has only scratched the surface of the complex processes taking place in the 
aftermath of ethanol exposure. The study of ethanol exposure and withdrawal changes in 
vivo involves replicating the biochemical and behavioral effects of chronic ethanol in an 
appropriate model system. A combination of pharmacologic and genetic engineering 
approaches are currently being used to understand the many effects of ethanol. Genetically 
engineered murine models have greatly advanced our ability to study ethanol-behaviors. 
These studies have yielded some interesting results and are reviewed in [182]. The studies 
involving GABA A receptor mutant models are summarized in Table 1.2. 
 
 
 
Subunit Genetic 
Alteration 
Behavioral Response References 
α1 KO ↑ locomotor stimulation 
↓ LORR 
= LORR 
= motor ataxia 
= anxiolysis 
= chronic withdrawal 
= seizures 
= tremors 
[119, 121, 183, 
184] 
Table 1.2: Ethanol effects in genetically engineered murine models 
Numerous studies have assessed the contribution of different GABA A receptor subunits to 
alcohol actions. 
KO : Knockout; KI : Knockin; CKO: Conditional Knockout 
= no change with respect to genotype; ↓ decreased in comparison to controls ; ↑ increased in 
comparison to controls 
 
40
 α2 KO ↓ LORR 
= anxiolysis 
[185] 
α4 KO = motor ataxia 
= hypnosis 
= anxiolysis 
= locomotor stimulation 
[186] 
α5 KO ↑ locomotor stimulation 
= LORR 
= anxiolysis 
[185] 
α6 KO = LORR 
= chronic withdrawal 
[120, 187] 
β2 KO = locomotor stimulation 
↓ LORR 
= chronic withdrawal 
[121, 183] 
β3 KO = LORR [80] 
γ2 L KO = LORR 
= anxiolysis 
= motor activity 
= chronic withdrawal 
[188] 
δ KO = LORR 
= anxiolysis 
= hypothermia 
↓ chronic withdrawal 
↓ drinkng behavior 
↓ protracted tolerance 
[189] 
α1 
(S270H, 
L277A) 
KI ↓ motor ataxia 
↑ anxiolysis 
= hypnosis 
= locomotor stimulation 
[190, 191] 
α2 
(S270H, 
L277A) 
KI ↑ hypnosis 
↓ locomotor stimulation 
[192] 
γ2 S Tg = hypnosis  [193] 
γ2 L Tg = hypnosis [193] 
 
 
 1.8  Neuroprotectives during Chronic ethanol withdrawal: 
Because alcoholism is a widespread disease, with so many far reaching effects, the 
search is on for agents that can be used to effectively combat the endpoints of withdrawal 
and dependence. Parameters of chronic ethanol withdrawal behavior have been replicated 
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 and studied in numerous murine models in an effort to better understand the processes 
underlying withdrawal behavior. The severity of alcohol withdrawal is thought to be 
another motivating factor in alcoholism relapse. Hence, drugs that are effective at reducing 
the negative symptoms of ethanol withdrawal may also find use in the treatment of chronic 
alcohol withdrawal and dependence.  
1.8.1   Taurine and ethanol:  
The interaction of taurine with ethanol has been the focus of several research groups 
since the early 1970's and continues to garner interest even today. Taurine derivatives and 
metabolites were found to interact with ethanol, albeit to varying potencies [194-196]. It 
has been shown that cysteic acid [197] and taurine [198] reduced circulating alcohol levels 
while taurocholic acid decreased ethanol preference [197]. Taurine itself combats increases 
in glutamatergic activity during ethanol withdrawal [199-202]. It is not known if this is due 
to direct inhibition of glutamatergic receptors or due to an indirect action via GABA or 
glycine receptors.  
Taurine is a sulfonated β amino acid, that is structurally similar to GABA. Not 
surprisingly, it potentiates GABA and glycinergic neurotransmission [203-207]. It is 
abundantly found in excitable tissues such as heart and brain [208, 209]. Taurine is 
synthesized from methionine in the body through a muli-step enzymatic process. It is 
implicated in calcium homeostasis, osmoregulation, neuroprotection, antioxidation and 
neurotransmission [208]. Taurine is thought to be in the low millimolar levels in synaptic 
clefts and taurine immunostaining is observed in presynaptic nerve terminals as well as in 
dendrites and cell bodies [207, 209]. In binding studies, taurine displaced direct and 
allosteric agonists of the GABA A receptor [210-214]. Several brain regions such as 
hippocampus, striatum, cortex and substantia nigra show GABA-A receptor mediated 
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 inhibition when taurine is added exogenously [204, 215-217]. The use of glycine and 
GABA antagonists produced a reduction in the current potentiation by taurine [205, 206, 
218], further solidifying the view that actions of taurine are mediated through GABA A and 
glycine receptors.  
Given the actions of taurine on GABA A receptor, it was intuitive that taurine 
would have some interactions with ethanol. But what kind of behavioral outcomes would 
such interactions have?  Behavioral experiments with ethanol and taurine indicated that 
taurine acts as an ethanol antagonist. At low doses of ethanol, taurine inhibited ethanol-
induced locomotor stimulation, whereas at higher doses of ethanol the sedative effects of 
ethanol were diminished [196]. It appears that the route of administration of taurine also 
differentially affected its mechanisms. For example, taurine administered 
intracerebroventricularly following a sedative/hypnotic dose of ethanol administered 
intraperitoneally (i.p.) potentiated the effects of ethanol [219, 220]. However, a peripheral 
injection of taurine reduced the impairing effects of ethanol [220-222]. Several groups have 
reported that stimulation of glutamate receptors evoked taurine release into the extracellular 
spaces [223-225]. Additionally, glutamatergic over-excitation can be countered by 
exogenous taurine via GABA A and glycine receptors [226-228]. Interestingly, chronic 
ethanol withdrawal resulted in hyperexcitability of glutamatergic neurotransmission [229-
232]. Hence, it was possible that taurine could reduce the excitatory glutamatergic 
neurotransmission during ethanol withdrawal. 
Diaz-Granadoz et al [233] tested the effects of taurine administration in C3H/HeJ 
mice receiving chronic ethanol treatment. Taurine-treated mice showed reduced propensity 
to handling-induced convulsions (HIC) during withdrawal compared to control mice. This 
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 result indicated that taurine was indeed successful in alleviating withdrawal. But the 
mechanism by which this effect was mediated is unknown.  
Recent work by Jia et al showed that contrary to popular notion, extrasynaptic 
GABA receptors were greatly sensitive to taurine and showed robust tonic current 
potentiation with taurine [234]. Whereas synaptic receptors required 1-10mM for current 
potentation [204, 235], extrasynaptic α4-containing receptors responded to only 10-100µM 
of taurine [234]. In addition, ventrobasal thalamic neurons from α4 KO mice did not show 
current potentiation with taurine. This demonstrated that α4-containing receptors were 
required for mediating taurine-induced current potentiation. It is noteworthy that during 
ethanol withdrawal, α4 levels increase dramatically [178]. Thus, recent evidence indicates 
that α4-containing GABA receptors may be useful targets for alleviation of ethanol 
withdrawal symptoms. However, it is not known if α4-containing receptors mediate the 
protective effects of taurine during ethanol withdrawal.  
 Understanding the mechanism of action of taurine could provide insight into the 
mechanism of action of its derivative, acamprosate. Acamprosate, approved by the Food 
and Drug Administration in 2004, is very successful in treating alcoholism and preventing 
relapse. However, its mechanism of action is not currently known. In a series of studies, 
Dahchour and DeWitte demonstrated that acamprosate was capable of reducing several 
behavioral and biochemical measures of hyperactivity in the aftermath of chronic 
alcoholism [236-238]. The pharmacological effects of acamprosate have been related to its 
actions upon central neuromediator systems and both GABA and glutamate pathways have 
been implicated [239-241]. Acamprosate is remarkably effective in the treatment of chronic 
alcoholism and several studies have related its effects to local increases in taurine [238]. 
Therefore, if the mechanism of action of taurine was known, it may aid the understanding 
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 of the mechanism of action of acamprosate as well. This in turn could lead to the 
development of newer drugs for the treatment of alcohol relapse. 
 
1.9  Ethanol antagonists: 
Binge drinking of alcohol produces effects of headache, nausea, dehydration. 
Consumption of ethanol leads to undesirable behavioral effects but also increases the risk 
for cancer, alcoholic dementia, liver disease and stroke. Not only this, but alcohol has 
strong abuse potential. While many generalized GABAergic antagonists such as picrotoxin 
and bicuculline are effective in antagonizing the effects of ethanol and other GABA 
agonists, due to their non-specific actions, they also reduce essential inhibitory 
neurotransmission in the brain leading to undesirable side effects. Currently, the drug of 
choice for reversing acute ethanol toxicity, is flumazenil. The high incidence of emergency 
cases of ethanol toxicity, the short half life of flumazenil, coupled with its intravenous 
route of administration, urgently call for the developement of better, efficacious ethanol 
antagonists. A more effective ethanol antagonist would be one that is a selective ethanol 
antagonist. Such a drug should selectively reverse the actions of ethanol alone without 
producing side effects. If such a drug were to be developed, one can envision a scenario in 
a social setting where the effects of acute ethanol consumption are reversed prior to 
driving, or operating machinery, thereby minimizing accidents. In addition, reversal of 
some effects of ethanol could prevent or slow the advent of a hangover and dehydration. In 
cases of chronic alcoholism, the use of such a drug during ethanol exposure may prevent 
the likelihood of development of addiction. In addition, such a drug may find use in the 
treatment of alcoholism. The possible applications of an ethanol antagonist are endless. 
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 Even if such a drug did not find immediate clinical applications, the drug could be used in 
research settings to provide additional information about the pharmacology of ethanol.  
Current pharmacotherapies for treatment of alcoholism (naltrexone, acamprosate, 
disulfiram) are few in number and surprisingly, have been discovered serendipitously. 
Considering the possibilities of a putative ethanol antagonist, it is time systematic drug 
discovery paradigms were undertaken with vigor to address this problem. In fact, some 
groups have already taken the lead and have synthesized drugs and developed structure-
activity relationships for putative ethanol antagonists.  
1.9.1   Atypical benzodiazepines as ethanol antagonists:  
Typical benzodiazepines, such as diazepam and flunitrazepam, potentiate GABA A 
receptor channels. With ethanol, they cause synergistic effects and increase the net chloride 
current mediated by target GABA A receptors. Behaviorally, they enhance the effects of 
ethanol - induced anxiolysis, motor incoordination, sedation and hypnosis. 
Benzodiazepines act primarily on synaptic GABAA receptors. These are usually composed 
of α1, α2, α3, α5 and γ2 subunits. The benzodiazepine binding site is thought to lie at the 
interface of an α and γ2 subunit. Extrasynaptic receptors containing α4, α6 and δ subunits 
are thought to be benzodiazepine–insensitive, since drugs belonging to this class do not 
bind appreciably to or potentiate current through these receptors [242-244].  
Ro15-4513 is an imidazobenzodiazepine synthesized in 1984 by Hoffman-
LaRoche. It bears structural similarity to flumazenil- a benzodiazepine antagonist. Ro15-
4513 antagonizes ethanol-mediated chloride flux [150, 245, 246]. In behavioral studies, 
Ro15-4513 was more efficaceous than flumazenil, the parent benzodiazepine antagonist in 
antagonizing the effects of ethanol [247]. Several groups demonstrated antagonism of 
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 ethanol-induced LORR, motor ataxia, and sedation by Ro15-4513 [247-249]. Additionally, 
at the doses tested, Ro15-4513 did not possess any intrinsic effects [248, 250].  
Encouraged by the behavioral antagonism of ethanol by Ro15-4513, several other 
drugs bearing structural similarity were synthesized in the 1990's [251, 252].  RY023, 
RY024 and RY080 are structural analogues of Ro15-4513, and as such, all three drugs 
behave as ethanol antagonists [253-256]. Binding studies on recombinant GABAA receptor 
subtypes revealed that the RY series of drugs had higher binding affinity to α5γ2-
containing receptors compared to α1/α2/α3/α4/α6-γ2 containing receptors (Lui 1995, 
1996, Cook 2005) [251, 253, 255, 257]. In functional studies, the RY series of drugs 
negatively modulated all αβ3γ2 subtypes, but were most effective at the α5β3γ2 subtype 
[253, 255]. However, it is important to note that these drugs were not tested against all 
possible combinations of GABA receptor subunits. 
Behavioral assays with RY023 revealed that this drug was effective in reducing 
ethanol preference as tested by the operant conditioning assay [253]. Ethanol-induced 
motor ataxia, tested on the oscillating bar test, was also reversed by all tested doses of 
RY023 [253]. When locomotor effects of ethanol were studied by the open field assay, 
RY023 was successful in reducing the sedative effect of a 1.25g/kg dose but not of a 
0.75g/kg dose of ethanol [253].  However, a 7.5mg/kg dose of RY023, when give alone, 
produced strong intrinsic effects of sedation [253]. Intrinsic effects of RY023 were not 
observed on the oscillating bar test for motor ataxia. 
An intrinsic effect is defined as a change in behavior caused by a drug compared to 
a non-active placebo. Since the RY series of drugs produce changes in behavior when 
given alone [253, 254, 256], they are said to possess intrinsic effects. The relative 
magnitude of intrinsic effect is often dependent upon the behavioral paradigm under study 
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 [258, 259]. Like with RY023, ethanol antagonism and intrinsic effects were seen with both 
RY080 and RY024 [254, 256]. Because these drugs are inverse agonists, it was thought 
that the ethanol antagonism was a result of inverse activity at specific GABAA receptor 
subtypes. However, the intrinsic effects of RY drugs on open field showed increased 
sedation not hyperactivity as would be expected for an inverse agonist. Hence, the actions 
of RY drugs on ethanol cannot be explained entirely by a subtractive hypothesis.  
Based on behavioral studies and binding affinity, it was proposed that the RY series 
of drugs acted predominantly at α5-containing receptors to bring about ethanol antagonism 
[251, 253, 255-257, 260]. Actions at α5-containing receptors alone do not explain the 
differences in intrinsic effects on motor coordination and sedation on the one hand but 
similar antagonism at ethanol-induced motor ataxia and sedation on the other. Further, the 
dose and behavior-dependency of the actions of RY drugs suggests that there is more to 
this story than meets the eye. Thus, our understanding of the actions of these drugs is still 
incomplete. 
Recent work by Wallner, Hanchar and Olsen has challenged the belief that α5-
containing receptors may be the predominant site of action for the RY drugs. Evidence 
towards this was obtained from the observation that Ro15-4513 reversed the effects of 
ethanol alone at specific doses but not of barbiturates [261]. Thus, its activity was less 
likely due to inverse agonism and more likely due to a specific site of action that is 
common to ethanol.  
Advances in the study of ethanol actions have shown that certain GABAA receptor 
subtypes are more sensitive to ethanol-induced current potentiation than others. As 
mentioned above, extrasynaptic receptors containing α4/α6-δ subunits have been 
implicated in low dose ethanol effects [157, 158], although this is controversial [160]. 
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 These receptors are more sensitive to GABA and produce tonic current that is modulated 
potently by ethanol compared to the phasic current produced by synaptic receptor 
counterparts. Importantly, studies on recombinant α4β3δ receptors showed antagonism of 
ethanol-induced current by Ro15-4513 [262]. It is important to note that at least one other 
group did not observe displacement of Ro15-4513 by low doses of ethanol from native δ-
containing receptors [263]. However, the reasons for this are currently unknown. 
On recombinant α4δ-containing receptors, Ro15-4513 was functionally silent, i.e. it 
did not potentiate any current. In addition, bound Ro15-4513 was competitively displaced 
by ethanol as well as other benzodiazepine site ligands such as flumazenil and the RY 
drugs, RY080 and RY024 [262]. This indicated that Ro15-4513 and the RY drugs shared a 
common site of action with ethanol on the ethanol sensitive α4/6δ-containing receptors.  
Based on these observations, Olsen, Wallner and Hanchar proposed the presence of 
a common binding pocket for ethanol and these drugs [156, 158, 262, 264]. According to 
this theory, receptors possess a high affinity and low affinity binding site for ethanol- the 
former is important for Ro15-4513 reversal. Ro15-4513 and the RY series of drugs possess 
a core imidazobenzodiazepine ring structure with differing substitutions at positions C7 of 
the ring. Substitutions at this position are thought to occupy the ethanol binding pocket 
[265]. It was proposed that the size of the residue at position 7 of the 
imidazobenzodiazepine ring dictates the ethanol-antagonizing potential of the drug. Ro15-
4513 and the RY series of drugs have groups at their C7 positions that likely preclude the 
binding of ethanol concurrently. Thus, they antagonize the effects of ethanol. In contrast, 
flumazenil (Ro15-1788) has a fluorine atom at this position - the fluoride residue being 
small in size does not inhibit the binding of ethanol and allows co-occupancy of the pocket, 
thus allowing for ethanol effects. In 2006, Hanchar et al showed that some of these drugs 
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 also bound with high affinity to α4δ- 
containing receptors and suggested that binding of Ro15-4513 and its analogs to α5β2γ2 
BZ site may be a coincidence, unrelated to their ethanol-antagonist potential [262]. Thus, 
α4δ-containing receptors are proposed to be the primary target for the ethanol antagonistic 
actions of Ro15-4513 and RY drugs.  
Regardless of their site of action, these drugs have great potential for combating 
acute ethanol toxicity. In addition, the ability of the RY series of drugs to confer resistance 
to ethanol-reinforcing effects indicate that they act on sites involved in the addiction 
pathway. Hence, its possible that these drugs may have anti-addiction potential as well. 
These ideas hold great promise for the development of a specific ethanol antagonist. 
Further research in this area has the potential to revolutionize the field of ethanol research 
and treatment.         
 
1.10 Relevance of GABA A receptor α4-containing receptors:  
 
The architecture and role of receptor isoforms containing the α4 subunit has gained 
a lot of focus over the past couple years and studies are only beginning to understand the 
constellation of effects executed by α4-containing receptors. The α4βγ2 subunit 
combination is encountered both synaptically and extrasynaptically, whereas the α4βδ 
receptor is exclusively extrasynaptic [16, 179, 181, 266-268]. In addition, an α4β3 binary 
receptor has been proposed although its presence has not been encountered physiologically 
[269]. α4-containing receptors are located in the dentate gyrus, thalamus, striatum and 
cortex, where they conduct tonic and synaptic currents [242].  
Tonic current has gained a lot of importance over the last several years as being the 
target of modulation by several ligands. The role of a persistent tonic current was unclear 
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 until a few years ago. Recent evidence indicates that tonic current is important for 
homeostasis of neuronal excitability [12].  Neuronal network excitability and information 
processing is thought to be regulated by tonic current. The effects of tonic current differ 
depending upon the brain region. In certain regions, tonic currents regulate the noise 
associated with neuronal firing. An increase in GABA levels leading to increases in tonic 
current can help decrease neuronal excitability and prevent neuronal saturation [270] This 
reduces the number of neurons that are simultaneously excited, resulting in sparseness of of 
neuronal firing [271]. Computational modeling studies have revealed that enhancing the 
sparseness of coding can help record and store greater information over time [272] Thus, 
the presence of tonic current in the hippocampus and the cerebellum play an important role 
in regulating the neuronal firing burden over time.  
In regions where both phasic and tonic inhibition occur, changes in the extracellular 
GABA levels could dictate the predominance of type of neuronal currents [11]. For 
example, in hippocampal pyramidal cells, tonic GABA currents are small and phasic 
GABA currents predominate. Addition of picrotoxin which selectively inhibits tonic 
currents, resulted in an increase in frequency of spontaneous inhibitory postsynaptic 
currents (sIPSC). This indicated that tonic current in the hippocampus served to regulate 
the excitability of pyramidal cells [273]. Thus, tonic currents have an important role in 
regulating neuronal excitability and parsing of information. The modulation of tonic 
currents by endogenous and exogenous ligands holds vast implications for the 
physiological processes regulated by them such as cognition, memory, sleep and 
movement.  
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 1.10.1 α4 and steroid regulation: 
Studies show that some GABA A receptors are modulated directly by steroids [274-
277] and respond by increases in Cl- current. This is achieved by increasing open duration 
and frequency of channel openings [278]. Very high doses of exogenous neurosteroids can 
cause significant inhibition of GABA A receptors to produce anesthetic-like effects.  An 
important source of circulating neurosteroid precursors are peripheral tissues such as 
adrenal glands and the ovaries [279]. However, in addition to these, the brain is also 
capable of synthesizing steroids [280, 281]. Obligatory enzymes and steroid mitochondrial 
transporters required for the synthesis of pregnane steroids are present in the CNS [280]. A 
recent investigation utilizing in situ hybridization and immunohistochemical techniques 
revealed that enzymes required for steroid synthesis were expressed in mouse brain in a 
region specific manner [281]. This study showed the presence of steroid-synthesizing 
enzymes in Purkinje neurons of cerebellum, neurons of nucleus reticularis of the thalamus 
and principal neurons of hippocampus and cortex [281]. Based on these studies, it is 
hypothesized that neurosteroids act in a paracrine as well as an autocrine manner to 
influence excitability of neurons.  
Certain GABA A receptors are particularly sensitive to neurosteroids. Specifically, 
δ-containing receptors are important for neurosteroid actions [181, 282-285]. It is proposed 
that changing levels of neurosteroids can modulate the expression of certain δ containing 
receptors - α4β2δ receptors [267, 286-288]. Depending on the brain region that these 
receptors are expressed in and the local Cl- gradient, these receptors show diversity in 
function which in turn regulates the response to fluctuating levels of steroids. Puberty [289, 
290], ovarian cycle associated changes [288], pregnancy [286] and stress are some 
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 conditions during which GABA A receptors play a role in regulation of excitability by 
neurosteroids.  
It is important to note that while fluctuating levels of steroids do influence levels of 
expression of GABA A δ receptor subtypes, these changes are not always in linear relation 
to the levels of neurosteroids. It is proposed that during puberty, as levels of the 
progesterone metabolite 3α-OH-5α[β]-pregnan-20-one (THP) decrease, α4β2δ increases 
are instrumental in maintaining the level of inhibition due to their polarity dependent 
response [289, 291]. So, in areas of outward Cl- current, such as the CA1 hippocampus, 
THP reduced inhibition [292]. But in areas where Cl- current is inward, such as dentate 
gyrus and cortex, neurosteroids enhance inhibition [293-295]. These changed responses 
likely underlie the modulation of anxiety and stress during puberty. During puberty, mood 
swings and aversive responses to stress are observed [296-298]. The onset of puberty is 
marked by a fall in the levels of the endogenous neurosteroid THP [299, 300]. Concurrent 
with this decline in endogenous neurosteroid, levels of α4β2δ receptors increase in the 
hippocampus [291]. The increased levels of α4β2δ  are thought to be an attempt to 
normalize neuronal excitability when confronted with reduced levels of neurosteroids.  
During the ovarian cycle, levels of endogenous neurosteroids fluctuate so that THP 
levels are low during the follicular phase, increase during the midluteal phase and finally 
decline during the late luteal phase [301, 302]. During late diestrous phase of the ovarian 
cycle, increased δ and decrease in γ2 subunit proteins has been observed in the dentate 
gyrus granule neurons of the hippocampus of mice [288]. This increase is concurrent with 
the increases in progesterone and related metabolites [288]. In contrast, during the estrous 
phase, when progesterone levels are reduced, δ subunits in the dentate gyrus granule 
neurons are also reduced [288]. Consistent with this, decreased tonic conductance is 
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 observed in these neurons. These changes in GABA A receptor function are associated 
with decreased seizure susceptibility and anxiety associated with menstrual cycle changes. 
A corollory to this theory is that dysregulation of GABA A receptor dynamics during 
menstrual cycle changes could then result in premenstrual dysphoric disorder and other 
associated syndromes. 
When levels of receptor subtypes do not change dynamically with fluctuations in 
neurosteroids, control of neuronal excitability is disrupted and this in turn is related to 
disorders associated with fluctuations in neurosteroids such as catamenial epilepsy. 
Increases in frequency and worsening of seizures across the menstrual cycle have been 
reported, especially during the mid-menstrual cycle and late luteal phase  [303-305]. The 
increased incidence of seizures during the late luteal phase is attributed to THP withdrawal 
[306]. Since increases in α4 receptors are observed during THP withdrawal, it was 
speculated that the increase in α4 could be responsible for excerbation of seizures. 
Decreasing α4 expression by antisense oligonucleotides in the hippocampus during this 
period successfuly averted increases in seizure susceptibility [307]. 
During pregnancy as well, hormonal changes occur with prolonged increases in 
progesterone levels and its metabolite THP [308, 309]. THP levels increase gradually 
during the course of pregnancy and are highest around full term pregnancy [310]. During 
the postpartum period, a rapid decline in THP levels are observed [311]. Levels of α1/2/4 
and β1/2/3 did not change during pregnancy in mice [312, 313]. However, decreases in δ 
and γ2 subunit was observed in the hippocampi of pregnant mice concurrent with the 
presence of high levels of neurosteroids [311-313]. This corresponded with a decrease in 
tonic currents and spontaneous inhibitory postsynaptic currents in the hippocampus. Forty-
eight hours postpartum, levels of δ and γ2 came back to normal suggesting that rapid 
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 reversal and normalization of inhibition [311]. Thus, GABA A receptors which are 
sensitive to high levels of neurosteroids are downregulated during pregnancy to prevent 
excesss inhibition and come back to normal during postpartum once again re-establishing 
neuronal excitability. However, inability to regulate receptor expression can have adverse 
behavioral consequences.  
It is also important to note that these α4δ-containing receptors undergo a different 
pattern of regulation in rats [314] suggesting that regulation of GABA A receptor 
expression during pregnancy maybe more complex and also vary in a species-specific 
manner. In a rat model, it has been shown that α4 levels do not change during pregnancy 
when THP levels are high. However, 7 days postpartum, reductions in progesterone occur 
and this period sees increases in α4 [308]. In a rat model of pseudopregnancy, a reduction 
in levels of THP was concurrent with increases in levels of α4 expression [315].  
Consistent with this, THP withdrawal produced increases in anxiety and insensitivity to 
benzodiazepines, suggesting a model of postpartum dysphoria. Regardless of the species, it 
is clear that GABA A receptor α4δ-containing receptors have specific responses to 
fluctuating levels of neurosteroids that may underlie the behavioral responses observed 
during this period. Given their role in regulating neuronal excitability, the changes that 
these receptors undergo need to be better characterized in humans. 
Although changes in receptor expression appear to be an attempt to normalize 
neuronal excitability, dysregulation of such receptor expression can result in premenstrual 
dysphoric disorder and postpartum depression. Evidence substantiating this claim was 
obtained from the δ KO mice. Ablation of the δ-containing receptors resulted in resistance 
to neurosteroid-induced loss of righting reflex and anxiolysis [17]. In addition, the δ KO 
model showed a propensity for postpartum depression-like symptoms, abnormal maternal 
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 care and reduced offspring survival [311]. During pregnancy, δ receptor levels in the 
hippocampus, thalamus and striatum were normally reduced [286]. Since endogenous 
neurosteroid levels are increased during pregnancy, the downregulation of highly sensitive 
δ-containing receptors is considered a homeostatic mechanism of retaining normal 
neuronal excitability. However, although an increase in endogenous neurosteroids was 
observed in δ mice, changes involving the δ subunit could not take place. Hence, neuronal 
excitability could not be re-established suggesting that changes in neuronal excitability 
were an outcome of the deletion of δ receptors [286]. The lack of homeostatic regulation of 
δ is thought to be responsible for neurological and psychiatric disorders associated with 
pregnancy and postpartum. Given the plasticity of α4 expression during changed hormonal 
situations, a similar role for α4-containing receptors could be envisioned. In addition, 
compensatory changes in the δ mice involved reductions in α4 subunit expression, 
suggesting that deficiencies in the δ KO mice could result from reduced levels of α4 
protein as well. Hence, α4 subunit related changes may also be critical to regulation of 
neuronal excitability during hormonal changes.  
The studies summarized above indicate that acute and chronic changes in levels of 
neurosteroids are critical in modulation of GABA A receptor-mediated neurotransmission. 
Considering the variety of processes in which α4-δ containing receptors play a role in and 
their importance in tonic current, further understanding of neurosteroid-α4δ receptor 
interactions would aid development of pharmacological therapies geared to holistically 
address hormonal imbalances.   
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 1.10.2 α4 and Ethanol:  
 While GABA A receptor subtypes respond to ethanol, the sensitivity of different 
subtypes varies widely. Synaptic GABA A receptors respond to ≥ 50mM of ethanol [14, 
154, 316] whereas extrasynaptic receptors are thought to respond to lower concentrations 
such as 3-30mM of ethanol, although this is controversial [157-159]. The legal limit for 
alcohol in the US is 0.08% or 17mM. Therefore, receptors that respond to such 
concentrations of alcohol are more likely be relevant to the physiological symptoms of 
alcohol intoxication. A concentration of 50mM corresponds to nearly 3 times the legal limit 
for alcohol intoxication. Therefore, synaptic receptors present targets that are sensitive to 
very high levels of ethanol and are likely responsible for high dose effects. 
 Numerous studies have implicated δ-containing receptors in the low dose effects of 
ethanol. The study of recombinant α4/α6δ-containing receptors in isolated cell systems 
showed that ethanol-induced tonic current potentiation was observed at concentrations of 
3mM-10mM [157] [158, 317]. Independent research groups also provided evidence of 
tonic current potentiation with ethanol (at concentrations ranging from 3-30mM) in 
cultured neurons and in neurons from brain slices ( from cerebellum- [318, 319] and also 
from the hippocampus – [320], [159, 179, 321]). Concentrations of 3-30mM are within the 
range of ethanol amounts that produce low levels of intoxication in humans.  
However, an equal number of research groups has failed to observe the effects of 
low doses of ethanol on α4/α6δ-containing receptors in neuronal cultures or recombinant 
receptors in isolated cell systems and in neurons from slice preparations [160, 322-324]. 
The reasons for these discrepancies have not been understood yet. While some of the 
proposed reasons include difficulties in expression of significant amounts of δ subunit in 
isolated cell systems, levels of endogenous neurosteroids, posttranslational modifications, 
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 phosphorylation states, etc. However, these reasons alone do not explain the differences in 
results obtained by different groups. 
Although the effects of ethanol on δ-containing receptors have not been resolved 
unequivocally, a fair amount of evidence suggests that these receptors may be involved in 
the behavioral effects of ethanol. In fact, the results obtained with Ro15-4513 on α4δ-
containing receptors and its ethanol antagonism [156, 262] observed at physiologically 
relevant concentrations of ethanol lean towards the possibility of α4/6δ-containing 
receptors as important targets for low dose effects of ethanol.  
In addition to potentiation of GABA-mediated current, changes in subunit 
expression have been observed following chronic ethanol treatment in multiple studies. 
Based on increased binding of the inverse agonist Ro-15-4513 after chronic ethanol 
treatment, increases in α4 and α6 subunits were predicted [325, 326]. The chronic ethanol 
treatment model by Olsen et al [178] provided detailed information about the changes 
occuring during chronic ethanol withdrawal. A reduction in α1 and δ subunits and an 
increase in α4 and γ2 subunits were reported in the hippocampus [178]. The change in α4 
subunit was greatest in the hippocampus even though this subunit is expressed in other 
brain regions. It is thought that the increase in α4 contributes to the increased seizure 
susceptibility during ethanol withdrawal based on the correlation between α4 levels and 
incidence of seizures in several other models [327-329].  Levels of α2 and α5 subunits in 
the hippocampus were not reduced [178, 330]. A change in localization of α4 subunits was 
observed from an extrasynaptic location to a synaptic location during ethanol withdrawal 
[331].   
In addition, a reduction in chloride flux was observed in the hippocampus but not in 
other brain regions such as cortex, striatum or cerebellum [176]. Hippocampal CA1 
58
 neurons and dentate gyrus granule neurons from CIE withdrawn rats showed reduced tonic 
current potentiation in reponse to ethanol, however high doses of ethanol continued to 
potentiate miniature inhibitory postsynaptic currents (mIPSC) [332]. This difference in 
sensitivity to ethanol is thought to underlie behavioral tolerance as well. Decrease in the 
benzodiazepine sensitive subunit α1 and increase in α4γ2-containing receptors in synaptic 
locations during ethanol withdrawal is thought to be responsible for the reduced sensitivity 
to classical benzodiazepines as well. The decrease in δ subunit is proposed to be 
responsible for the decreased response to neurosteroids during withdrawal. Thus, 
biochemical and functional changes in GABA A receptors during ethanol withdrawal likely 
mediate the behavioral responses. Thus, the α4 subunit is capable of a great deal of 
plasticity following ethanol exposure.  
A recent sudy demonstrated the role of α4 subunit-containing receptors in ethanol 
drinking behavior [333]. The nucleus accumbens is implicated in addictive behaviors 
associated with drugs of abuse such as ethanol [137, 334-336]. α4-δ-containing receptors 
are expressed robustly in the nucleus accumbens [337, 338] Knockdown of α4 mRNA in 
the nucleus accumbens shell decreased alcohol intake and preference [333]. Additionally, 
knockdown of α4 mRNA in the nucleus accumbens core did not influence alcohol 
preference or intake [333] indicating that α4-containing receptors in the nucleus 
accumbens shell, but not core, were critical for intitation of ethanol drinking behavior. 
Since the δ knockout mice also showed reduced alcohol intake [189], together, these 
studies imply that α4δ-  containing receptors could have a role in ethanol drinking 
behavior.  
The studies summarized above suggest a major role for α4-containing receptors in 
ethanol behavior. While these studies have advanced our understanding of changes during 
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 ethanol withdrawal and their consequences, resolution of the full spectrum of effects of 
alcohol is yet to be achieved.   
 
1.11 α4 global knockout mouse model: 
A global knockout (KO) of the α4 subunit in mice was engineered by Chandra et al [339]. 
These mice showed complete ablation of α4 subunit expression in thalamus, dentate gyrus, 
cortex and striatum [16]. KO mice were viable, reproduced normally and had no overt 
phenotypes [16].  
Electrophysiological studies revealed that picrotoxin-sensitive tonic conduction in 
the KO mouse brain was reduced by ~80% in thalamic relay neurons as well as dentate 
granule neurons compared to the WT [339]. In addition, a small but significant decrease in 
mIPSC rise and decay time constants was observed indicating a reorganization of synaptic 
receptors to compensate for the lack of α4-containing receptors. Response to gaboxadol (a 
novel sedative-hypnotic that is sensitive for extrasynaptic receptors; THIP) was ablated in 
the ventrobasal thalamic neurons, indicating insensitivity to this drug [339]. Consistent 
with this observation, the motor ataxic, sedative and analgesic effects of THIP were greatly 
reduced in the α4 KO mice compared to WT mice. In a pentylenetetrazole-induced seizure 
susceptibility assay, KO showed higher seizure susceptibility [339]. Studies with ethanol 
showed that tonic current potentiation by ethanol was reduced greatly in KO dentate 
granule neurons compared to WT [340].  
However, presumably due to reorganization of synaptic networks, ethanol sensitivity of 
mIPSC's was greatly enhanced in KO compared to WT [340]. Indeed, behavioral responses 
to acute ethanol-induced loss of righting reflex, motor ataxia and locomotor behavior did 
not differ between KO and WT [186]. In addition, ethanol metabolism and clearance was 
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 comparable between the genotypes [186]. Considering the proposed role of α4 in low dose 
ethanol effects, the finding that the KO mice had normal behavioral responses to ethanol 
was surprising. However, it is possible that the increased synaptic responses to ethanol 
observed in vitro may have masked a role for α4 in these behaviors. 
Ro15-4513, an inverse agonist which binds with high affinity at α4-containing receptors 
[340] was also tested for its effect in the α4 KO. Ro15-4513 has agonist activity at α4β3γ2 
receptors but does not modulate α4β3δ receptors [156, 283]. In dentate granule neurons 
from WT mice, Ro15-4513 potentiated the tonic current but had no effect on synaptic 
current [340]. This potentiation of tonic current was reduced dramatically in recordings 
from KO mouse neurons [340]. Synaptic responses to Ro15-4513 in the KO were not 
different from those in WT. Behavioral studies of ethanol antagonism by Ro15-4513 in α4 
KO mice revealed that while WT responded to Ro15-4513, KO mice did not show reversal 
of ethanol-induced motor ataxia and loss of righting reflex by Ro15-4513 (Fig. 1.2) [341]. 
This dramatic lack of response to Ro15-4513 in the KO indicates that α4 is critical for 
modulating the effects of this ethanol antagonist. This result is consistent with the 
hypothesis proposed by Olsen et al that α4-containing receptors may be the main site of 
action of Ro15-4513 [262]. This evidence forms the basis of experimentation with another 
ethanol antagonist, RY023, described in Chapter 3. 
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Figure 1.2 Ro15-4513 antagonism of ethanol-induced motor ataxia and loss of righting reflex 
α4 KO and WT mice did not differ in responses to ethanol alone at both doses as expected. However, Ro15-4513 
antagonism of ethanol-induced motor ataxia at two dose-combinations was greatly reduced in the α4 KO mice 
compared to WT. 
A. 3mg/kg of Ro15-4513 and 1.5 g/kg of ethanol (p≤ 0.001) 
B. 10mg/kg of Ro15-4513 and 2g/kg of ethanol (p< 0.05) 
Similarly, the loss of righting reflex responses to ethanol alone did not differ between genotypes. However, Ro15-
4513 antagonism of ethanol-induced loss of righting reflex differed significantly between sexes, hence males and 
females were analyzed separately. While WT mice of both sexes showed significant reductions in their sleep times 
with Ro15-4513, male and female α4 KO mice were not responsive to the ethanol-antagonizing effect of Ro15-4513. 
C. Ro15-4513 antagonism of ethanol-induced LORR in Males  
D. Ro15-4513 antagonism of ethanol-induced LORR in Females  
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 Analysis of the universal GABA agonist, muscimol, in α4 KO mice revealed a 
reduction in binding of muscimol in areas of α4 expression such as caudate putamen, 
thalamus and hippocampus [342]. In addition, the motor-ataxic effects of muscimol were 
reduced in the α4 KO implying that at least some effects of muscimol were mediated 
through α4-containing receptors [342]. Muscimol has long been regarded as a universal 
agonist of all GABA A receptors. The study with α4 KO mice suggests that rather than 
being a universal agonist, muscimol acts on specific high affinity sites to mediate its 
effects, with α4-containing receptors being one of them. 
Isoflurane at low concentrations (25-250µM) was found to potentiate tonic currents 
from ventrobasal thalamic neurons in WT but not in KO [343]. At higher concentrations 
(250-500µM), synaptic currents (mIPSC's) were potentiated similarly in both WT and KO. 
Because tonic currents have been implicated in the effects of anesthetics, it is possible that 
the changes observed at the cellular level may translate behaviorally. Fear conditioning 
assays evaluating the amnestic effects of isoflurane were conducted by our collaborators 
(Dr.Vinuta Rau, Dept. of Anesthesiology, University of California, San Francisco, CA) 
[344]. Amnestic effects of isoflurane were reduced in α4 KO [344] implying that they were 
resistant to the effects of isoflurane (Fig. 1.3). Thus a reduction in response to isoflurane 
was observed at the behavioral level. Hence it was likely that other behavioral effects of 
isoflurane may also be changed in the α4 KO. This  
hypothesis was tested in Chapter 2. 
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Alphaxalone, a synthetic neurosteroid anesthetic, potentiated the magnitude of tonic 
current and synaptic current in WT but both tonic and synaptic current potentiation were 
reduced significantly in the KO [340]. This observation raises the possibility of α4 KO 
mice being resistant to the effects of neurosteroids. The reduction in behavioral responses 
to neurosteroids in the δ KO mice [17] also tips the balance in favor of α4 KO mice having 
reduced reponses to neurosteroids. The possibility of α4 KO mice have reduced behavioral 
responses to the neurosteroid, anesthetic, alphaxalone has been evaluated in Chapter 2.  
Lastly, taurine, an endogenous amino acid that is also a GABA- and glycine-
mimetic was studied for its effects on GABAergic current modulation in α4KO and WT. 
A. 
 
B. 
 
 
Figure 1.3 Amnesic effects of isoflurane in WT and α4 KO mice  
Because a sex difference was observed, males and females were assessed separately. 
(A) KO females appear resistant to the amnesic effects of isoflurane (WT EC50 = 0.08±0.03%; 
KO EC50 = 0.28 ± 0.03%; p < 0.005 ) 
(B) Because baseline freezing scores were different between WT and KO males, freezing was 
equated by changing tha training paradigm for KO. Following exposure to isoflurane at 0.16% 
and 0.52%, a genotypic difference was noted (p< 0.05) 
Rau,V.,Iyer,SV.,Oh,I.,Chandra,D.,Harrison.,NL.,Eger,EI.2nd,Fanselow,MS.,Homanics,GE., 
Sonner,JM, GABA type A receptor α4 subunit knockout mice are resistant to the amnestic 
effects of isoflurane. Anesth Analg, 2009. 109 (6): p.1816-22. 
64
 Previously, it was thought that taurine had greater activity at glycine receptors and was less 
potent at GABA A receptors. However, only synaptic combinations of GABA A receptor 
were previously tested.  The landmark study by Jia et al, showed that contrary to prior 
belief, taurine acted potently at extrasynaptic GABA A receptors [234]. Also, ventrobasal 
thalamic neurons from α4 KO mice showed reduced current potentiation by taurine 
compared to WT mice over a range of taurine concentrations. A recent study by Granadoz 
et al showed that taurine treatment alleviated handling-induced convulsions in mice that 
received continuous chronic ethanol treatment [233]. Given the plasticity of α4-containing 
receptors during ethanol withdrawal  (see review [345] and the evidence tying the actions 
of taurine to α4 receptors [234], the withdrawal- alleviating effects of taurine could be 
mediated through these receptors. This forms the basis for Chapter 4 in which the effects of 
taurine on ethanol withdrawal behavioral were assessed. 
Because α4 has robust expression in the hippocampus, α4 KO and WT mice were 
tested for differences in learning and memory. An enhancement of hippocampal-dependent 
learning and memory was observed in α4 KO mice compared to WT mice [346]. Sex 
differences were also noted with KO females exhibiting enhanced memory compared to 
KO males. The significance of this sex difference in memory is not well-understood but it 
is hypothesized to reflect increased defensive behavior in female rodents [347, 348]. A role 
for differences in endogenous neurosteroid sensitivity is also hypothesized to underlie the 
enhanced memory in females. This finding is particularly significant in light of the recent 
study by Shen et al, demonstrating a role for α4βδ-containing receptors in learning during 
puberty [290]. Pubertal δ KO mice were successful in learning a hippocampal-dependent 
spatial task that WT mice were unable to [290]. Thus, α4δ-containing receptors may be 
relevant for sex specific differences in memory and learning. 
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 Lastly, deletion of the α4 subunit resulted in compensatory responses in the α4 
global knockout mice [349, 350]. An increase in γ2 subunits and a decrease in δ subunit 
were observed [349, 350]. Immunogold labeling studies of the δ subunit revealed the 
presence of δ subunits in the cytoplasm, specifically in the endoplasmic reticulum and 
Golgi complex of thalamic neurons [349, 350]. This indicates that the lack of α4 subunit 
affects the trafficking of δ subunits to the membrane surface. This implies that the levels of 
functional δ-containing receptors are reduced in the α4 KO mice. This finding has 
implications for ethanol and neurosteroid induced behaviors where α4δ-containing 
receptors play an important role. The reduction in tonic current in the α4 KO mice could 
thus arise in part by reductions in δ subunit containing receptors. In addition to γ2 subunits, 
α1 and α2 subunits were also increased [350]. This increase was greatest in those regions 
with the least amount of change in surface expression of δ subunits. This indicates the 
possibility of novel α1βδ or α2βδ receptor combinations. In fact, α1δ- containing receptors 
have been discovered in the hippocampus of both WT and α4 KO mice [320]. These 
receptors were found to mediate tonic currents that were potentiated by low doses of 
ethanol [320]. Such changed receptor combinations could also affect behavioral responses 
in the α4 KO mice.  
1.12 Gaps in our knowledge: 
Although a lot is known about changes in α4 receptor levels at the biochemical and 
cellular level, the behavioral implications of these changes are not clearly understood. 
Because of the regions of expression of α4-containing receptors (thalamus and 
hippocampus) and the role of tonic currents in anesthetic actions, it would be interesting to 
determine if anesthetic sensitivity is changed in α4 KO mice. The lack of potentiation by 
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 isoflurane in the α4 KO [343] points towards this possibility. The widespread expression of 
the α4 subunit and its combination with β3 and β2 subunits, (each of which have been 
implicated in intravenous anesthetic actions, [15, 82]) gives rise to speculations about the 
role of α4 subunit-containing receptors in intravenous anesthetic actions. The thalamus has 
been implicated as an important player in sleep mechanisms [351]. Additionally, tonic 
current mediated by ventrobasal thalamic neurons are thought to regulate natural sleep 
pathways [352]. Because sedation and unconsciousness caused by anesthetics are thought 
to overlap with natural sleep pathways, it is possible that α4-containing receptors could 
modulate these effects.  
The dramatic decrease in response to neurosteroids in the δ KO mice indicated that 
δ receptors were important modulators of steroid effects [17]. By virtue of their partnership 
with δ subunits [38, 337], α4 subunits could also have a critical role in neurosteroid 
modulation. Additionally, fluctuating steroid levels during physiological processes such as 
ovarian cycle changes and pregnancy have been accompanied by changes in levels of α4 
subunit as well [289]. δ KO mice showed a reduction in levels of α4 subunit protein [353]. 
Therefore, the reduction in behavioral responses to neurosteroids could have been, in part, 
due to reduced α4 levels as well. Therefore, the relative contributions of α4 subunit and δ 
subunit remains to be dissected.  
Based on this evidence, I hypothesize that α4-containing receptors are a site of 
action for the effects of anesthetics and neurosteroids. Different behavioral endpoints will 
be assessed in α4 KO and WT mice with anesthetics and with neurosteroids to investigate 
the role of α4 containing receptors in anesthetic effects. Understanding the effects of 
neurosteroids in α4 KO mice and contrasting them against results obtained in the δ KO will 
allow determination of the relative role of α4 subunit in neurosteroid actions. 
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 Could α4 subunit-containing receptors be a target for ethanol antagonism? Again, 
α4-containing receptors have been implicated in acute low dose effects of ethanol [156, 
158]. As inferred from the reduced effects of Ro15-4513 in α4 KO (Fig. 1.2), these 
receptors are a site of action for reversal of ethanol effects. Analogs of Ro15-4513 that 
antagonize the effects of ethanol could function via the same mechanism. Evaluating this 
possibilty will open up opportunities for development of newer, more specific ethanol 
antagonists. To understand if α4-containing receptors are a universal target for all known 
ethanol antagonists, I propose to test another ethanol antagonist, RY023, in WT and α4 KO 
mice. Both intrinsic effects and ethanol antagonistic effects of RY023 on different 
behaviors will be assessed in WT and KO mice. 
α4 exhibits remarkable plasticity during ethanol withdrawal (see review, [345]). In 
fact, increases in α4 during chronic ethanol withdrawal are concurrent with the behavioral 
endpoints of withdrawal such as seizure susceptibility and tolerance to ethanol and classical 
benzodiazepines. Could the lack of α4-containing receptors affect ethanol withdrawal 
behavior? Alternately, could the increase in α4 seen during ethanol withdrawal be 
harnessed to treat withdrawal symptoms better? Because α4-containing receptors have 
been implicated in seizure susceptibility and are benzodiazepine-insensitive, novel drugs 
that increase inhibitory neurotransmission through α4-containing receptors could be used 
to alleviate withdrawal.  Recent evidence links taurine to α4 receptors [234] and the fact 
that taurine alleviates withdrawal seizures [233] suggests that taurine could be acting on 
increased α4 receptors during ethanol withdrawal.  
To assess this possibility, I propose studying chronic ethanol withdrawal responses 
in α4 KO and WT mice with and without taurine. This will allow us to understand the role 
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 of α4 containing receptors in ethanol withdrawal as well as the role of α4-containing 
receptors in taurine-induced alleviation of withdrawal. 
Thus, a great deal of evidence ties α4-containing receptors to anesthetic, 
neurosteroid and ethanol effects and determining these effects could resolve conflicts about 
our understanding of the role of α4 GABA A receptors. Pursuit of such information will 
advance our knowledge of the mechanism of action of anesthetics, neurosteroids, ethanol, 
ethanol antagonists and taurine.  
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 1.13 Dissertation: 
Specific Aims:  
Anesthetics are thought to exert at least some of their effects via the GABA A 
inhibitory system. Anesthetics bring about a spectrum of effects that consist of sedation, 
immobilization, analgesia and amnesia. The various components of the anesthetic state are 
thought to be mediated by discrete targets in the central nervous system [354]. Our 
understanding of the mechanism of action of currently used anesthetics is far from 
complete.  
Like, anesthetics, alcohol is also thought to mediate some of its effects through 
GABA A receptors. Alcoholism is a major problem worldwide. 85,000 deaths in the US 
alone, are attributable to alcohol consumption, annually [355]. Alcohol consumption is 
associated with a number of social evils such as aggression, accidents, and domestic 
violence. The acute effects of alcohol include anxiolysis, sedation, ataxia, hypnosis, 
analgesia and amnesia. Chronic effects of ethanol are more severe, characterized during 
withdrawal by hyperactivity of the CNS [3]. Our understanding of the mechanism of action 
of both anesthetics and alcohol is limited.  
I am interested in understanding the contribution of a specific GABA receptor 
subunit, α4, to anesthetic and ethanol action. Extrasynaptic and synaptic GABAA receptors 
containing the α4 subunit are widespread in the thalamus and the dentate gyrus, and lower 
levels are present in the cortex and striatum [339]. The thalamus is considered as a region 
of major sensory flux in addition to being responsible for states of sleep, consciousness and 
a motor center, whereas the dentate gyrus is associated with memory. Therefore, it may be 
inferred that the anatomical localization of the α4 subunit correlates with those areas that 
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 are responsible for mediating the effects of anesthetics and alcohol on behavior such as 
amnestic effects (hippocampus) and sedative and sensory effects (thalamus).  
An α4 KO mouse model was created in the Homanics Lab [16]. 
Electrophysiological studies on the ventrobasal thalamocortical neurons and dentate 
granule cells in the α4 KO mice indicated reduced sensitivity to isoflurane and 
alphaxalone, respectively [186, 356]. In α4 KO mice, tonic current potentiation by Ro15-
4513 was ablated. Additonally, behavioral studies revealed that α4 KO mice were resistant 
to the ethanol-reversing action of Ro15-4513 on ethanol-induced motor ataxia and loss of 
righting reflex.  
In the mid 1990's, the interest in Ro15-4513 as a putative ethanol antagonist 
resulted in a series of drugs being synthesized that had similar ethanol-antagonist actions 
[251]. RY023 was one such drug that antagonized the behavioral effects of ethanol [253, 
357]. While the drug shows high affinity for α5 containing receptors, its involvement with 
α4δ-containing receptors has not been evaluated [253]. In light of new knowledge of Ro15-
4513's actions on α4-containing receptors, I hypothesize that like Ro15-4513, RY023 also 
exerts its actions preferentially through α4-containing receptors.  
α4 subunit levels undergo upregulation during ethanol withdrawal [178, 181, 358, 
359]. Further, the α4 subunit inserts synaptically instead of the α1 subunit [358]. These 
changes may be responsible for ethanol withdrawal behavior. Ethanol actions in the CNS 
can also be modulated by concurrent administration of taurine. Taurine is a chloride current 
modulator and acts on both glycine and GABA receptors. Taurine is believed to exert a 
protective effect during ethanol withdrawal [360].  
Recent evidence indicates that taurine is more potent at extrasynaptic GABA 
receptors than synaptic GABA or glycine receptors. In fact, studies by Jia et al,  revealed 
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 that the α4 subunit may be the site of action of taurine and that α4KO did not show tonic 
current potentiation with taurine [234].  
Overall, my aim is to elucidate the contribution of α4 subunit containing GABA 
receptors to anesthetic, ethanol-antagonistic (RY023), chronic ethanol withdrawal and 
taurine effects. I propose to do this by studying behavioral effects of anesthetics, RY023 
and taurine in mice deficient in α4 GABA A receptors and compared their responses to 
WT controls.  
I hypothesize that the α4 subunit is essential for: 
1) Behavioral response to anesthetics  
2) ethanol antagonist behavioral responses 
3) chronic ethanol withdrawal-induced behavioral effects 
4) taurine-induced suppression of chronic ethanol withdrawal symptoms 
 To test these hypotheses I propose the following aims:  
Specific Aim 1A: To elucidate the role of the α4 subunit in the behavioral effects of 
volatile anesthetics.  
WT and KO mice will be compared for the behavioral effects of inhaled anesthetics, 
halothane and isoflurane, using the loss of righting reflex and tail clamp/withdrawal assays.  
Specific Aim 1B: To elucidate the role of the a4 subunit in the behavioral effects of the 
intravenous anesthetics, etomidate, propofol and the neurosteroid anesthetic, alphaxalone. 
The behavioral effects of intravenous anesthetics (alphaxalone, etomidate, propofol) will be 
evaluated by examining ataxia (rotarod), hypnosis (sleep time), and locomotor effects 
(open field). 
Specific Aim 2: To determine if a4 is essential for the ethanol antagonist action of RY023 
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 Antagonistic effects of a RY023 on acute ethanol will be evaluated on two behavioral 
parameters. Ethanol-induced motor ataxia (rotarod) and ethanol-induced loss of righting 
reflex will be studied for antagonism by RY023. In addition, the role of α4 GABA A 
receptors in the intrinsic effects of RY023 (on motor ataxia and sedation) will be studied by 
comparing the genotypes following injection of RY023 alone. 
Specific Aim 3: To evaluate the role of α4-containing receptors in chronic ethanol 
withdrawal behaviors and in mediating taurine-induced supression of chronic ethanol 
withdrawal behaviors. 
α4-containing receptors have been implicated in ethanol actions. These receptors are very 
sensitive to low physiologically relevant concentrations of ethanol and they undergo 
changes in expression and relocalization during ethanol withdrawal. The characteristic 
changes in behavior during withdrawal suggest that changes in α4-containing receptors 
play a role in ethanol withdrawal effects. In addition to a role for α4 in withdrawal, literary 
evidence also indicates that taurine has a protective effect during ethanol withdrawal and 
that taurine modulates current through the α4 subunit.  
Hence, to assess these possibilities, α4 KO mice will be assessed for differences in chronic 
ethanol withdrawal behavior. Seizure susceptibility (handling induced convulsion scoring; 
HIC), locomotor changes (open field) and protracted tolerance (ethanol-induced loss of 
righting reflex) will be assayed. In addition, the effect of taurine on these withdrawal 
parameters will be studied concurrently in these mice.  
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 Chapter 2.0: Role of α4-containing GABA A receptors 
in behavioral responses to general anesthetics 
NOTE: Portions of this chapter have been published [344] and some sections are 
reproduced here verbatim - these sections have been denoted in italics. 
2.1 Introduction  
 Anesthetics cause a variety of desirable effects such as unconsciousness, 
immobilization and amnesia. The mechanism underlying these effects is unknown. In 
addition to their desirable effects, anesthetics also cause severe side effects in a small 
percentage of the population. The manifestation of these side effects in some but not all 
people is thought to result from differences in targets of anesthetics. For example, 
differences in gene expression profiles in different populations may cause the decreased or 
increased presence of an anesthetic-sensitive target. Hence, understanding how anesthetic 
effects are mediated will provide some answers as to the molecular targets of these drugs. 
α4-containing GABA A receptors are expressed at high levels in dentate gyrus of 
hippocampus, thalamus, cortex and striatum [337]. They mediate tonic inhibitory current 
which is thought to play an important role in regulating neuronal excitability [11]. Tonic 
current has special significance for processes such as memory, sleep, motor coordination, 
etc. The thalamus in particular is involved in modulation of sleep and consciousness in 
addition to serving as a sensory gateway along with the cortex [361-364]. The 
hippocampus is implicated in processes of learning, memory and anxiety [112]. The 
location of α4-containing receptors and the fact that they conduct tonic currents make them 
attractive targets for the effects of anesthetics.  
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 It was previously demonstrated that α4-containing extrasynaptic receptors are 
essential for the cellular and behavioral responses of the sedative/hypnotic, THIP [16, 365]. 
α4 KO mice showed reduced sensitivity to THIP-induced motor ataxia, loss of righting 
reflex, and analgesia [16]. Recently, Jia et al [343] demonstrated that α4-mediated 
extrasynaptic inhibition in the ventrobasal thalamic neurons was markedly enhanced by 
isoflurane, and this enhancement was absent in α4 KO mice [343]. Based on these studies, 
it was hypothesized that as with gaboxadol, α4-containing receptors may mediate some of 
the behavioral effects of isoflurane.  
α4 subunits are often co-assembled with β3 and/or β2 subunits (and a γ or δ 
subunit) either in synaptic or extrasynaptic locations. The β3 subunit has been implicated in 
the effects of etomidate and propofol-induced LORR. A β3 KI (N265M) mouse model 
revealed that the mutant mice were resistant to the hypnotic and immobilizing actions of 
etomidate and propofol [15]. The subsequent generation of a β2 KI (N265M) mouse also 
revealed that the sedative actions of etomidate but not propofol were mediated by β2-
containing receptors [82]. A recent study proposed that the binding site for etomidate lies at 
the interface of an α and a β subunit at transmembrane sites [366]. The identity of the α 
subunits that pair with β2/β3 subunits to mediate the effects of etomidate are unknown at 
present. It has been proposed that ~50% of α4 subunits form binary receptors in 
combination with β1-3 subunits [269]. Additionally, recombinant receptors expressing 
binary α4β3 receptors were responsive to current modulation by etomidate [367].  Hence, 
it is possible that α4 subunits are important for the actions of intravenous anesthetics. 
While the contribution of β subunits to the actions of intravenous anesthetics etomidate and 
propofol is now known, the contribution of the partnering α subunit is not clearly 
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 delineated. Therefore, I hypothesize that α4-containing receptors are essential for the 
actions of etomidate and propofol.  
α4-containing receptors have also been implicated in neurosteroid effects. α4 
subunits combine with δ subunits to form extrasynaptic receptors that are uniquely 
sensitive to neurosteroids [282, 283, 295, 368] and show modulation by varying levels of 
endogenous neurosteroids (see reviews [287, 289]. α4δ-containing receptors have special 
significance in steroid hormone effects (e.g., premenstrual syndrome [288], post-partum 
depression[311], pregnancy [286], and learning during puberty [290]). Preventing the 
cycling of δ-containing receptors via antisense RNA techniques resulted in increased 
excitability during diestrous phase of the ovarian cycle [288]. This was consistent with a 
role for δ-containing receptors in catamenial epilepsy and anxiety during premenstrual 
dysphoric disorders. A global knockout of the δ subunit resulted in mice that had 
dramatically reduced sensitivity to neurosteroids both at the cellular and behavioral level 
[17, 369]. In addition, the δ KO mice failed to show reductions in neuronal excitability 
during pregnancy [286], suggesting that the lack of δ-containing receptors led to an 
inability to regulate homeostatic neuronal control. This in turn was thought to be 
responsible for psychiatric disturbances during pregnancy and post partum. Consistent with 
this, δ KO mice showed evidence of postpartum depression and poor maternal behavior 
[311]. Because the α4 subunit is commonly paired with the δ subunit, it was hypothesized 
that α4 itself may contribute in some measure to the behavioral effects of neurosteroids.  
In this chapter, I report on studies that tested the hypothesis that α4-containing 
receptors are critical for the behavioral effects of volatile anesthetics (halothane and 
isoflurane), intravenous anesthetics (etomidate and propofol) and the neurosteroid 
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 anesthetic (alphaxalone). To do this, I compared behavioral responses to these drugs in WT 
and KO mice. 
2.2 Materials and Methods  
Homozygous α4 KO and WT littermate controls were created by breeding heterozygous 
mice that possessed only one copy of the GABA A receptor α4 subunit allele [16]. Mice 
were of the F3–4 generations, and their genetic background was a mixture of C57BL/6J 
and Strain 129S1/X1. Mice were genotyped using Southern Blot analysis of tail DNA at 
weaning, as previously described [16]. Mice were group housed, kept on a 12-h alternating 
light/dark cycle, and allowed access to food and water ad libitum. For all experiments, 
both sexes of mice were used for experimentation unless otherwise stated. Due to limited 
numbers, analysis of results by sex was not performed unless stated. All protocols were 
approved by the committee on animal care and use at the University of Pittsburgh.  
2.2.1 Volatile anesthetic-loss of Righting Reflex (LORR) 
Mice of both sexes (10-20 weeks of age) were tested for isoflurane (n=11-13 per genotype) 
and halothane (n=16 per genotype) -induced loss of righting 
reflex. For each LORR determination, six to eight unrestrained mice were placed in 
individual wire-mesh cages mounted on a carousel in a sealed Plexiglas chamber 
maintained at 33–35°C. Soda lime scattered on the chamber floor maintained the ambient 
CO2 tension at <0.05 atmosphere. Controlled concentrations of halothane (Halocarbon 
Laboratories, River Edge, NJ) or isoflurane (Abbot Laboratories, North Chicago,IL) were 
delivered to the testing chambers by means of agent-specific vaporizers. A Datex 
Capnomac Ultima device continuously monitored the concentration of anesthetic gas 
within the chamber. The mice were equilibrated with anesthetic for 15 minutes and then 
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 scored for the righting reflex while the carousel rotated at 4 rpm. After testing at one 
concentration of anesthetic, the mice were allowed to recover in anesthetic-free air for 20 
min. Anesthetic gas concentrations tested ranged from 0.6%- 
1.1% atm with an increment of 0.1% in each trial.  
2.2.2 Minimum Alveolar Concentration (MAC) of volatile anesthetics:  
Mice (10-20 weeks of age) were monitored for response to noxious stimuli in the presence 
of isoflurane (n= 26-27 per genotype) and halothane (n=16 per genotype) using the tail 
clamp-withdrawal assay. Briefly, mice were equilibrated with anesthetic agents in a 
heated, enclosed chamber. The monitoring of chamber temperature, FIO2 (inspired oxygen 
concentration), and anesthetic concentrations were similar to procedures used for the 
LORR assay. Following equilibration with anesthetic, a hemostat was applied to the tail 
and the mouse was scored for purposeful, gross movement in response to the tail clamp. A 
positive response was defined as the lack of any movement to the noxious stimulus, i.e., the 
tail clamp. Mice were allowed to recover for 15 minutes in air before testing at the next 
concentration. The range of concentrations tested was 1.0%-1.8% with 0.2% increments.  
For LORR and MAC assays, half maximal effective concentration values (EC50) 
were obtained from concentration response curves using the iterative nonlinear least-
squares method for quantal responses [370]. The Z statistic was used to compare 
genotypes on both assays. Males and females were combined for analysis owing to limited 
number of mice. Previous experiments have shown that sexes do not differ in their 
responses to these anesthetics.  
 2.2.3 Recovery of Righting Reflex (RORR) with volatile anesthetics:  
Mice (12-20 weeks of age, n=7-11 per genotype) were exposed to 1.4% atm of each 
anesthetic for one hour inside a sealed plexiglass chamber. Thirty minutes into the 
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 exposure, mice were placed on their backs and exposure resumed for the remainder of the 
hour. Following this, the gas was turned off, the exhaust fan was turned on and pure 
oxygen was allowed to flow into the chamber at a flowrate of 5L/min. The time for the 
mice to right themselves was recorded. During the experiment, normothermia was 
maintained by a heat lamp. Data were analyzed by one-way ANOVA with genotype as 
main effect.  
2.2.4 Intravenous anesthetic-induced LORR: 
Drug Solutions: 
Etomidate (Amidate, 2mg/ml, Hospira Inc., Lake Forest, IL), propofol (Diprivan, 10mg/ml, 
Astra Zeneca, Wilmington, DE),  and alphaxalone (Cat. No. P5052, Sigma Aldrich, 
St.Louis, MO) were used. Alphaxalone was solubilized in 22.5% β-hydroxycyclodextrin 
(Cat. No. H107, Sigma Aldrich, St.Louis, MO) and sonicated to arrive at a stock 
concentration of 7mg/ml. All injections were administered intraperitoneally (i.p.) except 
propofol which was administered by the retro orbital (r.o) route. 
Age-matched mice (8-20 weeks) of both genotypes and sexes were injected with 
propofol (40mg/kg, r.o., 0.004ml/g body weight, n=8-15 per genotype), etomidate 
(20mg/kg, i.p., 0.01ml/g body weight, n=10-13 per genotype) or alphaxalone (70mg/kg, 
i.p., 0.01ml/g body weight, n=20 per genotype) for the LORR assay. Immediately after 
they lost their righting reflex, mice were placed supine on a V-shaped plexiglass trough 
until recovery. A heat lamp was used to ensure that body temperatures were maintained 
throughout the experiment. Endpoint of time to return of righting reflex was determined by 
ensuring that a mouse was able to right itself consecutively three times within 30 seconds. 
For these assays, mice that had durations of LORR greater or lower than two standard 
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 deviations from the mean were excluded from the analysis. Data were analyzed by one-way 
ANOVA with genotype as main effect. 
2.2.5 Recovery from injectible anesthetic-induced motor ataxia: 
Mice were tested for recovery of motor ataxia with etomidate, propofol and alphaxalone. 
All training and testing was performed on a fixed speed rotarod (Ugo Basile 7650, Varese, 
Italy) at 8RPM.  
A) Etomidate (Amidate) 
Only male mice were used for this assay. Mice were trained on the day of the test to a 
criteria of 120 sec on fixed speed rotarod at 8RPM. Training trails were spaced 20 minutes 
apart and at least 4 such trials were administered. Mice that did not achieve the criterion 
were excluded from the assay. Following training, etomidate was injected (i.p., 0.01ml/g 
body weight) at 20mg/kg. Mice lost their righting reflex briefly. Upon recovery they were 
tested on the rotarod every 20 minutes until recovery to baseline performance (120 sec) 
was regained.  Area under the curve (AUC) was measured as the area between baseline 
performance (120sec) and the impairment produced by etomidate over the time course of 
the experiment. AUC were compared by one-way ANOVA with genotype as main effect.  
B) Propofol (Diprivan)  
Mice were trained on the previous day to a criterion of 100 sec. Each mouse was given at 
least 4 trials to ensure that the task was learned. The inter-trial duration was 5 minutes. 
Once training was complete, mice were housed overnight in the testing room in their home 
cages. On the test day, mice were subjected to 2-3 trials to confirm compliance to criteria. 
Subjects that did not achieve the criterion of 100sec consecutively on the rotarod were 
excluded from the test. Following this, propofol was administered at 25mg/kg, retro-
orbitally (0.005ml/g body weight) by diluting the clinical preparation with saline to a 
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 concentration of 5mg/ml. Mice briefly lost their righting reflex. Following recovery of 
righting reflex, mice were placed on the rotarod at intervals of 5 minutes until recovery to 
baseline performance (100 sec) was regained. Area under the curve (AUC) was measured 
as the area between baseline performance (100 sec) and the impairment produced by 
propofol over the time course of the experiment. AUC were compared by one-way 
ANOVA with genotype as main effect.  
C) Alphaxalone  
On the day of the experiment, mice were subjected to training trials on a fixed speed 
rotarod. At least 4 training trials were administered at 10 minute intervals so that mice 
achieved a criterion of 180 sec on the rotarod. Mice that did not achieve a performance of 
180 sec on the rotarod at least three times consecutively were excluded from the assay. 
Alphaxalone was solubilized in 22.5% β-hydroxycyclodextrin and injected at 50mg/kg 
(i.p., 0.01ml/g body weight). Mice were tested every 10 minutes after injection until 
recovery to baseline performance (180 sec) was achieved. Area under the curve (AUC) was 
measured as the area between baseline performance (180 sec) and the impairment produced 
by alphaxalone over the time course of the experiment. Results were analyzed by one way 
ANOVA with genotype as main effect. 
 
2.2.6 Intravenous anesthetic-induced changes in locomotor behavior: 
          A) Etomidate was diluted with saline to a concentration of 0.3mg/ml. The sedative 
effects of etomidate were evaluated at a dose of 3mg/kg for a period of 10 minutes by an 
open field assay. Mice were placed in the testing room one day prior to the experiment. On 
the morning of the experiment, mice were weighed and then injected with etomidate (i.p., 
0.01ml/g body weight) and placed separately in new cages. Five minutes later, mice were 
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 placed in the center of a plexiglass walled arena each, (43.2 cm X 43.2 cm X 30.5 cm) for 
automated recording of locomotor behavior. The chambers were located within sound-
attenuating cubicles (Med Associates, St.Albans, VT) that were provided with a red light 
and a fan (top right corner). Distance traveled (cm) over a 10 minute period was recorded 
by an automated program (Med Associates, St.Albans, VT). Between mice, the chambers 
were cleaned with 70% ethanol followed by water to remove any evidence of smells and 
excrements left behind. Because baseline (saline) scores did not differ between genotypes 
[16] in this assay, only drug-induced behavior was measured between genotypes. Data 
were analyzed by one way ANOVA. Only males were used in this assay. 
   B) Alphaxalone was diluted with 22.5% β-hydroxycyclodextrin and sonicated to 
make a solution of 1.5 mg/ml. The locomotor stimulatory effect of alphaxalone (15mg/kg) 
or vehicle (22.5% HBC in saline) was tested 10 min after injection in the open field. 
Activity was recorded for a period of 10 min as described above. Total distance covered 
over a 10 min period and distance covered in the center zone were measured. The center 
zone was demarcated as the central portion of the open field (11.25 X 11.25cm). Center 
zone activity was expressed as percent distance covered in center zone.	  For this assay, if 
total distance was greater or lower than two standard deviations from the mean, mice were 
excluded from the analysis. 
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 2.3 Results: 
 2.3.1 Effects of Isoflurane and Halothane on LORR: 
For isoflurane-induced LORR (Fig. 2.1 A), the EC50 for WT (0.73 ± 0.02) and KO (0.74 ± 
0.02) mice did not differ. For halothane-induced LORR (Fig.2.1 B), the EC50 for KO mice 
(0.90 ± 0.01) was increased (p<0.05) compared with WT controls (0.84 ± 0.02).      
  2.3.2 Effect of Isoflurane and Halothane on MAC: 
WT and KO mice did not differ in their isoflurane MAC (Fig.2.1 A) (WT EC50 =1.45 ± 0.03 
vs. KO =1.37 ± 0.03). Similarly, genotype did not affect response to halothane (Fig.2.1 B) 
on this assay (WT EC50 = 1.61 ± 0.03 vs. KO EC50 = 1.59 ± 0.03). 
  
 B.                           Halothane 
 
 A.                        Isoflurane 
 
Figure 2.1 Loss of righting reflex (LORR) and minimum alveolar concentration (MAC) 
(A) Isoflurane: Concentration response curves did not differ between WT and KO on isoflurane-
induced LORR and MAC 
(B) Halothane: With halothane, a small but significant difference was observed on the LORR assay. 
No difference was observed between genotypes on halothane-induced MAC.  
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 2.3.3 Effects of Isoflurane and Halothane on RORR: 
A one-way ANOVA showed that WT and KO mice did not differ in their mean recovery 
time with isoflurane- and halothane-induced loss of righting reflex at 1.4% atm. Time taken 
by WT to recover from isoflurane was 7.13 ± 1.16 min. KO mice were comparable in time 
to recovery as well (KOmean recovery time = 7.02 ± 1.42 min). Similarly, time taken to recover 
from a 1.4% atm concentration of halothane did not differ between the genotypes (WTmean 
recovery time = 8.15 ± 1.07 min vs. KOmean recovery time = 9.6 ± 0.88 min). 
2.3.4 Etomidate- and propofol - induced LORR: 
The duration of LORR with etomidate is depicted in Figure 2.2 A. For etomidate-induced 
LORR, a two way ANOVA by sex and genotype revealed an an effect of sex (F (1,20) = 
5.4; p < 0.05). Hence, males and females were analyzed separately.  
A.                              Etomidate 
 
B.                             Propofol
 
 
 Figure 2.2. Loss of righting reflex with injectible anesthetics - etomidate and propofol 
(A) A 20mg/kg dose of etomidate produced loss of righting reflex in both WT and KO. Since an overall 
ANOVA elicited an effect of sex, the genotypes were analyzed separately. However, no differences 
were seen between genotypes within either sex.  
(B) Propofol, 40mg/kg, produced loss of righting reflex in both WT and KO mice No differences were 
observed between genotypes.  
Data are expressed as mean ± SEM. 
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 Genotypes did not differ in response to etomidate within either sex. Propofol-induced 
LORR is depicted in Figure 2.2 B. A one-way ANOVA revealed no differences between 
WT and KO on the duration of LORR with propofol.  
 
2.3.5 Alphaxalone induced-LORR  
The LORR effect of the neurosteroid anesthetic, alphaxalone, was compared between WT 
and KO mice. A one-way ANOVA indicated that alphaxalone-induced LORR did not 
differ between genotypes. (Fig. 2.3)  
 
 
 
 
 
 
 
 
 2.3.6 Etomidate- and propofol - induced ataxia: 
To test if α4 plays a role in motor ataxic effects of intravenous anesthetics, the motor-
impairment caused by 20mg/kg of etomidate and 25mg/kg of propofol was tested.  
 
 
 
Figure 2.3 Loss of righting reflex with Alphaxalone 
Alphaxalone-induced loss of righting reflex at 70mg/kg did not differ between WT and α4KO mice.  
Data are expressed as mean ± SEM. 
 
85
 The time course of performance on rotarod after etomidate (Fig. 2.4 A) and 
propofol (Fig. 2.4 B) administration in both WT and KO are shown. A one-way ANOVA 
analysis of AUC for performance on rotarod with etomidate showed no differences 
between the genotypes. Similarly, with propofol, one-way ANOVA did not yield a 
difference between genotypes.  
  
  
2.3.7 Alphaxalone-induced ataxia: 
The motor-incoordinating effects of alphaxalone on WT and α4 KO were assessed (Fig. 
2.5). A one-way ANOVA on the AUC for performance on rotarod did not show significant 
differences between genotypes.  
Figure 2.4 Motor ataxic effects of injectible anesthetics, etomidate and propofol 
A. Etomidate, 20mg/kg, produced motor ataxia in WT and KO mice. No genotypic differences were 
noted. 
B. Propofol, 25mg/kg, also produced motor ataxia in WT and KO mice. No genotypic differences 
were observed. 
  Each time point represents mean performance ± SEM 
A.                           Etomidate 
 
 B.                              Propofol 
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2.3.8 Etomidate-induced locomotor behavior: 
To test the hypothesis that low dose effects of etomidate are mediated by α4-containing 
receptors, sedative effects of etomidate were assesed by the open field assay (Fig.2.6). Pilot 
experiments revealed that a 3mg/kg dose of etomidate produced a significant sedating 
effect (not shown). Because saline-treated mice did not differ by genotype on 'total distance 
covered' measures, based on previous experiments with this line of mice [16], only sedating 
effects of etomidate were compared between genotypes. A one-way ANOVA of total 
distance covered with genotype as between-subjects factor showed no significant 
differences between WT and KO. Thus, the mean distance covered over a 10 min period 
under the influence of etomidate was comparable between WT and KO .   
 
Figure 2.5. Alphaxalone-induced motor ataxia 
Alphaxalone, a neurosteroid anesthetic, was assessed for its motor ataxic effects at 50mg/kg in WT 
and KO mice. No effect of genotype was observed. Each data point represents mean performance 
at that time point ± SEM. 
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 2.3.9 Alphaxalone-induced locomotor-behavior: 
Because high dose experiments (LORR and rotarod) with alphaxalone did not yield any 
differences between the genotypes, contrary to observations at the cellular level [340], 
behaviors at lower doses of alphaxalone were subsequently tested.  
For total distance covered over the 10 minute period (Fig. 2.7 A), an overall two-way 
ANOVA revealed a significant main effect of treatment [F(1,63) =7, p<0.05] and genotype 
(F(1,63) = 4, p<0.05), but no interaction. Subsequent pair-wise comparisons revealed that a 
treatment effect of alphaxalone was observed in WT (p< 0.05) but not in the KO. In 
addition, WT and KO differed in their response to alphaxalone (p< 0.05). Thus, 
alphaxalone produced a locomotor stimulatory effect in the WT but not KO. 
   
 Figure 2.6 Sedative effects of etomidate 
(A) A 3mg/kg dose of etomidate produced a sedative effect causing a reduction in the total 
distance covered over a 10 minute period compared to saline (based on pilot data). No 
differences were observed between WT and KO mice.  
Data are expressed as mean ± SEM. 
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  Next, percent distance covered in center zones was compared between WT and KO 
(Fig. 2.7 B). Percent distance covered in center zones was used as a surrogate for anxiety-
like behavior in mice in this assay.  However, a two-way ANOVA did not yield an effect of 
treatment or genotype, or an interaction. Thus, a 15mg/kg dose of alphaxalone did not 
produce anxiolytic effects on this assay.  
 
 
A. 
 
B. 
 
 
Figure 2.7 Locomotor behavior with the neurosteroid anesthetic, alphaxalone. 
(A) Total distance covered by WT and α4 KO mice with a 15mg/kg stimulatory dose of the neurosteroid, 
alphaxalone, over a 10 minute period was recorded. A significant treatment effect was apparent in the WT 
(p<0.05) that was absent in the KO. Alphaxalone-treated KO were resistant to the stimulatory effects of 
alphaxalone compared to WT (p<0.05) 
(C) Percent distance covered in center zone by WT and α4 KO mice with a 15mg/kg stimulatory dose of the 
neurosteroid, alphaxalone, over a 10 minute period was recorded. No differences were observed between 
vehicle-treated and alphaxalone-treated WT and α4 KO mice.  
Data are expressed as mean ± SEM. 
(B)  
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2.4 Discussion: 
2.4.1 Role of α4-containing GABA A receptors in effects of volatile anesthetics: 
Effects of isoflurane and halothane on LORR and immobilization were tested as 
part of this study. Halothane-induced LORR differed between WT and KO, with KO 
displaying some resistance to the effects of halothane on this behavior. However, given the 
small difference in EC50’s between WT and KO, it is unlikely that α4-containing receptors 
are a major target for halothane. No differences between WT and KO were noted on 
halothane-induced immobilization. Surprisingly, WT and α4 KO mice were comparable in 
their responses to isoflurane-induced LORR and immobilization. Duration of RORR at 
1.4% ATM of isoflurane and halothane were also assessed. Time taken by mice to recover 
did not differ between genotypes indicating that α4-containing receptors are not likely to 
be involved in this effect of isoflurane and halothane. The results obtained here are in 
contrast to results reported by Jia et al [343] at the cellular level, where isoflurane-induced 
tonic current potentiation was ablated in the ventrobasal thalamic neurons of α4 KO mice. 
 In parallel with the above studies, amnestic effects of isoflurane were assessed in 
WT and α4 KO mice by our collaborators at UCSF (Dr.Vinuta Rau, Dept. of 
Anesthesiology, University of California, San Francisco, CA). In fear conditioning assays, 
α4 KO mice showed resistance to the amnestic effects of isoflurane. KO mice required 
higher concentrations of isoflurane to achieve an amnestic effect. Thus, KO’s had higher 
EC50’s compared to WT. This result corroborates well with the reduced sensitivity to 
isoflurane in KO noted in cellular studies [343]. Thus, α4-containing receptors appear to be 
important mediators/modulators of inhaled anesthetic-induced amnesia. Each of these 
results is discussed in further detail below.  
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 α4 KO mice displayed reduced responsiveness to isoflurane-induced amnestic 
effects on the fear conditioning assay. In keeping with the results obtained by Moore et al 
[346], only hippocampal dependent memory showed reduced response to isoflurane. This 
finding is consistent with the observations that GABA A α4-containing receptors are 
highly expressed in the hippocampus and the hippocampus is selectively involved in fear 
conditioned to context but not tone. The roles of the amygdala and hippocampus in fear 
conditioning have been well characterized. Lesions of the amygdala block fear to tone and 
context, whereas lesions of the hippocampus block only fear to context and leave fear to 
tone intact [114, 371]. The high levels of expression of α4-containing receptors in the 
hippocampus and the selective role of the hippocampus in fear conditioned to context 
reinforce a specific role for the GABA A α4 receptor subtype in inhaled anesthetic- 
induced impairment of hippocampal-dependent learning.   
The α4-containing receptor combination that mediates this effect is of interest. 
Although the majority of hippocampal GABA A α4 receptors colocalize with the δ subunit 
extrasynaptically, there is a substantial portion of α4-containing receptors that colocalize 
synaptically with the γ2 subunit [372]. Therefore, it is possible that isoflurane produces its 
suppression of learning and memory by extrasynaptic as well as synaptic inhibition. 
However, synaptic effects of isoflurane are dependent on isoflurane concentration. 
Previous studies revealed that KO of the GABA A receptor α1 subunit, which is thought to 
primarily mediate phasic inhibition [6, 373] also produces a resistance to the amnestic 
effects of isoflurane [115]. The EC50 for α1 WT mice (males and females combined) was 
approximately 0.15% isoflurane, and the EC50 for α1 KO mice was approximately 0.37% 
isoflurane [119]. This is much higher for the KO in comparison to the results in this study: 
EC50 for α4 WT mice (averaged between males and females) was 0.12% isoflurane, 
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 whereas the EC50 for α4 KO mice was 0.21% isoflurane. Although the EC50 values for both 
GABA A α1 and α4 WTs are similar, more isoflurane was necessary to suppress freezing 
by 50% in the GABA A α1 KO than the α4 KO. This is consistent with the finding that 
isoflurane at a very low concentration (25µM) directly activates GABA A receptors 
containing the α4 subunit, but only higher concentrations (200µM) are able to directly 
activate GABA A receptors containing the α1 subunit.  
This activation of synaptic receptors with higher concentrations of isoflurane is one 
possible explanation for the resistance in response to isoflurane-induced amnesia but not on 
isoflurane-induced LORR or immobilizing effects in KO mice. On LORR assay, there was 
no significant difference between WT and α4 KO mice with isoflurane. Isoflurane-induced 
LORR is mediated at higher concentrations compared to amnestic effects of isoflurane. 
This gives rise to the possibility of activation of synaptic receptors at the concentrations 
used to assess LORR response of isoflurane. Since synaptic current responses to isoflurane 
are unchanged between WT and α4 KO mice [343], it is possible that this behavioral effect 
involves mainly synaptic current potentiation. A modest, but statistically significant, 
difference on halothane-induced loss of righting reflex was observed between genotypes. 
The halothane EC50 that was required to suppress this response in KO mice was increased 
by approximately 7% compared with WT mice. However, the biological significance of 
this modest change in anesthetic response is unclear. The possibility that compensatory 
responses may lead to overestimation or underestimation of the true contribution of α4-
containing receptors to anesthetic-induced loss of righting cannot be excluded. 
Nonetheless, I conclude that α4-containing GABAA -Rs are not required for mediating the 
hypnotic effect of inhaled anesthetics.  
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 No effect of α4 gene ablation was observed on immobility in response to halothane 
or isoflurane as measured by MAC. α4-containing receptors have restricted expression in 
the spinal cord and consistent with this [374], α4-containing receptors are likely not 
involved in mediating the immobilizing effects of volatile anesthetics. This observation 
agrees with the theory that GABAA receptors are not key mediators of volatile anesthetic-
induced immobilization (see review[109]). Similar results have been obtained with other 
genetic mutant mice. For example, a global α1 KO did not have changed MAC responses 
to isoflurane [119]. Although a global KO of the β3 subunit increased enflurane MAC by 
~26% and halothane MAC by ~7% [80], such increases were attributed to compensation 
[81]. Subsequent generation of the β3 KI also showed marginal increases in MAC (~15-
20%) for enflurane and halothane [15]. An isoflurane-insensitive mutation in the α1 
subunit of GABAA receptors did not affect the isoflurane- or halothane-induced MAC 
responses in mice [83, 123]. Similarly, mice bearing an isoflurane-insensitive mutation in 
the α2 subunit had no changes in MAC for isoflurane and halothane [84]. Apart from 
genetic screens, pharmacologic studies also do not support a role for GABAA receptors in 
immobilizing effects of volatile anesthetics [124]. These studies suggest a lack of 
correlation between in vitro potentiation of GABAA receptors and the in vivo responses for 
MAC. Adding to this, studies from the global α4 KO model here support the theory that 
GABAA receptor involvement in MAC of volatile anesthetics is negligable. 
Lastly, if α4 GABAergic receptors were involved in hypnosis induced by 
isoflurane, they could modulate resistance in two ways: 1) resistance to 'go under' 
(induction) or 2) shorter duration of effect, i.e., 'coming out' (emergence). The mechanisms 
by which anesthetic induction versus anesthetic emergence are achieved are not resolved. 
Because neural circuitry of sleep induction and arousal involve overlapping pathways, 
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 different receptors may play important roles in one process relative to the other. For 
example, orexigenic agonists and antagonists have the potential to disrupt the stability of 
the anesthetic state [375, 376]. The ablation of orexigenic neurons delayed the emergence 
from but not the induction of anesthetic state with isoflurane and sevoflurane [377]. 
Similarly, I hypothesized that α4-containing receptors may have a role in emergence from 
anesthetic influence. To assess this, RORR was measured in WT and α4 KO with both 
isoflurane and halothane. However, the lack of difference between the genotypes suggests 
that α4-containing receptors are not critical for modulating emergence from either 
anesthetic. A recent study by Gompf et al [378], showed that halothane-induced RORR 
occured normally in spite of lack of orexigenic neurons in contrast with isoflurane- and 
enflurane-induced RORR [377]. This supports the theory that different anesthetics act on 
diverse neuronal circuits to exert their effects. Hence, different wake-promoting systems 
must modulate emergence from anesthetics.   
 In conclusion, results obtained from the study of volatile anesthetic effects suggest a 
role for hippocampal α4 receptors in the low dose amnestic responses of isoflurane. In 
addition, results from this study suggest that α4-containing receptors are not involved in 
the LORR, immobilization and emergence from anesthetic state induced by isoflurane and 
halothane. The present results lend support to the hypothesis that different receptor 
subtypes likely mediate different anesthetic end points.  
 
2.4.2 Role of α4 containing- GABA A receptors in effects of intravenous anesthetics: 
Knockout of the α4-containing receptors did not alter response to the motor 
impairing effects of etomidate or propofol. No differences were observed between WT and 
KO on either etomidate or propofol-induced LORR. Low-dose effects of etomidate on 
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 sedation were also found to not differ between WT and KO mice. These results indicate 
that α4-containing receptors are not required for the motor ataxic and hypnotic actions of 
etomidate or propofol or the sedative actions of etomidate. 
Previous studies have shown that β3 and β2 subunits are important for the hypnotic 
and sedative effects of etomidate [15, 82]. A point mutation in the β3 subunit ablated 
sensitivity to the hypnotic and immobilizing effects of etomidate [15]. β2 subunits were 
responsible for the sedating actions of etomidate and propofol in a similar study [82]. Other 
lines of evidence have indicated that tonic current is subject to modulation by both 
etomidate and propofol. A study by Bai et al, assessed the sensitivities of synaptic and 
tonic current to propofol in hippocampal pyramidal neurons over a range of concentrations 
[379]. Both synaptic and tonic currents were potentiated by propofol. However, the net 
inhibitory charge mediated by tonic conductance was significantly greater than that 
mediated by synaptic conductance. Similarly, etomidate produced robust tonic current 
potentiation in thalamic neurons compared to synaptic currents [352]. Thus, tonic current is 
sensitive to modulation by both etomidate abd propofol. Both β2 and β3 subunits which are 
associated with the sedative and hypnotic effects of etomidate are strongly expressed in the 
ventrobasal thalamic nuclei and the reticular thalamic nuclei respectively [337]. Because 
α4 subunits can combine with β2 or β3 subunits and γ2 or δ subunits, and because α4-
containing receptors have strong expression in the thalamus, I sought to determine if the 
absence of α4-containing receptors affected the actions of etomidate and propofol. My 
results indicate that α4 subunit-containing receptors are not critical for the effects of 
etomidate- or propofol-induced LORR or motor ataxia.  
An overview of effects of etomidate-induced LORR in various GABA A subunit 
mutant models show interesting results. No changes in etomidate-induced LORR were 
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 observed with global KO murine models of α1, α5, γ2, β2 and δ subunits [17, 116, 119, 
121, 122]. In contrast, the global β3 KO, conditional β3 KO and β3 KI mice, all showed 
reduction in the LORR effects of etomidate [15, 80, 125]. This suggested that the β3 
subunit of GABA A receptors was critical for effects of etomidate. The lack of effect in 
other mutant mouse models suggests the possibility that the actions of etomidate may be 
dictated solely by the β3 subunit while the identity of the α subunit may not be as critical. 
To confirm this, however, mice bearing deletions of α2, α3 and α6 subunit-containing 
receptors will have to be studied with etomidate.  
As in the case of volatile anesthetics, it is possible that the high dose effects of 
etomidate are mediated predominantly by synaptic current potentiation. To determine if 
low dose effects of etomidate depended upon tonic current mediated by α4-containing 
receptors, sedative effects of etomidate were studied at a 3mg/kg dose. However, no 
differences were observed between the genotypes implying that α4-containing receptors 
are not required for this effect.  
Thus, at least for the behaviors studied here, α4-containing receptors are not 
required for the effects of etomidate and propofol. However, the involvement of α4-
containing receptors in other behavioral effects of etomidate and propofol cannot be 
excluded. One behavior worth further study is the amnestic effect of etomidate. Knockout 
of α5 subunit-containing receptors led to a reduction in the amnestic response to etomidate 
[116]. Like the α5 KO mice [117], α4 KO mice also have enhanced memory [346]. In 
addition, α4 KO are resistant to isoflurane-induced amnesia [344]. Since α4-containing 
receptors were required for the low dose amnestic effect of isoflurane, it can be speculated 
that α4 KO mice would show a similar reduction in amnestic response to etomidate. Based 
on the results seen with isoflurane and the increased memory in α4 KO, it is likely that α4 
96
 KO may show resistance to the amnestic effects of etomidate as well. Such a result would 
then reinforce a role for tonic current potentiating receptor subtypes in the hippocampus as 
being critical for low dose effects of anesthetics such as anesthetic-induced amnesia. 
While these results suggest that α4-containing receptors are not essential for the 
effects of etomidate and propofol, it is possible that compensatory responses in the global 
α4 KO mask the true role of α4-containing receptors. Increases in α1, α2 and γ2 subunits 
have been observed in α4 KO mice [350]. This could result in novel combinations of 
receptors that take over the role of α4 receptors for etomidate and propofol actions. 
Another possibility arising from novel subunit combinations is ‘silent receptors’. Given 
that many anesthetics act as allosteric modulators of GABA A receptors [380, 381], an 
otherwise ‘silent receptor’ may showed increased GABA sensitivity in the presence of 
anesthetics, thus giving rise to anesthetic-induced tonic GABA inhibition [367]. Such 
receptors may explain how anesthetic sensitivity is maintained in α4 KO mice in spite of 
reductions in tonic current in the thalamus and hippocampus.  
In conclusion, the results indicate that α4 subunit-containing receptors are not 
essential for the actions of etomidate and propofol on the behaviors studied here. However, 
further analysis of compensatory changes and responses to these anesthetics on additional 
behaviors is required before a comprehensive understanding of the role of the α4 subunit in 
anesthetic actions is achieved.  
 
2.4.3 Role of α4 containing-receptors in neurosteroid effects: 
The lack of α4 subunit-containing receptors affected the locomotor behavior of the 
KO mice at a low dose of the neurosteroid, alphaxalone. WT mice had increased 
locomotion in response to alphaxalone whereas KO mice did not. Thus, it appears that α4 
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 containing receptors are critical for the locomotor stimulatory effect of neurosteroids. This 
is particularly interesting because the locomotor stimulatory effect was studied at a 
relatively low dose of the neurosteroid alphaxalone. In contrast, experiments with 
alphaxalone revealed no differences between genotypes on the high dose effects of LORR 
or motor incoordination. This suggests that α4-subunit containing receptors are not 
required for these behaviors.  
The α4 subunit undergoes extensive changes in expression with changes in levels of 
endogenous steroids during hormonal cycles (for review, see [382]). When combined with 
the δ subunit, the resulting receptor is highly sensitive to actions of neurosteroids [282-
284]. Knockout of the δ subunit resulted in mice that had reduced sensitivity to 
neurosteroid-induced anxiolysis and hypnosis implying that the δ subunit was critical for 
the behavioral effects of neurosteroids [17]. Hippocampal dentate gyrus neurons from δ 
KO mice showed reduced tonic current potentiation in response to neurosteroids [369]. 
Characterization of the δ KO mouse brains revealed that expression of α4 was also reduced 
in critical regions such as thalamic nuclei, dentate gyrus and caudate putamen [353]. 
Therefore, the reduction in neurosteroid sensitivity in δ KO could, in part, be attributed to 
reduction in α4 levels as well. In the α4 KO, tonic and synaptic current potentiation due to 
alphaxalone was reduced in hippocampal dentate gyrus granule neurons [340]. Hence, I 
hypothesized that α4 subunit-containing receptors were critical for the behavioral effects of 
neurosteroids.  
In contrast to my expectations, high dose effects of alphaxalone on LORR and 
motor ataxia were unchanged in α4 KO mice. The findings here indicate that α4-containing 
receptors are not required for the hypnotic and motor ataxic effects of neurosteroids. 
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 Motor behavior is articulated by participation of several brain regions. While the 
cerebellum is considered critical for motor coordination, the thalamus is involved in relay 
of information between the cerebellum and the primary motor cortex. Thus, disruption of 
motor activities could occur anywhere along the cerebello-thalamo-cortical pathway. For 
example, with α4 KO mice, tonic current potentiation by gaboxadol was reduced in the 
ventrobasal thalamic neurons of the α4 KO [16]. A concurrent reduction in the motor 
ataxic effects of gaboxadol was seen [16]. Although cellular responses to alphaxalone were 
reduced in the α4 KO mice, decreases in motor ataxia with alphaxalone was not observed 
suggesting that alphaxalone mediates its effects in a manner different from that of 
gaboxadol. It is possible that the motor ataxic effects of alphaxalone depend upon brain 
regions that do not express α4 such as the cerebellum [242, 337]. Indeed, α6-δ containing 
receptors that are strongly expressed in the cerebellum are also sensitive to neurosteroids 
[295]. Since α4 subunits are absent in the cerebellum, it is unlikely that α6δ-containing 
receptors in the cerebellum are changed in the α4 KO mice. Hence, it is possible that motor 
ataxic influence of neurosteroids is mediated by these cerebellar receptors.  
A similar explanation can be put forth for the LORR effects of alphaxalone. Like 
motor ataxic effects of alphaxalone, the hypnotic effects of neurosteroids could similarly be 
attributed to the effects on brain regions that do not involve α4-containing GABA 
receptors. This explains the lack of a difference between the WT and KO on the LORR 
effects of alphaxalone.  
However, both motor ataxia and LORR were assessed at relatively high doses of 
alphaxalone. In the α4 KO, hippocampal dentate gyrus neurons showed reduced current 
potentiation with alphaxalone [340]. The possibility of α4δ-containing receptors being 
responsible for low dose effects of alphaxalone was, therefore, tested by assessing 
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 locomotor behavior. Consistent with my hypothesis, α4 KO mice did not respond to a 
stimulatory effect of alphaxalone in the open field assay. Thus, α4-containing receptors 
appear important for this effect of neurosteroids. The fact that a change in behavior of α4 
KO was observed at a low dose of alphaxalone suggests that like with isoflurane, α4-
containing receptors play an important role in the low dose effects of alphaxalone. Coupled 
with the results obtained with amnestic effects of isoflurane, this finding suggests that tonic 
current-mediated by α4-containing receptors is sensitive to low doses of anesthetics and 
neurosteroids. 
It is possible that compensatory changes may have masked a role for α4 containing 
receptors at higher doses. In the α4 KO mice, there is evidence of compensatory response 
in terms of increased α1, α2 and γ2 [349, 350]. The increased α1 and α2 subunits could 
combine with δ subunits to form receptors responsive to neurosteroids. α1δ-containing 
receptors that are sensitive to low doses of ethanol and potentiate tonic current in response 
to them have been discovered recently [320]. Such receptors may be potentiated by 
neurosteroids as well. This could explain why high dose effects of neurosteroids are 
unchanged in the α4 KO mice. Novel combinations of these receptors may be involved in 
mediating the effects of neurosteroids thus masking the true role of the α4-containing 
receptors in neurosteroid actions.  
  2.5 Summary: 
 
In conclusion, the above experiments shed light on the role of α4-containing 
receptors in anesthetic actions. The involvement of α4-containing receptors in amnestic 
effects of isoflurane and locomotor stimulatory effects of alphaxalone suggest that α4- 
containing receptors modulate these anesthetic behaviors. The lack of effects with 
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 etomidate and propofol indicate that α4-containing receptors are less likely to be involved 
in their effects in spite of being critical modulators of tonic currents. 
Contrary to the vast amount of data linking α4 subunit-containing receptors to 
neurosteroid effects, deletion of α4-containing receptors affected only the response to low 
doses and not high doses of neurosteroids. It is possible that α4-containing receptors 
become relevant only in cases of changed levels of endogenous neurosteroids such as 
premenstrual syndrome and pregnancy. Previous studies with neurosteroids have indicated 
that changes in behavior were coincident with changes in levels of endogenous 
neurosteroids and expression of α4 protein (see review [382]). However, α4 homozygous 
knockouts are known to reproduce normally [16], and have normal maternal behavior 
although this has not been studied formally. Hence, it appears that α4 subunits have a 
lesser role than δ in modulation of neurosteroid effects.  
An important observation is the common theme of effects observed in the α4 KO 
with isoflurane and alphaxalone. Differences between WT and KO were observed on the 
amnestic effects of isoflurane and the locomotor stimulatory effect of alphaxalone. It is 
interesting that both drugs showed differences on behaviors that were studied at low doses 
but not of high doses of these drugs.  
The inhibitory charge transfer associated with tonic current potentiation is greater 
than that associated with synaptic current potentiation in presence of anesthetics. This was 
demonstrated by Bai et al while studying the effects of propofol and midazolam on tonic 
and synaptic current potentiation [379]. Similar results have been shown with effects of 
etomidate and gaboxadol on tonic and synaptic current potentiation in thalamic neurons 
[352]. These observations coupled with the differences in behavioral effects of low doses 
of isoflurane and alphaxalone in the α4 KO compared to WT suggest that the tonic current 
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 mediated by α4-containing receptors may be particularly sensitive to low doses of 
anesthetics and neurosteroids, i.e. the initial effects of anesthetics may be modulation of 
tonic current potentiation. This is consistent with the reductions in low dose behaviors of 
anesthetics observed with deletions of receptors involved in tonic current potentiation such 
as α5, δ and now α4 [116] [17, 311]. Hence, there is a greater likelihood that low dose 
anesthetic effects such as cognitive impairment, locomotor behavior and anxiety are 
modulated by tonic current mediating GABA A receptors. 
Interestingly, this result also correlates with the theory that α4δ-containing 
receptors are sensitive to low doses of ethanol. At present there is a lack of appropriate 
behavioral assays that can effectively measure the low dose effects of ethanol. Behaviors 
such as sedation, motor ataxia and hypnosis reflect moderate intoxication induced by 
ethanol. Recently, Moore et al developed an assay to specifically evaluate the low dose 
cognition-impairing effects of ethanol [383]. With the development of such assays, 
dissection of low dose effects of ethanol and anesthetics should be easier. 
Thus, results from the study of anesthetic effects in α4 KO mice implicate α4-
containing receptors in the low dose effects of isoflurane and alphaxalone. In addition, thes 
results corroborate with the idea that tonic current potentiation is important for low dose 
anesthetic responses. 
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 Chapter 3: Role of α4-containing GABA A receptors in 
the intrinsic and ethanol antagonizing effects of RY023  
3.1 Introduction: 
The negative effects of acute and chronic alcohol consumption place huge 
economic and social burdens on society. Overconsumption of alcohol leads to sedation, 
motor-incoordination, memory deficits in addition to severe nausea, headache, dehydration, 
etc. [3]. Repeated consumption of alcohol also holds the risk of addiction and development 
of alcohol dependence.  
For the above stated reasons, it is enticing to consider the possibility of an ethanol 
antagonist that would allow one to counter the ill effects of alcohol. The discovery of 
effective ethanol antagonists will also aid in treatment of acute toxicity caused by ethanol. 
In addition, a fast acting ethanol antagonist will be useful as a therapeutic agent in 
reversing the effects of acute ethanol. For example, a drug that can reverse the motor-
incoordinating, sedating, and cognition-impairing effects of ethanol before operation of 
vehicles or machinery will cause fewer accidents and thus, allow for more responsible 
drinking. Because ethanol has strong addiction potential, it produces effects that increase 
the urge to drink more frequently and in greater amounts. An ethanol antagonist could 
conceivably prevent such changes in the brain and thus prevent dependence on ethanol as 
well.  
The development of specific ethanol antagonists has been the focus of much 
research since the discovery of Ro15-4513 – an imidazobenzodiazepine drug synthesized 
by Hoffman-La Roche Pharmaceuticals [384]. Ro15-4513 acts as an ethanol antagonist 
both in behavioral studies [247, 249, 385, 386] and biochemical assays [150, 245, 246]. 
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 Being a benzodiazepine-like compound, Ro15-4513 was proposed to function via 
benzodiazepine-sensitive GABA A receptors. The true mechanism of action of Ro15-4513 
was unknown until the discovery of ethanol-sensitive GABA A receptors.  
Ethanol-sensitive receptors are thought to contain α4/α6 and δ subunits [158]. 
These receptor subtypes are involved in mediation of tonic current upon activation by low 
amounts of GABA which makes them suited to modulation by ethanol as well [156-158, 
317, 318]. In studies with recombinant receptors expressed in heterologous systems, these 
subtypes were potentiated by 3-50mM of ethanol whereas α1, α2, γ2 -containing receptors 
were potentiated by much higher amounts of ethanol (~100mM) [14, 154, 318, 387]. 
Initially, it was thought that Ro15-4513 reversed ethanol actions due to its partial inverse 
agonist activity on synaptic receptor subtypes. However, further study of the specificity of 
Ro15-4513 for ethanol antagonism and its comparison with other inverse agonists showed 
that the antagonistic effects of Ro15-4513 was specific for ethanol [156, 262], thus arguing 
in favor of a unique ethanol - Ro15-4513 binding pocket. A series of studies by Olsen, 
Wallner and Hanchar provided evidence towards a common binding pocket [156, 158, 262, 
264]. In brief, the findings of Wallner, Hanchar and Olsen can be summarized as follows 
(reviewed in [265]):  
1) Ro15-4513 binds with high affinity to α4δ and α6δ -containing receptors.  
2) Ro15-4513 has mild partial agonist activity on α4β3γ2, does not modulate α4β3δ 
receptors and has inverse agonist activity at other α1/2/3/5 subunit-containing 
receptors. 
3) Low concentrations of ethanol displace bound labeled Ro15-4513 from α4δ-
containing receptors. 
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 4) Flumazenil and β-carboline derivatives also displace bound Ro15-4513 from α4-δ 
receptors. 
The generation of an α4 KO mouse model provided conclusive evidence towards 
the role of α4-containing receptors in the actions of Ro15-4513. In electrophysiological 
studies, tonic current potentiation by Ro15-4513 was reduced in dentate gyrus granule 
neurons of α4 KO mice [340]. Analysis of the ethanol antagonistic effects of Ro15-4513 
revealed that while WT responded with a reversal of ethanol-induced motor ataxia (Fig. 
1.2), KO did not respond to Ro15-4513 [341]. At high doses of ethanol, (3.5g/kg), LORR 
effect was reduced by Ro15-4513 in WT but was unchanged in KO (Fig. 1.2) [341]. This 
indicated that α4-containing receptors are critical for the ethanol-antagonizing effects of 
Ro15-4513. Since other ethanol antagonists had been derived from the prototypical Ro15-
4513, it was likely that these derivatives also mediate their effects through α4-containing 
receptors. In fact, binding studies by Hanchar et al indicated that compounds that were 
structurally similar to Ro15-4513 also showed affinity to α4-containing receptors and 
displaced Ro15-4513 from its binding site [262]. 
RY023 is one of a series of substituted imidazobenzodiazepines that was originally 
synthesized from the prototypical ethanol antagonist, Ro15-4513 [251]. Characterization of 
the binding profile of RY023 revealed that it had both high affinity (Kd= ~2.7nm) and 
selectivity (~75 fold) for α5β2γ2 GABA A receptors [251]. At recombinant receptors, 
RY023 produced a small reduction in GABA binding (~25%) [251, 260]. It possesses 
convulsant properties at doses ≥ 40mg/kg [251, 260]. RY023 was assessed for its 
functional modulation at α1β3γ2, α2β3γ2,  α5β3γ2, α4β3γ2, α6β3γ2 -containing receptors 
in xenopus oocytes [253, 255]. It was found that RY023 negatively modulated all the above 
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 subtypes, but was more effective at the α5β3γ2 receptors than at the others. The binding 
affinity and modulation of RY023 at δ-containing receptors was, however, not assessed.  
Behavioral characterization of RY023 showed that it was effective in antagonizing 
ethanol effects on multiple behavioral paradigms. In drinking behavior experiments, 
RY023 infusions in the CA1 and CA3 regions of the hippocampus produced a reduction in 
ethanol drinking behavior [255, 357]. In addition to drinking behavior, RY023 was 
evaluated for its ethanol-antagonistic potential on motor ataxia (oscillating bar test) and 
locomotor behavior (open field activity) [253]. On both these behaviors, RY023 was 
successful in antagonizing the effects of ethanol in rats. These experiments revealed that 
RY023 was effective in antagonizing several behavioral endpoints of ethanol, just like 
Ro15-4513.  
Prior to the findings of Wallner, Hanchar and Olsen, because the RY series of drugs 
had only been tested against α-γ subunit combinations, the affinities and the efficacies of 
these drugs at α4δ subunit combinations was not known. Although RY023 itself has not 
been studied in competition binding assays with Ro15-4513 or in current modulation 
through α4δ-containing receptors, other compounds of the same family (RY024 and 
RY080) have been tested [262]. The findings indicate that these drugs may also be potent 
modulators of ethanol through binding at the α4-δ receptors. To test this hypothesis, α4 
KO mice were subjected to several behavioral assays with ethanol and RY023. RY023 has 
a better solubility profile compared to the other RY drugs (personal communication with 
Dr. H. June, University of Maryland, Baltimore, MD) and well-characterized responses in 
rats and hence this drug was chosen for use in our experiments.  
106
 3.2 Materials and Methods: 
3.2.1 Drugs and Solutions: 
Solid RY023 (tert-butyl 8-[trimethylsilyl] acetylene-5,6-dihydro-5-methyl-6- oxo-4H-
imidazo [1,5a] [1,4] benzodiazepine-3-carboxylate) was provided by Dr. J. Cook (Dept. of 
Psychology, Indiana University-Purdue University, Indianapolis, Indiana) and Dr. H. June 
(University of Maryland, Baltimore, MD). On the day of the experiment, the solid drug was 
weighed directly in the final container and suspended in the vehicle solution. Vehicle 
solution was prepared by mixing 0.1ml of Tween 80 (Sigma Aldrich, St.Louis, MO) in 
100ml of saline. The drug suspension was briefly vortexed and sonicated by a probe 
sonicator (Branson Sonifier 250, Duty cycle-30%, Output control-3) for three 15 sec 
periods while on ice. Ethanol solutions were prepared by mixing absolute ethanol 
(Pharmco, Brookefield, CT) with saline to arrive at doses of 2g/kg and 3.5g/kg. Ethanol 
and RY023 solutions were injected at 0.01ml/gm body weight for all experiments except 
LORR, for which ethanol solution was injected at 0.02ml/gm body weight.  
In all assays, males and females of all three genotypes (WT, HET and KO), aged 8-16 
weeks were used. However, due to limited number of subjects and multiple treatment-
genotype combinations, sex differences were not analyzed. 
 3.2.2 Intrinsic effects and RY023 antagonism of ethanol-induced motor ataxia: 
Both intrinsic effects and ethanol antagonistic effects of RY023 were determined. 
Because intrinsic effects could confound the interepretation on ethanol antagonism assays, 
I sought to determine the highest dose of RY023 that produced minimal intrinsic effects. 
Hence, different dose combinations of RY023 and saline were tested on HET mice to 
determine the dose of drug to be used in WT and KO mice.  
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 Mice were weighed and subjected to training trials on the previous day on the fixed 
speed rotarod (Ugo Basile 7650, Varese, Italy) at 8RPM. Mice were given at least 4 
training trials to achieve a performance of 100s on the rotarod. Training trials were 
administered 15 minutes apart. Following training, mice were housed overnight in the 
testing room. On the test day, mice were tested twice on the rotarod to ensure compliance 
with criteria. Mice that did not achieve the criterion of 100s on two consecutive trials were 
excluded from the experiment. Two injections were administered - RY023 and saline (RY 
dose: 8, 10, 15, 20, 30mg/kg), All injections were administered i.p., in a volume of 
0.01mls/g body weight of subject. The order of the injections was RY023 followed by 
saline injection, 5 min later. Ten minutes after the second injection, performance on rotarod 
was tested. Trials were then conducted every 15 min for 60 min.  
Dose-determination experiments were conducted on HET mice first, followed by 
testing on WT and KO mice. Only 10mg/kg of RY023 with and without 2g/kg of ethanol 
was tested in WT, HET and KO. Area under curves (AUC- area under curve refers to area 
between curve and line at 100sec) were compared at each dose-combination by one-way 
ANOVA and Fisher's post hoc tests.  
3.2.3 RY023 antagonism of ethanol-induced LORR: 
Antagonism of ethanol-induced LORR was tested using 15mg/kg RY023 and 3.5g/kg 
ethanol. Mice were injected with RY023 (i.p, 0.01ml/g body weight) or saline, followed by 
ethanol 5 minutes later (i.p, 0.02ml/g body weight). Thus, two treatment groups were tested 
– saline-ethanol (SE) and RY023-ethanol (RY-E). Upon losing their righting reflex, mice 
were placed in a supine position on V-shaped troughs. Mice were considered to have 
regained their righting reflex if they were successful in righting themselves three 
consecutive times within 30sec. A heat lamp was used during the course of the experiment 
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 to ensure normothermia. Data were analyzed by two-way ANOVA and Fisher's post hoc 
tests. 
3.2.4 RY023-induced impairment of locomotor behavior: 
Intrinsic effects of RY023 on locomotor activity were tested at a dose of 15mg/kg. Pilot 
studies were conducted to confirm that this dose of RY023 produced a sedating effect and 
reduced locomotion compared to vehicle-treated mice. Mice were placed in the testing 
room one day prior to the experiment. On the morning of the experiment, mice were 
weighed, injected with RY023 or vehicle and placed separately in new cages. Fifteen 
minutes later, mice were placed in the center of a plexiglass walled arena each, (43.2 cm X 
43.2 cm X 30.5 cm) for automated recording of locomotor behavior. The chambers were 
placed within sound-attenuating cubicles (Med Associates, St.Albans, VT) that were 
equipped with a red light and a fan (top right corner). Distance traveled (cm) over a 10 
minute period was recorded by an automated program (Med Associates, St.Albans, VT). 
Between mice, the chambers were cleaned with 70% ethanol followed by water to remove 
any evidence of smells and excrements left behind. Data were analyzed by two- way 
ANOVA and Fisher's post hoc tests.  
3.2.5 Immunoblotting: 
Untreated WT, HET and KO mice were sacrificed, and hippocampi and cortex were 
isolated from whole brains. Brain regions were flash frozen and stored at -80°C until 
processing. Samples were homogenized in a sucrose homogenization buffer (10.95g 
sucrose in 100ml 1X PBS, pH 7.2). The homogenates were centrifuged at 1000g for 10 min 
followed by spinning the supernatant at 10,000g for 25 min. The resultant pellet was 
resuspended in 1X PBS (Gibco-phosphate buffered saline, pH 7.2, Invitrogen, Carlsbad, 
CA) and consisted of the P2 membrane fraction. Protein concentrations for each sample 
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 were determined spectrophotometrically via a bicinchonic acid method. Known protein 
concentrations were used to generate a standard curve and resulting sample protein 
concentrations were determined. Stock protein solutions were diluted to a concentration of 
2.5µg/µl and stored at -80°C for further use. Twenty-five µg of protein per sample was 
electrophoresed on precast SDS-10% polyacrylamide gels (Bio-Rad, Hercules, CA) and 
subsequently transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, 
Hercules, CA) for detection by subunit-specific antibodies. The PVDF membranes were 
blocked overnight with 3% non-fat blotting grade dry milk buffer (Biorad, Hercules, CA) 
in PBS-comtaining 0.1% Tween 20 (Biorad, Hercules, CA). The following day, 
membranes were incubated overnight with GABA A receptor anti-α4 (1:1000, NB 300-
193, Novus Biologicals, Littleton, CO) antibody. On day 3, membranes were washed three 
times with PBS-containing 0.1% Tween-20 (PBS-T) for 15 min each. Primary antibodies 
were detected with horseradish peroxidase-conjugated goat anti-rabbit polyclonal antibody 
(1:5000, NB-730H, Novus Biologicals, Littleton, CO). Secondary antibodies were detected 
by enhanced chemiluminescence (Western Lightning; PerkinElmer Life and Analytical 
Sciences, Boston, MA). Blots were stripped using Re-blot (Chemicon International, 
Millipore, Billerca, MA) and reprobed with an anti-β-actin polyclonal antibody (1:10,000, 
ab8227-50; Abcam, Cambridge, MA ) for normalization. Multiple exposures of each 
membrane were used to ensure that the measured signal was within the linear range of the 
film. Band intensity was measured densitometrically (PDSI, Personal densitometer, 
Amersham Biosciences, Piscataway, NJ) and analyzed by ImageQuant software 
(Amersham Biosciences, Piscataway, NJ). Each sample was analyzed on two different 
blots. Data were analyzed by unpaired Student’s t-test. 
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 3.3 Results: 
3.3.1 Intrinsic effects of RY023 on motor ataxia: 
To determine the highest dose of RY023 that had minimal intrinsic effect on motor ataxia, 
HET mice were first tested with various doses of RY023 in a pilot study. From previous 
experience it was known that untreated mice were capable of achieving the criterion of 100 
sec, every 15 min for 1 hour on the rotarod. Hence, I compared the impairment produced 
by different doses of RY023 in HETS to baseline performance (Fig. 3.1 A). Next, area 
under the curve (AUC) for the performance on rotarod at different doses of RY023 was 
calculated. AUC's were calculated as the sum of the area between the curve and baseline 
performance over a 60 minute period. Doses of 8 and 10 mg/kg had the smallest AUC 
among the drug-treated mice. Since the goal of this assay was to determine the highest dose 
of RY023 that had the least intrinsic effect, the 10mg/kg dose of RY023 was chosen for 
further study in WT and KO.  
To test the hypothesis that α4-containing receptors are involved in the actions of 
RY023, WT and KO mice were injected with 10mg/kg dose of RY023 and tested for 
performance on rotarod. AUC's for WT and KO mice were calculated and compared with 
data from HET mice. Analysis of AUC by a one-way ANOVA revealed a main effect of 
genotype [F (2, 22) = 6, p < 0.01]. Fisher's post hoc tests revealed that HET mice showed 
significantly lowered impairment compared to WT (p < 0.005) and KO (p < 0.05). WT and 
KO mice did not differ from each other. Thus, HET mice were less sensitive to the motor 
ataxic effects of RY023 compared to WT and KO.  
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 Note: HET mice data used for this comparison was the same as that obtained from 
preliminary tests, shown in Fig. 3.1 A, B. 
Figure 3.1 Intrinsic effects of RY023 on motor ataxia (Data are expressed as Mean ±  SEM) 
(A) Intrinsic effects of RY023 in HET mice at different doses of RY023 (8-30mg/kg). All doses 
produced motor ataxia.  
(B) AUC of performance on rotarod at all doses of RY023 in HET mice. Doses 8 and 10mg/kg produced 
the least impairment of motor performance. 
(C) Line graph of performance on rotarod at a dose of 10mg/kg of RY023 in WT, HET and KO mice 
(D) AUC of performance on rotarod of WT, HET and KO mice at 10mg/kg of RY023 showed a 
significant difference between HET and WT (p< 0.005) and between HET and KO (p< 0.05). KO and 
WT did not differ from each other in the intrinsic effects of RY023 on motor ataxia.  
  
 A.  
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  3.3.2 RY023-induced antagonism of ethanol impairment on motor ataxia: 
To test the hypothesis that α4-containing receptors are required for the ethanol 
antagonistic actions of RY023, WT, HET and KO mice were assayed for response to 
RY023 antagonism of ethanol-induced motor ataxia. Prior assays had been conducted to 
confirm that WT, HET and KO did not differ in their response to ethanol alone under the 
conditions of this assay (not shown). The same result was obtained under slightly different 
conditions by Chandra et al [186]. Line graphs of performance on rotarod over 60 minutes 
for all three genotypes are shown in Fig. 3.2 A. A one way ANOVA on the AUC's (Fig. 
3.2 B) did not show a difference between genotypes.  
 
 
   A. 
 
  B.         
    
   
Figure 3.2 Effects of RY023(10mg/kg) on ethanol-induced (2g/kg) motor ataxia 
(A) Line graph of performance on rotarod by all three genotypes. 
(B) AUC's for performance on rotarod by all three genotypes. No differences were observed between 
genotypes on the effects of RY023.  
Intrinsic effects of RY023 preclude an interpretation of antagonistic effects of RY023 on ethanol-
induced motor ataxia.  
Data are expressed as mean ± SEM. 
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 Antagonism of ethanol-induced ataxia could not be measured in WT, HET and α4 
KO. A comparison of the AUC's from ethanol-induced motor ataxia and from RY-E 
induced motor ataxia in HETS (recorded as pilots)  indicated that 10mg/kg RY023 did not 
antagonize the effects of 2g/kg ethanol. Based on pilot experiments, higher doses of RY023 
would also not be suitable for ethanol-antagonism owing to strong intrinsic effects. Since 
intrinsic effects of 10mg/kg RY023 differed among genotypes, I sought to determine if the 
effect of 10mg/kg RY023 on 2g/kg ethanol was different between genotypes. However, 
WT, HET and KO did not differ in their response to 10mg/kg RY023 and 2g/kg ethanol on 
motor ataxia.  
 
3.3.3 RY023 antagonism of ethanol-induced LORR: 
The ethanol antagonistic potential of RY023 was tested at a dose of 15mg/kg with 3g/kg 
ethanol. An overall two-way ANOVA showed a significant effect of treatment [F (1,67) = 
40; p<0.0001] but not of genotype (Fig. 3.3 A). However, there was a significant 
interaction of treatment and genotype [F (2,67) = 4; p<0.05]. Fisher's post hoc tests 
revealed a significant effect of treatment within each genotype (Fig. 3.3 A). Thus, all 
genotypes showed a reduction in ethanol-induced LORR with RY023. A significant 
difference was found between KO and HETS on the SE group (p<0.05) but no difference 
between genotypes on the RY-E group.   
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Due to the baseline difference on the durations of LORR between KO and HETS, RY-E -
durations of LORR were also analyzed as percentages of the mean baseline LORR (SE) 
within each genotype (Fig. 4.3.B). Analysis of the percent sleep times (% LORR) showed a 
difference between genotypes that was borderline significant [F(2,45)=3, p = 0.06]. Post 
hoc tests revealed that HETS were significantly different compared to the KO (p<0.05). 
The difference between WT and HET % LORR approached significance at p = 0.06. No 
difference was seen between WT and KO % LORR.  
 
  A. 
 
 
 
   B.  
 
 
Figure 3.3 Effect of RY023 (15mg/kg) on ethanol (3.5g/kg) -induced loss of righting reflex (LORR) 
(A) Durations of LORR in WT, HET and KO mice with saline and ethanol (SE) and with RY023 and 
ethanol (RY-E). A significant effect of treatment was observed (p< 0.0001) in all three genotypes. 
In addition, a baseline difference between SE-HET and SE-KO groups was observed. Data are 
expressed as Mean ± SEM. 
(B) Durations of LORR with RY023 expressed as a percentage of durations of LORR with ethanol 
alone for each genotype. A significant difference was observed in the magnitude of reversal of 
ethanol-induced LORR by RY023. HETs had the greatest reductions in durations of LORR 
compared to WT (p = 0.05) and KO (p< 0.05). No differences were observed in % LORR between 
WT and KO mice.  
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 3.3.4 Intrinsic effects of RY023 on locomotor behavior: 
Because study of motor ataxic effects of RY023 on rotarod presented some difficulties due 
to overlap of intrinsic effects, the study was extended to include intrinsic effects of RY023 
on locomotor behavior at a dose of 15mg/kg. This dose of RY023 had a stong sedating 
effect on mice compared to vehicle treatment as evidenced by the reduction in distance 
covered over the 10 min period between the two treatment groups. A two-way ANOVA 
with genotype and treatment as between factors measures indicated a  strong effect of 
treatment [F(1,81) = 23; p<0.0001], but not an effect of genotype (Fig. 4.4) or interaction 
between genotype and treatment.  
 
Fisher's post hoc tests were conducted to determine where the differences in treatment lay. 
Post hoc tests revealed that a significant effect of treatment was noted in HETS, p<0.01 and 
WT, p<0.0001 but not in KO. Thus, while WT and HET mice responded to the sedating 
 
 
Figure 3.4 Intrinsic effects of RY023 (15mg/kg) on locomotor behavior over a 10 minute period. 
A 15mg/kg dose of RY023 produced significant sedation in WT (p<0.0001) and in HET (p< 0.01) 
but not in KO compared to vehicle-treated mice. Thus, KO did not respond to the intrinsic sedating 
effects of RY023. Data are expressed as mean ± SEM. 
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 effects of RY023, KO mice did not indicating that they were resistant to this effect of 
RY023. Post hoc tests also revealed near-significant differences on the baseline response to 
vehicle between the genotypes. While KO and HET mice were comparable on their 
baseline response, they differed slightly from the WT (WT and HET: p = 0.07; WT and 
KO: p = 0.07). However, previous experiments with different vehicle controls have not 
yielded significant differences in baseline behaviors (saline controls -[186]; 22.5% HBC, 
Fig. 2.7A). Hence, it is unlikely that this difference represents a role for α4-containing 
receptors in baseline locomotor behavior.   
 
3.3.5 Immunoblotting: 
While WT have normal levels of α4 protein expression and KO have none [339], the level 
of expression of α4 protein in HET mice was unknown. Since HET mice showed reduced 
motor ataxic effects with RY023 compared to WT and KO mice, we hypothesized that 
differences in levels of protein may be responsible for the same. Semi-quantitative analysis 
of α4 subunit protein from hippocampi and cortex of WT and HET mice revealed that 
HETs had significantly lower levels of protein relative to WTs in the hippocampus but not 
in the cortex (p<0.05). This suggests that protein levels maybe differentially compensated 
in different brain regions. However, it is important to note that this data was collected from 
a small sample set ( n=2-3/geno) run in duplicate. It is likely that the reduction of α4 
protein in HET mice is overestimated here due to the small sample set and blot 
irregularities.  
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Figure 3.5 Western blot analysis of α4 protein from hippocampus and cortex of WT, HET and KO 
mice. 
(A) Representative blot of hippocampal α4 protein from WT, HET and KO mice. Band intensities 
appear lower in HET lanes compared to WT. KO lanes do not show discernible levels of α4 
protein. 
(B) Summary data for levels of hippocampal α4 protein in WT, HET and KO. α4 levels in HETs were 
significantly reduced compared to WT (p < 0.05). 
(C) Representative blot of cortex α4 protein from WT, HET and KO mice.  
(D) Summary data for levels of cortical α4 protein in WT, HET and KO mice. α4 levels in HETs were 
not significantly reduced compared to WT.  
Data are expressed as mean ± SEM of % change in band intensity relative to WT controls 
following normalization to β actin. 
 
B. 
 
D. 
 
β Actin 
A.  Hippocampus 
 
 
α4 
C. Cortex  
 
α4 
β Actin 
118
  3.4 Discussion: 
The goal of this series of experiments was to determine if α4-containing receptors 
were required for the intrinsic and the ethanol-antagonistic effect of RY023. Different 
parameters of RY023 effect were studied – motor ataxia by RY023 alone, reversal of 
ethanol-induced motor ataxia by RY023, reversal of ethanol-induced LORR and sedating 
effect of RY023 alone. Results reveal that α4-containing receptors may be involved in 
mediating the intrinsic effects of RY023 in motor ataxia and sedation but not in its 
antagonistic effect on ethanol-induced LORR.  
3.4.1 Role of α4-containing receptors in intrinsic and ethanol antagonistic effects of 
RY023 on motor ataxia: 
All tested doses of RY023 produced intrinsic impairment of motor performance on 
the rotarod. This is in contrast to the results reported by Cook et al [253]. Cook and 
collegues used an oscillating bar test to assess the ataxic effects of a 15mg/kg dose of 
RY023. This dose of RY023 did not alter the baseline performance of rats on the 
oscillating bar test. In contrast, all tested doses of RY023 (8mg/kg-30m/kg) produced 
intrinsic effects in mice on the rotarod assay in this study. The difference in response to 
RY023 between studies may have arisen due to a species-specific or behavior-specific 
effect. The level of complexity for motor ability on the rotarod assay is higher than that on 
the oscillating bar assay. Therefore, behavior-specific effects may be confound the 
response to RY023. 
Surprisingly, the intrinsic effect of RY023 was the least in α4 HET mice compared 
to WT and KO mice. WT and KO mice, themselves, did not differ in the degree of 
impairment produced by RY023. This implied that a difference in amount of α4 protein 
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 between HETs and WT may be responsible for a lowered response to the motor-impairing 
effects of RY023 in HETs. To determine this, membrane protein fractions from 
hippocampus and cortex of WT, HET and KO mice were compared. Lowered levels of α4 
protein were observed in hippocampus of HET mice compared to WT. Reduction in GABA 
A receptor subunit mRNA in HETS of other GABA A receptor mutants is a common 
observation [17, 120, 388]. As expected, no α4 protein was observed in KO brain samples. 
While it is not known definitively how much of a role the hippocampus plays in regulation 
of motor activities, it is plausible that the reduction in α4 protein in this region could be 
mirrored in other brain circuitry involved in motor co-ordination. This may be responsible 
for the reduced response to RY023 on intrinsic motor ataxic effects. 
Such differences in region-specific expression of proteins have been noted in other 
mutant mouse models as well. In an α1 KI mouse model, α1 protein expression in the 
cerebellum of homozygous KI was comparable to that in WT [153]. However, α1 protein 
expression in cortex of homozygous KI was reduced compared to WT [153].  
Given the reduction of α4 in the HET mice and the reduced motor ataxic response 
to RY023, KO mice would be expected to have an even greater reduction in RY023-
induced motor ataxia compared to HET mice. However, this was not the case. KO mice 
were similar to WT in their response to the motor ataxic effects of RY023. It is conceivable 
that reduction of α4 in HET fails to induce marked compensation and this allows for the 
role of α4 in RY023 response to be visible. In contrast, in KO mice, compensation is 
possibly much more extensive and this compensation masks the role of α4 in the actions of 
RY023. 
Due to limited number of mice and nature of the study design, I was unable to 
compare directly the effects of ethanol-induced ataxia and the effects of RY023 antagonism 
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 on ethanol induced ataxia between genotypes. However, ethanol-induced motor ataxia was 
assessed separately in HETs, WT and KO and found not to differ between the genotypes 
(data not shown). Antagonism of ethanol-induced motor ataxia by RY023 was tested at 
multiple doses of RY023 in HET mice (not shown). At no dose of RY023 was an 
antagonism of ethanol-induced motor ataxia observed on rotarod. In addition, combined 
RY023 and ethanol treatment produced hyperactive effects in mice as a result of which 
motor ataxic effects on rotarod could be assessed effectively. 
Nevertheless, because intrinsic effects of 10mg/kg RY023 differed among the 
genotypes, the effect of 10mg/kg of RY023 on ethanol-induced motor ataxia in all three 
genotypes was assessed. In contrast to intrinsic effects, no differences between genotypes 
were observed on the effects of RY023 on ethanol-induced motor ataxia. These 
observations imply that RY023 was not capable of antagonizing the effects of ethanol 
effectively on motor coordination at the dose tested.  
These data are in contrast to data reported by Cook et al [253] in rats. The said 
study involved the use of an oscillating beam test to assess ethanol-induced motor 
incoordination and its antagonism by RY023. Under those conditions, RY023 was 
successful in antagonizing the effect of ethanol. While the doses of RY023 used were 
7.5mg/kg and 15mg/kg, a lower dose of ethanol (0.75-1.25 g/kg) was used in that assay. 
Although the dose of RY023 used in our experiments (10mg/kg) was in the same range as 
that used by Cook et al [253], an antagonizing effect of RY023 was not observed on 
ethanol-induced (2g/kg) motor ataxia tested by the rotarod assay. The higher dose of 
ethanol in my assay could affect multiple receptor combinations which may have varying 
affinities to RY023 and hence reversal of ethanol effects was not apparent. Interestingly, in 
the oscillating bar assay, a 15mg/kg dose of RY023 alone did not alter the time spent on the 
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 oscillating bar, indicating that this dose was without intrinsic effect in rats. This suggests 
either a species difference in response or a behavior-specific modulation of  the RY023 
effect. Thus, the effects of RY023 may be both ethanol dose specific as well as behavior 
specific.  
Results obtained from experiments on HET mice suggest that α4-containing 
receptors may be involved in the intrinsic motor-ataxic effects of RY023. Because ethanol-
antagonistic effects of RY023 on motor ataxia could not be tested here, it is difficult to 
comment about the role of α4-containing receptors in this effect of RY023. The use of 
multiple behavioral assays for motor ataxia (oscillating bar test, rotarod, beam walking, 
pole walking etc.) coupled with different dose combinations of ethanol and RY023 are 
required to be able to dissect the role of α4-containing receptors in RY023 antagonism of 
ethanol-induced motor ataxia.  
 
3.4.2 Role of α4-containing receptors in effects of RY023 on ethanol-induced 
LORR: 
RY023 was effective in reversing the effect of ethanol-induced LORR in all three 
genotypes. This observation implies that α4-containing receptors are not required for this 
effect of RY023 and that the drug acts at non-α4 sites to reverse the effects of ethanol. 
Surprisingly, the greatest reduction of ethanol-induced LORR by RY023 was observed in 
HETS. At present, the reasons for this dramatic response in HETS are not understood.  
Regardless, it is safe to conclude that α4 subunit-containing receptors are not essential for 
the ethanol-antagonizing effect of RY023 on LORR.  
This result is in contrast with that obtained with Ro15-4513. The antagonizing 
effect of Ro15-4513 on ethanol-induced LORR was absent in α4 KO indicating that α4-
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 containing receptors are required for the effects of Ro15-4513. Similar results were seen on 
the antagonizing effects of Ro15-4513 on motor ataxia. In 2006, Hanchar et al proposed 
that the RY series of drugs and Ro15-4513 act via a common site, namely α4δ- and α6δ-
containing receptors to mediate their ethanol-antagonistic effects [262]. However, the 
results obtained here indicate that in contrast to Ro15-4513, RY023 does not require α4-
containing receptors for its antagonistic effects on ethanol-induced LORR.  
In the LORR assay, WT and KO mice did not differ in their responses to ethanol-
induced LORR. This is consistent with the effects noted by Chandra et al [186]. Of course, 
this automatically begs the question of whether α4-containing receptors are even involved 
in LORR induced by ethanol. Since previous studies indicate that the KO did not differ 
from the WT in their response to high doses of ethanol [186], one might conclude that α4-
containing receptors are not involved in ethanol effects. However, the changed cellular 
responses to ethanol indicate that the lack of α4-containing receptors results in functional 
reorganization such that synaptic currents are more sensitive to ethanol in the α4 KO.  This 
is likely responsible for maintained ethanol responses in the α4 KO [340]. The absence of 
discernible behavioral differences between WT and KO may be attributed to extensive 
synaptic compensation by α1, α2 and γ subunit-containing receptors in the KO [349, 350]. 
It is also possible that only low dose behavioral effects of ethanol such as impariment of 
cognition may be affected by α4-containing receptors. Behavioral effects of sedation, 
motor ataxia and hypnosis refer to moderate to high levels of ethanol intoxication. 
Unfortunately, very few behavioral assays are available for the assessment of low dose 
effects of ethanol. The development of a novel behavioral assays, such as the test for 
ethanol-induced cognition impairment developed by Moore et al [383], will enable a more 
detailed study of low dose ethanol responses is required.  
123
 A significant baseline difference was noted in the SE group with the HETS having 
durations of LORR greater than that experienced by KO. This observation suggests that 
moderate reduction of α4 in HETS likely unmasks a more sensitive target of ethanol. Thus, 
it may be possible that α4-containing receptors regulate the effects of ethanol due to their 
increased sensitivity. Given the limited evidence of this in my studies, I acknowledge the 
need to better study HET mice with ethanol to confirm my hypothesis.  
 
3.4.3 Role of α4-containing receptors in RY023-induced sedation:  
Last, the sedating effects of RY023 alone were evaluated. A dose of 15mg/kg 
produced marked reduction in distance traveled over a period of 10 minutes in a novel 
environment. The sedative response to this dose of RY023 is consistent with that noted by 
Cook et al, [253]. In fact, other RY drugs tested on the open field assay were found to 
produce similar sedative effects [254, 256].  
The sedative effects of RY023 were mainitained in WT and HET mice, but not in 
α4 KO mice. These results imply that RY023 requires α4-containing receptors for 
modulation of this behavioral effect in mice.  
Due to limited numbers of subjects, it was not possible to include ethanol-treated 
mice and study the antagonizing effects of RY023 on ethanol-induced locomotor behavior. 
In rats, RY023 anatagonized the effects of ethanol on locomotor behavior [253].  
Slight differences were observed in baseline behavior between genotypes during the 
study of the sedating effects of RY023. While KO and HET mice had comparable baseline 
behavior, they both had reduced locomotor activity compared to the WT. However, these 
differences were found to be only borderline significant. In previous experiments with 
saline and with 22.5% HBC, WT and KO were not found to differ ([186] and this study, 
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 Fig. 2.7A). Because the same has not been noted in previous experiments with different 
vehicle controls, it is unlikely that this represents a major physiological difference between 
WT and KO mice.  
 
3.4.4 Role of α4-containing receptors in RY023 effects: 
Evidence gathered so far in relation to intrinsic effects and ethanol-antagonizing 
effects of RY023 indicate that these two effects are likely mediated by distinct receptor 
subtypes. My results demonstrate that: 
1) α4-containing receptors may be involved in RY023's intrinsic motor ataxic effects, 
based on the reduced response seen in HET mice, although this warrants further 
study. 
2) α4-containing receptors are not required for RY023's reversal of ethanol-induced 
LORR. 
3) α4-containing receptors are a site of action for the intrinsic sedating effect of RY023. 
4) Ethanol antagonistic actions of RY023 on LORR are different from those of Ro15-
4513 on the same behavior – while RY023 does not require α4-containing receptors 
for its effects, Ro15-4513 does require α4-containing receptors for its effects. 
It is interesting to note that while HETS differed from WT on certain behaviors 
(motor ataxia), they were not significantly different on other behaviors where the KO 
differed from WT (sedation). It is possible that compensation was succesful in recovery of 
certain behaviors but not of others in the KO (e.g., motor ataxia versus sedation). The 
behavioral differences between HET and KO suggest that α4-containing receptors may be 
important for motor behaviors, hence their complete absence triggers widespread 
compensation that rescues motor behavior in the KO whereas a moderate reduction in 
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 HETs does not trigger the same compensatory response. In contrast, α4-containing 
receptors may play a lesser role in sedating behavior, hence a moderate reduction does not 
affect this behavior much but a complete lack of α4-containing receptors has some 
repercussions that cannot be compensated for.  
These contrasting behaviors between HETS and KO resulting from ablation of a 
target likely hold some clues about the evolutionary roles of particular targets – why 
compensatory mechanisms exist for some behaviors but not for others. These questions 
bear further study and from an evolutionary standpoint, it would be interesting to 
investigate the differences between HET and KO at the gene transcription level.  
 
3.4.5 Summary of α4-containing receptors as targets of ethanol antagonists:  
 
In conclusion, results from this study indicate that α4-containing receptors may be 
involved in some intrinsic effects of RY023 (as studied on motor ataxia and sedation), but 
not in its ethanol antagonistic action (as studied on ethanol-induced LORR). This is in 
keeping with the global hypothesis that different subunit-containing receptors have critical 
roles in certain behaviors but not all. Hence, α4-containing receptors are involved in the 
locomotor behavior of RY023 and as noted earlier, of alphaxalone. Results from the above 
experiments also imply that RY023 is less specific for α4-containing receptors compared to 
Ro15-4513 for its ethanol antagonistic effects. Ro15-4513 produced a dramatic reversal of 
ethanol-induced ataxia and ~50% reduction in ethanol-induced LORR in WT but not in KO 
[341]. The ability of Ro15-4513 to bring about reduction in ethanol-induced effects in WT 
but not in KO also indicate that α4-containing receptors must be involved in ethanol-
induced LORR effect and are specifically targeted by Ro15-4513 to bring about reversal. 
RY023, presumably, is not as specific for α4-containing receptors, but by virtue of its 
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 potent actions on other receptors involved in this behavior, is able to reduce the effects of 
ethanol-induced LORR.  
It is possible that as originally proposed by Liu et al [260], RY023 may be acting 
primarily through α5-containing receptors. However, given the diverse effects of RY023, it 
is plausible that other receptor subtypes also contribute to the effects of RY023. RY023 is 
an inverse agonist with low affinity at α1/2β2γ2 containing receptors [253]. It is possible 
that the inverse agonist activity at these receptor subtypes modulates some of its behaviors. 
The effects of RY023 at δ-containing receptors have not been characterized. The recently 
discovered α1δ-containing receptors in the hippocampus [320] that potentiate tonic curents 
in response to low concentrations of ethanol are another attractive target for RY023. 
Further pharmacologic and functional characterization of RY023 at different receptor 
subtypes is required to better understand its effects.  
Finally, Ro15-4513 failed to reverse the ethanol-induced LORR effect in KO but 
RY023 reversed this effect across all three genotypes. These observations suggest that 
reversal of ethanol effects can be harnessed through diverse receptor combinations. Hence, 
further research into these novel ethanol-antagonistic compounds is required to understand 
the specificity of these compounds and behaviors affected by them. 
In summary, while Ro15-4513 requires α4-containing receptors for its ethanol 
antagonistic effects on LORR and motor ataxia, RY023 does not require α4-containing 
receptors for its ethanol antagonistic effects on LORR, at least. However, RY023 does 
require α4-containing receptors for its intrinsic sedating effects and possibly motor ataxia.  
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 Chapter 4: The role of α4-containing GABA A receptors 
in chronic ethanol withdrawal behaviors and in taurine-
induced alleviation of the same. 
4.1 Introduction: 
Alcohol withdrawal syndrome (AWS) results from an imbalance between excitatory 
and inhibitory neurotransmission. After cessation from ethanol exposure, a predominantly 
excitatory system persists with lowered inhibitory neurotransmission and increased 
glutamatergic neuronal firing leading to AWS which is characterized by irritability, 
anxiety, insomnia, seizure susceptibility, etc. The effects of AWS are often severe and are 
thought to be a factor in determining relapse [135].  
It is, therefore, proposed that drugs that reduce the negative aspects of withdrawal 
would be effective in preventing relapse. Among the current pharmacotherapies for alcohol 
dependence is acamprosate. Acamprosate, approved by the FDA in 2004, is effective in 
reducing relapse to alcohol. This, it does, in part, by acting on a hyperactive glutamatergic 
system. While the complete mechanism of action of acamprosate is not known, it is thought 
that acamprosate alleviates withdrawal by indirectly reducing excitatory glutamatergic 
neurotransmission (For review, see [389]). These indirect effects could be mediated 
through GABA transmission, antioxidant mechanisms or by modulating amino acids during 
withdrawal. Regardless, the prevention of a hyper-glutamatergic state appears to alleviate 
withdrawal symptoms and protects from relapse. In addition to these effects, acamprosate 
is thought to prevent changes in β endorphins [390, 391] and leptin [392], both of which 
are associated with dependence and craving mechanisms. Although the mechanism of 
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 action of acamprosate is not clearly understood, it is speculated that at least some of its 
actions are mediated mainly by glutamatergic systems at low doses  and by GABAergic 
systems at high doses [393].  
 
Acamprosate exists as a calcium salt of the taurine derivative- homotaurine (Fig. 
4.1, adapted from [360]). Interestingly, taurine itself has been implicated in antagonism of 
acute and chronic alcohol effects. Taurine is a sulphated amino acid that is synthesized 
from cysteine. It is thought to be involved in mutiple processes such as neuroprotection, 
antioxidant, calcium homeostasis, immune-modulation, chloride current potentiation and 
inhibition of excitatory glutamatergic neurotransmission [208]. Taurine bears some 
structural similarity to both GABA and glycine and acts as a chloride-mimetic agent. Thus, 
it potentiates inhibitory neurotransmission.   
In a study on chronic ethanol effects, Zalud et al, showed that taurine treatment 
reduced the incidence of handling induced convulsions (HIC) during chronic ethanol 
withdrawal in C3H/HeJ mice [233]. In the untreated group, significant seizure incidences 
 
 
 
Figure 4.1 Chemical Structures of GABA, Acamprosate, Taurine and associated entities 
Chemical structures of GABA, taurine, hypotaurine (precursor), isethionic acid (metabolite),  
homotaurine and the anti-addiction drug acamprosate. Acamprosate occurs as an acetylated form of 
homotaurine and is dimerized as a calcium salt, adapted from Olive, M.F. 2002. Interactions 
between taurine and ethanol in the central nervous system. Amino Acids, 23(4): p. 345-57 
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 were noted in addition to a reduction of taurine in several areas of the brain. Thus, a role 
for taurine in alleviation of ethanol withdrawal effects was proposed. A taurine-depletion 
study in adolescent mice also showed enhanced corticosterone levels post-chronic ethanol 
exposure in the taurine-depleted group but not the control group [394]. This indicated a link 
between increased stress and low levels of taurine following chronic ethanol treatment. In 
another study, a 7 day pre-treatment of taurine increased the open arm scores for ethanol-
withdrawn mice [395]. Thus, taurine alleviated ethanol withdrawal-induced anxiety. In 
conclusion, multiple studies have pointed out a link for taurine in alleviating biochemical 
and behavioral effects of chronic ethanol.  
However, the mechanism of action of taurine behind these effects is not known. It 
was previously thought that taurine acted more potently at glycine receptors (200uM-1mM) 
than at GABA receptors (1-10mM) [204, 213, 215, 218, 396-398]. However, recent work 
by Jia and collegues elicited that taurine showed greater sensitivity (10-100uM) for 
extrasynaptic GABA receptors than for glycine or synaptic GABA receptors [234]. This 
study also showed that taurine-induced current potentiation was due to a direct effect on 
GABA A receptors and not by indirect increases of ambient GABA. High levels of taurine 
are present in dentate gyrus, cerebellum and thalamus [203] and these regions also express 
high levels of α4/α6δ -containing receptors [337, 399]. Interestingly, taurine-induced 
GABAergic tonic current potentiation was ablated in the ventrobasal thalamic neurons 
from α4 KO mice confirming the idea that taurine acted on α4-containing receptors to 
produce chloride current modulation [234]. These findings implied that cellular responses 
of taurine could be preferentially mediated through α4-containing receptors. 
α4-containing receptors undergo remarkable plasticity during ethanol withdrawal. 
During chronic ethanol withdrawal, increases in the levels of α4 and γ2 subunits are 
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 consistently observed [178, 330]. Insertion of 'new' α4 containing receptors into synaptic 
locations along with γ2 takes place [331]. In addition, there is decrease of synaptic α1 and 
decrease of extrasynaptic δ subunits [178]. These changes lead to altered receptor kinetics 
and sensitivity to ethanol, neurosteroids and classical benzodiazepines [181, 325]. These 
changes are thought to underlie the changed behavioral responses to ethanol and to 
classical benzodiaepines [400]. The sensitivity of α4-containing receptors to gaboxadol and 
Ro15-4513 during chronic ethanol withdrawal [178, 181, 325] suggest that drugs acting on 
α4-containing receptors retain their activity during this period. Because α4-containing 
receptors are increased during ethanol withdrawal, it is possible that a drug such as taurine, 
that is potent at α4-containing receptors, may continue to exert its effects through these 
receptors.  
Because conventional sleep-aids and anticonvulsants have limited success in 
treatment of withdrawal symptoms, understanding the biochemical changes underlying 
chronic ethanol withdrawal and identifying drugs that are more effective at the changed 
receptor compositions may be the route to better treatment and management of chronic 
ethanol withdrawal and dependence. The availability of the α4 KO mouse and the fact that 
these mice develop chronic ethanol withdrawal parameters comparable to their WT 
counterparts (unpublished data) makes this an attractive project, which if succesful, could 
warrant detailed study and development of similar synthetic compounds. 
Because of the relevance of α4-containing receptors during chronic ethanol 
withdrawal, I hypothesized that α4-containing receptors are required for the effects of 
chronic ethanol withdrawal. I proposed to expand on previous studies and also examine the 
effects of taurine on three different withdrawal-related behaviors such as seizure 
susceptibility (HIC scoring), locomotor behavior, and protracted tolerance to ethanol. 
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 Given the sensitivity of α4-containing receptors to taurine and the fact that taurine 
improves chronic ethanol withdrawal HICs, I hypothesized that the increased α4-
containing receptors during chronic ethanol withdrawal mediate this protective effect of 
taurine. I predicted that taurine would protect against three withdrawal-related behaviors in 
WT mice but not in α4 KO mice.  
 
 4.2 Materials and Methods  
4.2.1 Chronic ethanol withdrawal induction: 
WT, HET and KO mice of both sexes were chronically exposed to ethanol by a vapor 
inhalation method adapted from that described by Dr.Goldstein [401, 402]. Ethanol vapors 
were conveyed to two inhalation chambers (60 X 82 X 39 cm, Plexiglas, Polycast 
Technology Corp., Stamford, CT). Each chamber was capable of housing 5 home cages of 
mice. Each chamber was fitted with an inlet (for ethanol vapor) and an outlet (for venting) 
port as well as a fan at the top right corner for circulation of vapors. Ethanol (Pharmco, 
Brookefield, CT) was conveyed at a measured rate (120-140ul/min) by means of a 
peristaltic pump (Cole Parmer, Model 75 23-20) into heated flasks, maintained at 55°C. Air 
was passed into each flask at a flow rate of 8L/min. Ethanol vapors were then carried into 
each chamber by the flowing air. Vapors were vented by means of outlet tubes into a fume 
hood. Chamber ethanol concentrations were not determined.  
 Ethanol treatment followed the multiple withdrawal model of Becker and Hale [403]. 
On day 1, at 3 PM, mice were injected with pyrazole (alcohol dehydrogenase inhibitor) at a 
dose of 68mg/kg (0.01 ml/g body weight) followed by a priming dose of ethanol (1.5g/kg, 
0.01 ml/g body weight). After injections, mice were placed in the inhalation chambers in 
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 their home cages for 16 hours. On day 2 at 7AM, home cages were removed from the 
chambers and placed on racks. Body temperatures were measured at the start of each 
abstinence period. A heat lamp was placed in the room to maintain temperature and each 
cage was provided with transgel for easy access to fluids. Four hours into each withdrawal 
period, at 11AM, mice were weighed and injected with taurine (500mg/kg, Sigma Aldrich, 
St.Louis, MO) or saline (0.01 ml/g body weight). This cycle was followed for 3 days. On 
day 4, mice were removed from inhalation chambers at 7AM and 50µl of blood was 
collected via the retro-orbital route for measurement of blood ethanol concentrations 
(BEC). Only HET mice from taurine (T) and saline (S) treatment groups from both 
chambers were bled. Ethanol-treated mice were excluded from behavioral analyses if BEC 
was <50 or >300 mg/dl. Mice that had temperatures lower than 32°C, or lost more than 
10% of their weight in one cycle or were visibly moribund/comatose were excluded from 
the experiment.  
Previously, α4KO and WT were compared for differences in HIC following chronic 
ethanol exposure (unpublished results). In that experiment, WT and KO mice that received 
air exposure (controls) did not differ in their behavior, i.e., baseline HIC was comparable. 
Chronic ethanol exposure produced comparable HIC in both WT and KO. In the chronic 
ethanol-taurine experiments, due to availability of limited numbers of subjects, and prior 
experience in inducing chronic ethanol withdrawal in this line of mice, Air-taurine and Air-
saline controls were omitted. For each of the behavioral experiments, data were analyzed 
by two-way ANOVA with genotype and treatment as main effects. Although, mice of both 
sexes were used towards this assay, due to limited numbers, data were not analyzed by sex.  
4.2.2 Blood ethanol concentration (BEC) determination:  
BEC were determined by means of a spectrophotometric process described elsewhere 
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 [404]. HET mice (n≥3 per treatment group per replicate of assay) from each cohort were 
bled at the start of the final withdrawal period. Approximately 50µl of blood was collected 
by heparinized capillary tubes via the retro-orbital route at the end of the third cycle of 
chronic ethanol exposure. Fifteen µl of blood was added to 1ml of ice-cold 0.55M 
perchloric acid. Samples were thoroughly mixed and centrifuged at 1500 X g for 10 min at 
4°C. Supernatants were subsequently used to assess ethanol concentration via an alcohol 
dehydrogenase enzymatic reaction and quantified with a spectrophotometer at a 340nm. 
BECs were calculated using a set of ethanol standards. BECs were averaged for each 
treatment group and means compared by unpaired Student’s t-test. 
4.2.3 Ethanol withdrawal-induced hyperexcitability (HIC scoring): 
Beginning the second hour following termination of the third and final ethanol treatment 
cycle, mice were scored for handling induced convulsions (HIC) at hourly intervals for 
nine hours, (9AM-5PM) of the withdrawal period using the scale of Becker and Hale [403]. 
Scoring was conducted by two observers who were unaware of the genotype or treatment 
of the mice being tested. Briefly, mice were scored as follows: 0 – No response after pick 
up or gentle 360° spin; 1 – facial grimace after gentle 360° spin; 1.5 – facial grimace on 
pick up; 2 - tonic convulsion after gentle 360° spin; 3 - tonic/clonic convulsion after gentle 
360° spin; 4 - tonic convulsion on pick up; 5 - tonic/clonic convulsion on pick up, that may 
be delayed by a few sec; 6 - severe tonic/clonic convulsion on pick up, no delay and often 
lasting after mouse was released, and; 7 - severe tonic/clonic convulsion prior to pick up, 
that may result in death. Responses from both observers were averaged to arrive at the final 
scores. Mean hourly HIC scores were used to generate HIC curves for each genotype-
treatment combination, e.g., WT-S; WT-T; KO-S; KO-T; HET-S; HET-T. Area under 
curve (AUC) was calculated as the sum of area between baseline and scores over time 
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 (Hours 2-24). AUC’s for each treatment group were compared by two-way ANOVA.   
4.2.4 Ethanol withdrawal-induced locomotor behavior: 
Twenty four hours into the final withdrawal period, mice were scored for HICs at the 24th 
hour time point. Following the scoring, mice were sequentially introduced into a novel 
environment to record exploratory locomotor behavior during withdrawal. Mice were 
placed in the center of a plexiglass walled arena, (43.2 cm X 43.2 cm X 30.5 cm) for 
automated recording of locomotor behavior. Two such chambers were used so that two 
subjects could be tested at a given time by placing within each chamber. The chambers 
were placed within sound-attenuating cubicles (Med Associates, St.Albans, VT) that were 
provided with a red light and a fan (top right corner). Distance traveled (cm) over a 5 
minute period was recorded by an automated program (Med Associates, St.Albans, VT). 
Between mice, the chambers were cleaned with 70% ethanol followed by water to remove 
any evidence of smells and excrements left behind. Total distance traveled in the 5 min 
period as well as percent distance traveled in center zone was calculated. The center zone 
was demarcated as the central portion of the open field (11.25 X 11.25cm). Center zone 
activity was expressed as percent distance covered in center zone.	  Data were analyzed by 
two-way ANOVA. Mice that had 'total distance' scores of 0 were excluded from the 
analysis. 
4.2.5 Protracted tolerance to ethanol: 
Following measurement of locomotor activity, each mouse was injected with 3.5g/kg of 
ethanol (0.02mls/g body weight) to assess tolerance to ethanol-induced loss of righting 
reflex (LORR). This testing took place between hours 24-26 of the final withdrawal period. 
For the duration of LORR, mice were placed on V-shaped troughs and under a heat lamp in 
order to maintain normothermia. Righting reflex was regained when mice were able to 
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 right themselves consecutively three times within 30 sec. Duration of LORR for each 
genotype and treatment combination were analyzed by two-way ANOVA and Fisher's post 
hoc tests.  
 
4.3 Results  
 4.3.1 Effect of taurine on blood-ethanol concentrations: 
At the start of the third withdrawal period, blood was collected from a subset of chronic 
ethanol-treated mice with and without taurine treatment. From pilot experiments, it was 
known that ethanol blood levels do not vary between genotypes. Due to the stress 
associated with the experiment, only HET mice were bled from each chamber per treatment 
group (S and T) as representative of the cohort of mice on the day of the experiment. Mean 
BECs for saline and taurine treated groups were 228.36±18.66 mg/dl and 
244.8±13.4mg/dl, respectively. No differences were seen in the blood ethanol levels in 
saline and taurine treatment groups. 
 
4.3.2 Effect of chronic ethanol treatment on body weight: 
Analysis of body weight in mice (from day 1 to day 4) undergoing chronic ethanol 
treatment by two-way ANOVA showed no effect of treatment but a strong effect of 
genotype [F(2,110) = 9; p < 0.001]. No interaction between genotype and treatment was 
observed. Pair-wise comparisons revealed that percent weight loss in saline-treated KO 
mice was significantly lower than HET mice (p<0.05). Significant differences between 
genotypes on taurine-treated mice was also observed. Percent weight loss in KO was 
significantly reduced compared to WT (p < 0.05) and HET (p < 0.001) mice. A treatment 
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 effect within each genotype was not observed. The percent weight loss for all three 
genotypes was below 10%. As mentioned earlier, mice that suffered >10% weight loss 
through the ethanol exposure period were not included in the withdrawal tests.  
 
Table 4.1 Percent change in body weight in WT, HET and KO mice undergoing chronic 
ethanol exposure with saline and taurine treatment ( * p < 0.05, comparing with saline-treated 
HET; ** p < 0.05, comparing with taurine-treated WT; # p < 0.001, comparing with taurine-
treated HET). 
 
      
Genotype Saline (%) Taurine (%) 
WT 
(n) 
-8.3 ± 0.7 
(16) 
-8.1 ± 0.8 
(19) 
HET 
(n) 
-9.6 ± 0.6 
(21) 
-9.3 ± 0.5  
(20) 
KO 
(n) 
-6.8 ± 0.9* 
(17) 
-6.2 ± 0.7 ** # 
(23) 
 
4.3.3 Effect of taurine on withdrawal-induced hyperexcitability (HIC scoring) : 
Handling-induced convulsions following chronic ethanol withdrawal were used to assess 
two parameters – the role of the α4-containing receptors in ethanol withdrawal-induced 
HICs and  the role of α4-containing receptors in effects of taurine on HIC. The time-course 
of ethanol withdrawal hyperexcitability in saline- and taurine-treated mice is depicted in 
Fig. 4.2A and 4.2B, respectively. The time-course of HIC scoring shows that withdrawal-
induced HICs increased reliably over a 10 hour period with a decrease at the 24 hour time 
point. This pattern of severity is consistent with withdrawal-induced HIC severity in other 
strains of mice [187, 191]. An overall two-way ANOVA was performed on AUCs (Table 
4.2) of saline-treated and taurine-treated genotypes. Main effects of treatment, genotype or 
an interaction between the two were absent. Thus, HIC scores in α4 KO mice did not differ 
from WT and HETs. Therefore, the lack of α4 containing receptors did not affect 
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 withdrawal-induced HIC. The lack of difference between treatment groups indicates that 
taurine treatment did not improve withdrawal-related HICs in any genotype. 
 
 
Table 4.2 Mean AUC's for saline and taurine-treated WT, HET and KO mice. 
 
Mean AUC's Saline Taurine 
WT 
(n) 
25 ± 2 
(16) 
23 ± 4 
(14) 
HET 
(n) 
25 ± 4 
(15) 
27 ± 3 
(12) 
KO 
(n) 
18 ± 4 
(15) 
24 ± 3 
(18) 
A.      
 
 B. 
   
Figure 4.2 Time course of Handling induced convulsions: 
(A) Saline-treated and (B) Taurine-treated WT, HET and KO mice. No differences were 
observed between the genotypes within either treatment group. A between-treatment analysis 
also did not reveal any differences between genotypes. (n=12-18 per genotype-treatment 
combination). Each time point represents mean score ± SEM. 
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3.3.4 Effect of taurine on withdrawal-induced locomotor and anxiety-like behavior: 
Locomotion and anxiety-like behavior in WT, HET and KO mice during ethanol-
withdrawal and the effect of taurine on this parameter was determined using the open field 
activity assay. It was expected that mice would have reduced locomotor activity during 
withdrawal and further that center zone locomotion compared to the total would be reduced 
as an indicator of anxiety-like behavior. Several groups have noticed similar reductions 
during ethanol withdrawal (See review [405]). Taurine treatment was expected to alleviate 
ethanol withdrawal – induced anxiety-like behavior.  
Following measurement of 24th hour HIC scores, mice were subsequently subjected 
to measurement of locomotor behavior by an automated activity monitor. An overall two-
way ANOVA on total distance covered over a 5 minute period revealed no effect of 
treatment, genotype or interaction. Thus, WT, HET and KO mice did not differ in the total 
distance covered with saline or taurine treatments (Fig. 4.3.A). This indicates that the lack 
of α4-containing receptors does not affect locomotor behavior during withdrawal. In 
addition, taurine-treatment did not produce any changes in locomotor behavior. Although 
air-exposed control mice were not tested in this assay, previous locomotor behaviors 
recorded on treatment-naive mice over a 5 minute period [186], were used to determine if 
chronic ethanol treatment affected locomotor behavior. As expected, a decrease in distance 
covered  was noted with chronic ethanol treatment.  
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Next, percent distance covered in the center zone was compared between the three 
genotypes with saline or taurine treatment (Fig. 4.3.B). An overall two-way ANOVA of the 
percent distance covered in center zones did not reveal a significant effect of treatment, 
genotype or interaction. The percent distance covered in center zones in saline- treated 
ethanol withdrawn mice was not reduced compared to that experienced by treatement-naive 
mice (recorded previously). This suggested that saline-treated ethanol withdrawn mice 
likely do not experience an anxiety-like effect during withdrawal. The lack of a difference 
by treatment also suggested that taurine treatment did not produce any changes to anxiety-
like behavior during withdrawal. Hence, the contribution of α4-containing receptors to 
anxiety-like behavior during withdrawal could not be measured.  
A. 
 
 
    B. 
 
Figure 4.3 Withdrawal-induced locomotor and anxiety-like behavior  
(A) Total distance covered did not differ due to treatment or genotype. 
(B) Percent distance covered in center zone also did not differ by treatment or genotype. 
Data are expressed as mean ± SEM. 
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 4.3.5 Effect of taurine on protracted tolerance to ethanol: 
Following testing of withdrawal-induced locomotion, between 24 to 26 hours post 
ethanol exposure, mice were assessed for tolerance to ethanol-induced LORR. An overall 
two-way ANOVA revealed no effect of treatment, however a near-significant main effect 
of genotype was observed [F(2,95) = 3, p = 0.078]. An interaction between genotype and 
treatment was not observed. Fisher's post hoc tests revealed no difference between the 
genotypes in the saline treated (S) groups indicating that genotypes did not differ in their 
response to ethanol-induced LORR. However, a significant difference between KO and 
WT (p< 0.05) and HET and KO (p< 0.005) was observed in the taurine-treated (T) groups 
(Fig. 4.4). Taurine-treated KO mice had reduced sleep times compared to WT and HET 
mice, suggesting that KO mice responded to taurine.  
     
Figure 4.4 Protracted tolerance to ethanol with saline- and taurine-treated WT, HET and KO mice.  
Protracted tolerance to ethanol-induced LORR was not different between the genotypes on saline-
treated mice. However, tolerance to ethanol-induced LORR was different between the taurine-treated 
genotypes. Taurine-treated KO mice had significantly reduced sleep times compared to WT and HET 
mice. Taurine-treated WT and HET mice were not different. Data are expressed as mean ± SEM. 
141
  3.4 Discussion: 
The purpose of these experiments was to determine if α4-containing GABA A 
receptors were essential for the withdrawal-alleviating effect of taurine and for ethanol 
withdrawal in general. According to the withdrawal model proposed by Liang et al [358], 
during chronic ethanol withdrawal, α4 levels increase and α4 specific agonists have 
enhanced effect during this time. Because α4 undergoes changes in expression and 
localization, I hypothesized that α4-containing receptors are critical for ethanol withdrawal 
behavior. In addition, since taurine is hypothesized to act through the α4-containing GABA 
A receptors [234] and has a protective effect during withdrawal [233], I proposed that lack 
of α4-containing receptors would nullify the effect of taurine during withdrawal. Several 
parameters of withdrawal effect such as HIC, locomotor behavior and tolerance to ethanol 
were evaluated in α4 WT, HET and KO mice. I also explored the effect of taurine on these 
withdrawal behaviors. In contrast to my expectations, α4 WT, HET and KO mice did not 
differ in the ethanol withdrawal behaviors assessed here. Further, a protective effect of 
taurine on chronic ethanol withdrawal was not observed on most ethanol withdrawal 
effects.  
 
3.4.1 Role of α4 in chronic ethanol withdrawal-induced HIC and effect of taurine: 
HIC scores between saline (S) and taurine (T) groups were compared from hours 2-
10 and at 24 hours of the final withdrawal period. The intensity of withdrawal-induced 
HICs followed a time course similar to that observed in other strains of mice [187, 191]. 
Following saline treatment, withdrawal-induced HICs did not differ between WT, HET and 
KO mice. The lack of difference on HICs between genotypes is consistent with previous 
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 observations on this line of mice and suggests that lack of α4-containing receptors does not 
affect this withdrawal phenotype.  
 Reduction in levels of α4δ-containing receptors has in been linked to catamenial 
epilepsy. Several studies have shown a role for α4-containing receptors in seizure activity 
associated with fluctuating neurosteroid levels [288, 406, 407]. The reduction in δ subunits 
and the subsequent pairing of α4 subunits with γ2 subunits during ethanol withdrawal also 
results in overall reduced charge transfer during potentiation of tonic current [178, 179, 
181]. This is thought to result in the overall reduction of inhibitory neurotransmission and 
predominance of excitatory neurotransmission, leading to seizures. From these results, it 
appears likely that α4-containing receptors must be involved in some manner in mediating 
withdrawal-induced seizures. Therefore, it is quite surprising that deletion of these 
receptors did not affect HIC. It is possible that residual δ containing receptors dominate this 
behavior during withdrawal. It is also possible that compensatory responses in the global 
KO model result in unchanged HIC in the KO. 
Surprisingly, a protective effect of taurine on HICs was not observed in any of the 
genotypes. Given the results presented by the Diaz-Granados' group [233], this was 
surprising. However, it is possible that differences in our results arise from the different 
background of mice used in our experiments. In our study, a mixed background of 
C57BL/6J and Strain129S1/X1 mice was used, whereas the Diaz-Granados group used 
C3H/HeJ mice. Previous studies by independent groups have revealed that the C3H/HeJ 
strain is particularly susceptible to handling-induced seizures. It has been shown previously 
that C57BL/6J are recalcitrant to seizures whereas Strain 129S1/X1 are susceptible to 
seizures [187]. Thus, our mixed background is likely only moderately susceptible to 
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 seizures. It is possible that a greater effect of taurine may be apparent only on severe 
seizures.  
An alternate explanation could be inherent differences in our methods of 
withdrawal induction. Difference in behavioral parameters owing to the method of 
induction of chronic ethanol withdrawal is a problem that has been chronicled in the 
literature (for review see [405]). Dr.Diaz-Granados’ group utilized the chronic continuous 
ethanol vapor inhalation paradigm whereas our treatment consisted of a chronic 
intermittent ethanol vapor inhalation paradigm. Differences in the intensity of withdrawal 
could have resulted due to this. The mean BECs in this study (~230mg/dl) were greater 
than that observed by Dr.Diaz-Granados’ group (~150mg/dl). The higher levels of blood 
ethanol concentrations in our study may translate to more severe withdrawal. This could 
also have precluded an effect of taurine at the dose used. 
Differences in sensitivity to taurine may also contribute to the lack of effects seen in 
this study. One group reported that acute taurine treatment produced different effects in two 
different lines of mice [408], namely C57BL/6J and DBA/2J mice implying a possible 
difference in strain responses to taurine. Some groups have also noted differences in 
endogenous levels of taurine in certain strains of mice [409]. Thus, apart from differences 
in susceptibility to convulsions, the lack of an effect of taurine may also be linked to the 
endogenous levels of taurine and lowered basal responses in different lines of mice. As a 
result of such differences, an effect of taurine may be more closely linked to the dose of 
taurine used. The dose of taurine in the assays, here, was decided following personal 
communication with Dr.Diaz-Granados. Because the methods of induction of ethanol 
withdrawal differed between the two groups, it is possible that a 500mg/kg dose of taurine 
may have been insufficient to counter the withdrawal effects seen in our experiments. If 
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 this is indeed the case, further studies with different levels of intoxication and different 
doses of taurine should be conducted. This will help determine if taurine alleviates 
withdrawal in a dose-dependent manner. 
 
3.4.2 Role of α4-containing receptors in locomotion and anxiety induced by chronic 
ethanol withdrawal and effects of taurine on the same: 
Locomotor behavior and anxiety-like behavior in mice that were exposed to chronic 
ethanol vapors with and without taurine administration were assessed at ~24 hours into 
withdrawal. Initially, pilot assays using the elevated plus maze experiment to study 
withdrawal-induced anxiety-like behavior were performed. However, anxiety-like behavior 
could not be measured on this assay due to highly reduced locomotor behavior on the plus 
maze. Hence, percent distance covered in center zone of an open field was used as a 
surrogate of anxiety-like behavior instead. Comparison with naïve mice previously 
subjected to the open field assay indicated that naïve mice have greater ambulation 
compared to ethanol-withdrawn mice in this assay (not shown). All genotypes of mice 
undergoing chronic ethanol exposure, thus, had reduced locomotion. 
Once again, saline-treated α4 KO and HET mice did not show differences in 
ambulatory behavior compared to WT mice. This indicates that lack of α4-containing 
receptor does not affect locomotor behavior during withdrawal. Next, percent distance 
covered in center zones was assessed. This measure is often used as a surrogate of 
anxiety-like behavior in rodents. However, comparison with previously tested naïve mice 
indicated that ethanol-withdrawn mice did not differ in the percent distance covered in 
center zones. Hence, it is not certain if ethanol-withdrawal produced anxiety in these mice. 
Regardless, no differences were seen among saline-treated WT, HET and KO mice. 
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 Hence, I conclude that based on the evidence here, α4-containing receptors are not 
involved in this withdrawal effect.  
A reduction in inhibitory neurotransmission has been linked to anxiety during 
withdrawal. Similar reductions in inhibitory neurotransmission are observed in disorders 
associated with hormonal imbalance. α4δ-containing receptors are hypothesized to play a 
major role in the behavioral effects resulting from fluctuations in endogenous neurosteroid 
levels [291, 306, 315, 329, 410, 411]. In fact, the incidence of anxiety, irritability 
(associated with premenstrual syndrome) and postpartum depression has been linked 
reduced levels of δ-containing receptors [286, 288, 311]. Chronic ethanol withdrawal 
leads to changes in levels of neurosteroids [412]. The reduced δ subunits, changes in 
levels of neurosteroids coupled with the increase in α4-containing receptors during 
ethanol withdrawal may contribute to increased anxiety and associated locomotor 
behavior.  
Based on the results obtained in the locomotor behavior assay, it appears that α4-
containing receptors are not required for reduced locomotor behavior observed during 
ethanol withdrawal. Whether α4-containing receptors are important for anxiogenic effects 
could not be tested here due to the lack of anxiety like behavior in ethanol-withdrawn 
mice. Hence, an assay that is sensitive to anxiogenic effects of withdrawal is required to 
assess the involvement of α4-containing receptors in this effect.  
No differences were observed on either measure (total distance or percent distance 
in center zone) between saline- or taurine-treated WT, HET and KO mice. This result 
suggests that taurine treatment did not improve ethanol withdrawal-induced locomotor 
suppression or anxiety-like behavior. This is in contrast to the results reported by Helfand 
et al, although their model differed from that used in the current study. Helfand et al 
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 showed that pre-treatment with taurine (50mg/kg) 7 days prior to continuous chronic 
ethanol withdrawal induction, alleviated withdrawal-induced anxiety-like behavior on the 
elevated plus maze assay [395].  
Interestingly, another study by the same group where taurine was depleted by pre-
treatment with guanidinoethane sulfonate (a taurine uptake antagonist) for 7 days prior to 
chronic ethanol withdrawal induction did not elicit dramatic behavioral changes. 
Depletion of taurine did not significantly alter the withdrawal-induced anxiety on elevated 
plus maze although plasma corticosterone levels were increased [394]. Thus, although 
biochemical changes indicative of increased stress were observed, no differences in 
behavior were observed in mice due to taurine depletion in the latter study. This suggests 
that the nature of interaction of taurine with ethanol effects may be weak. While 
biochemical changes due to taurine administration may be observed, behavioral effects of 
taurine are likely subtle. The lack of differences in behavior in the mice used in this study 
could result from a similar situation, although this needs to be confirmed. Biochemical 
characterization of levels of taurine and stress indicators such as plasma corticosterone in 
ethanol vapor-treated mice would help shed some light on this possibility. 
 
3.4.3 Role of α4-containing receptors on protracted tolerance to ethanol in chronic 
ethanol withdrawn mice and effect of taurine on the same: 
Lastly, I wanted to determine if lack of α4-containing receptors affected protracted 
tolerance to ethanol. In addition, I wanted to determine if taurine treatment is able to 
alleviate the effects of tolerance to ethanol and if these effects depend on α4-containing 
receptors. Mice were exposed to a single intoxicating injection of 3.5g/kg of ethanol 
between 24 - 26 hours of chronic intermittent ethanol withdrawal. The resulting duration of 
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 LORR was recorded. Previous experiments with α6 WT and KO had revealed that 
tolerance to ethanol was reliably observed at 26 hours post-ethanol vapor cessation [187]. 
Hence, the same timeline was followed in the current study for assessment of tolerance to 
ethanol.  
Ethanol-withdrawn WT, HET and KO mice did not differ in their responses to the 
acute ethanol suggesting that α4-containing receptors are not required for this effect. Given 
the dynamic changes that the α4 subunit undergoes during ethanol and the vast amount of 
evidence linking it to tolerant behavior, it is surprising that no difference in sensitivity to 
ethanol was observed in ethanol-withdrawn α4KO mice. This result is similar to the lack of 
difference in response to acute ethanol-induced behaviors [186]. This result is surprising 
given the changes in α4 expression during ethanol withdrawal [178, 181, 330, 413]. An 
increase in α4γ2-containing receptors and a decrease in α4δ-containing receptors is 
observed during ethanol withdrawal [178, 179]. The reduction in ethanol-sensitive α4δ-
containing receptors and the subsequent pairing of α4 subunits with synaptic γ2 subunit 
[178, 179, 181] could contribute to tolerance to ethanol observed during withdrawal. 
Because α4-containing receptors are deleted in the KO mice, I hypothesized that tolerant 
behavior during ethanol withdrawal would be changed. The lack of difference between 
saline-treated WT, HET and KO mice suggests that α4-containing receptors are not 
absolutely required for the changed sensitivity to ethanol during withdrawal. 
However, it is possible that compensation in the α4 KO mice may have masked a 
role for α4-containing receptors in ethanol responses. The unchanged responses to acute 
ethanol in the α4 KO mice are hypothesized to result from compensation in the global KO 
[186]. These compensatory changes may minimize a role for α4-containing receptors 
during ethanol withdrawal. 
148
 Administration of taurine did not significantly affect durations of LORR compared 
to the saline-treated group (although a genotypic effect in the taurine treated group was 
apparent, discussed below). The lack of an effect of taurine in the WT and HETs suggests 
that taurine may not be effective in reducing tolerance to ethanol in chronic ethanol-
withdrawn mice.  
A significant difference between genotypes on the taurine-treated groups was 
observed. Taurine-treated KO had reduced LORR compared to taurine-treated WT and 
HET mice. The physiological significance of this is not clear immediately. It is not known 
how taurine may act to modulate tolerant responses to ethanol in chronic ethanol-
withdrawn mice. In acute ethanol experiments, taurine is known to antagonize the effects of 
ethanol [196, 219, 221, 414]. Hence, the reduced response to ethanol in taurine-treated KO 
may be the result of such antagonism. However, the lack of a reduced response to ethanol 
in taurine-treated WT and HETs suggests a changed response response to taurine unique to 
the KO. Apart from extrasynaptic α4-containing GABA A receptors, glycine receptors are 
also known to be sensitive to taurine, even more so than synaptic GABA A receptors [215, 
396, 398, 415]. It is possible that compensatory responses in the KO may include changes 
in the glycinergic system, which in turn may be responsible for the response to taurine. 
However, at present, evidence supporting this hypothesis is lacking and a gene array study 
of the α4 KO may provide some much needed answers toward this possibility.  
 
4.4.4 Summary of role of α4-containing receptors in chronic ethanol withdrawal 
and actions of taurine: 
The above experiments were designed to assess the involvement of α4-containing 
GABA receptors in ethanol withdrawal behavior and in the withdrawal-alleviating effects 
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 of taurine. Although the α4 subunit undergoes increases in expression, relocalization and 
displays sensitivity to α4-specific ligands during ethanol withdrawal [178, 180, 181], it is 
unclear if changes in α4-containing receptors are the cause or the effect of chronic ethanol 
withdrawal. By understanding if ethanol withdrawal behaviors are differently modulated in 
the global α4 KO mice, I sought to resolve the conundrum of involvement of α4-
containing receptors in ethanol withdrawal.  
Withdrawal behaviors in saline-treated WT, HET and KO mice were comparable on 
all three endpoints of HIC, locomotor and anxiety-like behavior, and tolerance to ethanol. 
This indicates that α4-containing receptors are not absolutely required for the chronic 
ethanol withdrawal effects assessed here. In spite of changes in expression and altered 
kinetics, α4-containing receptors may not be a critical mediator of these ethanol 
withdrawal effects. It must be noted that the changes observed in α4 subunit expression 
and relocalization have been studied mainly in the hippocampus [178, 180, 181]. At present 
it is not known how α4-containing receptors are changed in other parts of the brain. It is 
possible that the changes in α4-containing receptors in the hippocampus are but a small 
part of the vast changes occurring in the brain. Hence, the contribution of hipoocampal 
changes to behavior during withdrawal may be limited. It is also possible that α4-
containing receptors are involved in other withdrawal behaviors that were not assessed as 
part of this study. Thus, results from this study can only add another piece of information to 
what is already known about the modulation of withdrawal effects – that α4-containing 
receptors are not essential for ethanol withdrawal behaviors studied here. 
  A second goal of the above experiments was to ascertain if α4-containing 
receptors were required for the actions of taurine during chronic ethanol withdrawal. 
However, I was unable to determine this due to lack of an effect of taurine on most 
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 behaviors. Results obtained in this study suggest that taurine does not alleviate the ethanol 
withdrawal effects of seizure susceptibility, anxiety and tolerance under the given 
experimental conditions. Although responses to ethanol-induced LORR in taurine-treated 
α4 KO were changed, it is unclear if this represents a major role for α4 receptors. Rather, 
this effect may be an expression of compensatory responses in the α4 KO mice.  
A hypothesis for the relatively minor effects of taurine in this study is put forth. The 
premise of the above experiments was that increases in α4 in the aftermath of ethanol 
exposure could be harnessed by taurine for alleviating withdrawal endpoints. A positive 
effect of taurine on chronic ethanol withdrawal-induced seizures was demonstrated in 
C3H/HeJ mice [233]. But in my hands, no major effect of taurine was visible in our mice 
on three different endpoints of chronic ethanol withdrawal.  
It has been noted that different background strains exhibit behavioral differences 
that can be linked to differences in particular receptor types [416, 417]. Thus, while 
increases in α4 maybe dramatic and sufficient for an effect of taurine in C3H/HeJ mice, 
levels of α4 may not be increased to the same degree in a mixed background of C57BL/6J 
and Strain 129X1/SvJ mice. It is noteworthy that α4 protein levels were measured at 30 
hours into withdrawal in WT mice that had been subjected to chronic ethanol and air-saline 
treatment (data not shown). Analysis of Western blots of α4 protein from these mice 
revealed an increase in levels of α4 in the ethanol-treated mice (n=3). However, this 
increase was not significantly different from air-saline treated mice (n=3), given the small 
sample size. This suggested that α4 levels were increased in our strain of mice with the 
chronic ethanol treatment paradigm used here. 
A comparison of gene expression profiles and concurrent biochemical changes in 
the aftermath of chronic ethanol exposure in C3H/HeJ and the mixed background strain of 
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 mice used in this assay may help explain the reasons for differences in behavioral 
responses. In addition, an analysis of gene expression profiles in the global α4 KO may 
also explain how response to ethanol withdrawal is maintained in these mice. In addition to 
changes in expression of GABA A receptor subtypes, it is possible that other receptor 
families compensate for the lack of α4-containing GABA  A receptors.  
It is noteworthy to mention that α4 subunit has been identified as being increased 
and combined with γ2 subunit in synaptic locations whereas δ subunit is reduced following 
chronic ethanol exposure [181, 358]. In a previous study by Jia et al, [234] taurine was 
shown to act potently at α4 -δ containing extrasynaptic receptors. However, its effects of 
novel α4 combinations have not been studied. Although α4δ-containing receptors are very 
sensitive to taurine, α4γ2-containing receptors may not be as sensitive to taurine. Thus, 
during chronic ethanol withdrawal, some other distinct targets may mediate taurine effects. 
Hence, further electrophysiological characterization of mice exposed to chronic 
intermittent ethanol paradigm is essential to understand if taurine affects current 
potentiation through α4-containing receptors.  
Although my results do not provide much insight, the interactions of taurine with 
ethanol certainly warrant more consideration. Given the fact that taurine is an important 
ingredient of energy drinks and energy drinks are frequently combined with ethanol, a 
better understanding of this interaction is required. A study of drinking behavior among 
college students revealed that close to 50% of students frequently combined energy drinks 
with alcohol [418]. An independent study showed that combination of energy drinks with 
alcohol only served to reduce the perception of headache, weakness, dry mouth and motor 
impairment [419]. However, performance on objective motor coordination and visual 
reaction time were not changed due to combination of energy drinks with alcohol [419]. 
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 These observations suggest alarming implications for modification of alcohol drinking 
behavior due to combination with energy drinks. The perception of reduced impairment 
may actually foster drinking behavior although reductions in behavioral impairment are not 
observed. Interestingly, the lack of behavioral effects in humans upon combining alcohol 
with energy drinks is similar to the lack of overt differences in behavior in this study.  
In conclusion, my efforts reveal that chronic ethanol withdrawal behaviors of HIC, 
locomotion and anxiety, and tolerance do not require α4-containing receptors. In addition, 
the effects of taurine on withdrawal parameters are ambiguous at best. Strain differences, 
differences in ethanol treatment paradigms may have precluded observing a robust effect of 
taurine. Although behavioral differences were not apparent between the genotypes, 
electrophysiological and biochemical characterization of taurine responses are required to 
conclude if α4-containing receptors are a behaviorally relevant target of taurine. 
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 Chapter 5: Summary and Conclusions 
The goal of this thesis was to elucidate the role of α4-containing receptors in 1) volatile 
and injectible anesthetic actions; 2) neurosteroid actions; 3) chronic ethanol withdrawal 
effects; 4) actions of taurine during chronic ethanol withdrawal. 
5.1 Potential mechanisms of a4 GABA receptors in anesthetic actions: 
 
α4 global KO mice were studied with different classes of anesthetics to understand 
the role of α4-containing receptors in anesthetic actions. Behavioral analyses revealed that 
α4-containing receptors are involved in the low dose amnestic effects of isoflurane and in 
the locomotor stimulatory effects of alphaxalone. However, in spite of evidence linking α4-
containing receptors to the actions of etomidate and propofol, α4 KO mice did not differ in 
their responses to etomidate or propofol.  
Behaviors are mediated by complex circuits. Drugs that modify behavior can act at 
different levels of circuitry to bring about their effects. In the α4 KO, gaboxadol-induced 
current potentiation was reduced in the ventrobasal thalamus [16]. Consistent with this 
observation, behaviorally, a reduction in gaboxadol-induced LORR, motor-incoordination 
and analgesic effects was observed [16]. However, the same behavioral resistance was not 
seen with isoflurane-induced LORR and MAC, although isoflurane reduced current 
potentiation in the KO ventrobasal thalamic neurons [343]. Consistent with the reduced 
cellular responses, a decrease in the amnestic effects of isoflurane was observed.  
The reduction in the amnestic effects of isoflurane in the KO implies that α4-
containing receptors are involved in the amnestic response to this inhaled anesthetic. 
Although hippocampal current potentiation to isoflurane was not measured, it is possible 
that current potentiation with isoflurane in the hippocampus shows the same reduction as 
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 that observed in the ventrobasal thalamus. Because the hippocampus is associated with 
memory and is a region of α4 expression, it is likely that α4-containing receptors in this 
region modulate isoflurane-induced amnesia. This possibility could be tested by creating a 
hippocampal specific knockout of the α4 subunit or by hippocampal-specific knockdown 
of α4-containing receptors by siRNA technique. A hippocampal specific knockout mouse 
can be created by crossing the floxed α4 gene[16]  bearing mice to tissue specific Cre 
deleter mice where Cre recombinase expression is under the control of a hippocampal 
specific promoter. α4 expression has been knocked down by siRNA techniques 
successfully in the nucleus accumbens [333]. Similar knockdown of α4-containing 
receptors can be achieved in the hippocampus. Studies on amnestic responses in such mice 
will reveal if hippocampal α4-containing receptors are involved in the amnestic effects of 
isoflurane and other drugs. 
The involvement of α4-containing receptors in amnestic effects opens up new 
vistas for therapeutic applications. α4-containing receptors are another addition in the list 
of α subunits that regulate memory processes. Global deletion of α1-containing receptors 
affected the amnestic effects of isoflurane dramatically [115]. The global deletion of α5-
containing receptors produced similar results with etomidate [116]. Thus, it appears that 
GABA A receptors may be critical in gating memory. Should α4 and α5 specific agonists 
be developed, such drugs may be of particular interest in the treatment of post-traumatic 
stress disorders. Such possibilities have already been discussed with regard to the α5-
containing receptors. In addition, the improved performance of both α4 [346] and α5 KO 
[117] on memory-based tasks give rise to the interesting possibility of development of 
specific nootropic agents. Such drugs are already being discussed as having applications in 
pathological processes where memory is affected such as Alzheimer's disease [420, 421].  
155
 Studies on several mutant mouse models have provided mixed results about the 
involvement of GABA A receptors in volatile anesthetic effects of LORR and MAC. Mice 
bearing an isoflurane-insensitive mutation in the α1 subunit showed reduced responses to 
the LORR effects of  isoflurane but unchanged MAC responses [83]. Mice bearing the 
isoflurane-insensitive mutation in the α2 subunits showed unchanged responses to 
isoflurane and halothane on LORR and MAC [84]. The RORR responses to isoflurane 
were, however, increased in these mice suggesting some role for α2-subunit containing 
receptors in the actions of isoflurane [84]. β3 KO [80] and KI [15] studies have both shown 
reduced MAC responses to volatile anesthetics. However, the change in response to LORR 
and MAC effects of volatile anesthetics in the above studies has ranged from 10-25% in 
these mutant mice. This suggests that the role for these GABA A receptor subunit-
containing receptors in the actions of volatile anesthetics is modest. An overview of studies 
that focused on effects of volatile anesthestics on GABA A receptor mutant mice indicates 
only moderate changes in LORR and TC responses to  volatile anesthetics suggesting that 
GABA A receptors may not be critical mediators for these effects of volatile anesthetics. 
Rather, it is now proposed that these volatile anesthetic effects are a result of action of 
volatile anesthetics on multiple discrete targets. 
Because the actions of the intravenous anesthetics, etomidate and propofol, were 
not changed in the α4 KO mice, I conclude that etomidate and propofol do not require α4-
containing receptors at least for the effects studied here. β2- and β3-containing receptors 
have been implicated in the sedating, immobilizing and LORR effects of etomidate and 
propofol [15, 82]. It is proposed that half of the α4-containing receptors are associated with 
a β subunit and no γ or δ subunit [269]. In vitro expression of α4β3 receptor combination 
in human embryonic kidney cells showed that such binary receptors showed high 
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 sensitivity to GABA and increases in current potentiation with etomidate and propofol, 
similar to α4β3δ receptors [367]. Thus, several lines of evidence pointed towards a 
possible role for α4-containing receptors in the actions of etomidate and propofol. 
However, behavioral characterization of α4 KO and WT mice revealed no differences in 
loss of righting reflex and motor ataxia induced by etomidate and propofol. Lower dose 
sedating effects of etomidate also did not differ in WT and α4 KO. Thus, α4-containing 
receptors are not required for the effects of etomidate and propofol on the behaviors tested 
as part of this study. It is possible that α4-containing receptors may be involved in other 
behaviors such as those observed at very low doses of anesthetics. For example, etomidate-
induced amnestic effects may be changed in α4 KO mice in parallel to the involvement of 
these receptors in the amnestic effects of isoflurane.  
What are the possible sites of action for etomidate? The β3 subunit has been 
strongly implicated in the actions of etomidate. Quinlan et al, showed that a β3 KO mouse 
model had reduced etomidate-induced LORR [80]. A forebrain specific KO of the β3 
subunit also displayed reduced sensitivity to etomidate-induced LORR [125]. Finally, a β3 
KI mouse had dramatically reduced responses to etomidate-induced LORR and 
immobilization [15]. Thus, substantial evidence indicate that β3 subunits are an essential 
target for at least some effects of etomidate. The binding site for etomidate is proposed to 
lie at the interface of an α and a β subunit [366]. While β subunits that are likely involved 
in actions of etomidate have been proposed, the identity of the α subunit, that participates 
in the actions of etomidate is unknown. Studies with α1, α5, γ2 and δ KO mice revealed no 
changes in the LORR effects of etomidate [17, 116, 119, 122]. While it is possible that 
compensation may have masked a role for these receptors in the actions of etomidate, it is 
possible that other α subunits such as α6, α2 and α3 may be involved in the actions of 
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 etomidate. Conditional knockouts and siRNA techniques could be used to generate 
selectively ablated subunits and thus the contribution of these subunits to etomidate actions 
could be evaluated. 
Another interesting possibility is that while the β3 subunit is critical for modulation 
by etomidate, the identity of the α subunit may not be as critical. This may explain why 
several α subunit KO mice do not show changes in responses to etomidate. However, the in 
vivo contributions of α6, α2 and α3 subunits to the actions of etomidate is required to 
substantiate this hypothesis. Further studies on an array of different receptor subtypes will 
have to be conducted to validate this possibility.  
A clearer understanding of the pharmacology of etomidate and propofol is required 
to explain the actions of these drugs. Electrophysiological data from different brain regions 
of WT and KO mice may also be used to resolve this issue. In order to take into account the 
effects of deletion of α4-containing receptors on general neurotransmitter-receptor system 
architecture, it would be worthwhile to conduct microarray studies. For example in the α6 
null mutant, cerebellar granule neurons were found to have increased expression of 
voltage-independent K+ channels [422]. A similar situation can be envisaged in the α4 KO 
mice. Hence, it is plausible that compensatory changes are not limited to the GABAergic 
system alone. Thus, a conclusive interpretation of results obtained here will require a better 
understanding of changed parameters in the α4 KO. 
 
5.2 α4 GABA receptors in neurosteroid actions:  
 
Behavioral effects of the neurosteroid anesthetic alphaxalone, were studied in the 
α4 global KO mice. The locomotor stimulatory effects tested at a low dose of alphaxalone 
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 were reduced in the α4 KO mice. However, effects produced by higher doses of 
alphaxalone such as motor ataxia and loss of righting reflex were not changed in the α4 KO 
mice.  
Because endogenous neurosteroids undergo changes in levels through different 
hormonal stages, GABAergic receptors are subject to fluctuations in expression and 
resulting inhibitory neurotransmission. Pubertal mood swings, pubertal learning, 
premenstrual syndrome, postpartum depression and perimenopause are stages during which 
GABAergic receptors are particularly critical for their responses to steroids [286, 288, 290, 
291, 311]. Progesterone and corticosterone metabolites (THP and THDOC) are released as 
an early-stress response and are thought to act on GABAergic receptors to modulate 
inhibitory neurotransmission [308, 423-425]. 
α4βδ-containing GABA receptors have special significance in modulating effects 
of neurosteroids. Several lines of evidence support this hypothesis. Compelling evidence 
towards this was obtained from the δ KO mice. Knockout of δ receptors produced a 
marked attenuation of neurosteroid effects [17]. δ KO mice had reduced sleep times, 
reduced anxiolysis and reduced pro-seizure activity with PTZ compared to WT mice [17]. 
δ KO also could not regulate neuronal excitability during pregnancy in the presence of 
elevated neurosteroid levels. This was proposed as a mechanism for psychiatric and 
neurological disturbances associated with pregnancy and postpartum [286]. Consistent with 
this observation, δ KO mice showed evidence of postpartum depresson due to inability to 
maintain tonic response to changed levels of neurosteroids (see section 10.1.1) [311]. These 
results pointed towards a prominent role for δ-containing receptors in the actions of both 
endogenous and exogenous neurosteroids. 
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 Dentate granule neurons of the hippocampus from α4 KO showed reduced tonic 
current potentiation in response to alphaxalone [340]. Such reduction in tonic current was 
likely reflected in the lack of a locomotor stimulatory response in the KO. However, 
normal response to LORR and motor ataxic effects was observed. Unlike the δ KO mice, 
α4 KO mice reproduced normally and cared for their offspring, although this was not 
studied formally. HET mice also produced offspring in keeping with Mendelian ratios. 
These results raise the question of involvement of α4 in neurosteroid effects. Since levels 
of δ subunit are also reduced in these mice [350], one would imagine a significant 
reduction in the effects of neurosteroids. However, this was not the case. This suggests that 
the presence of residual δ-containing receptors alone in α4 KO may be sufficient for the 
response of neurosteroids at high doses. Because α4βδ receptor combinations have been 
implicated in fluctuating steroid responses, the role of α4 may be more clearly apparent 
only in conditions of changed neurosteroid availability such as premenstrual syndrome, 
pubertal mood swings and perimenopause.   
The possibility that the existing δ subunits could give rise to novel combinations 
with other α subunits and result in normal behavioral response cannot be excluded. This is 
especially more plausible due to the compensatory increase in α1 mRNA in regions of α4 
and δ expression, such as hippocampus and thalamus in the α4 KO mice [350]. The 
suggestion of receptors of unknown stoichiometry consisting of α1, α4, β2 and δ mRNA 
has been proposed previously [36]. Given that α1 subunits are upregulated in the α4 KO 
[349], the possibiltity of α1 subunits taking the place of α4 subunits is a particularly 
enticing possibility. In fact, α1δ containing receptors have been discovered in the 
hippocampus of WT and α4 KO mice [320]. In WT and KO, these α1δ-containing 
receptors mediate tonic currents and are responsive to tonic current potentiation with low 
160
 doses of ethanol [320]. How this receptor combination may affect response to neurosteroids 
is yet to be investigated. At present, results from our α4 KO study point towards a role for 
α4 receptor combinations in the low dose actions of neurosteroids studied here. Thus, 
results obtained from the α4 KO model challenge the current hypothesis of a major role for 
α4δ-containing receptors in neurosteroid action.  
Another interesting possibility which is yet to be evaluated is the role of α4 and its 
modulation by neurosteroids in a sex-specific manner. No changes were seen in 
reproductive or maternal behavior, probably due to the residual δ-containing receptors.  In 
behavioral assays with the α4 KO, trends towards significant differences in responses of 
α4 KO males and females were observed in locomotor behavior with alphaxalone. 
However, due to limitations of number and design of experiments, I was not at liberty to 
pursue this design. Because subtle sex differences presented themselves in other assays as 
well, it is worth considering if the lack of α4 is compensated differently in males versus 
females. These differences could be particularly critical at lower levels of endogenous 
neurosteroids which influence anxiety, mood disturbances or seizure susceptibility. What 
might be the corresponding significance, if any, of these receptors in males? These 
possibilities raise some interesting questions about possible gender-specific regulation of 
these receptors and merit further scrutiny.  
5.3 α4 GABA A receptors and ethanol antagonists: 
 
The role of α4-containing receptors in the actions of an ethanol antagonist, RY023 
was assessed by studying α4 WT, HET and KO mice. α4-containing receptors were 
involved in the intrinsic effects of RY023 but not in the antagonistic effects of the same on 
ethanol-induced LORR. On motor ataxia, HET mice had reduced intrinsic response to 
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 RY023, whereas WT and KO were comparable. On the other hand, the intrinsic sedating 
effects of RY023 was reduced in the KO, while WT and HET were comparable. Upon 
comparison of expression of α4 levels in WT, HET and KO mice, it was found that 
compared to WT, HET mice display lowered levels of α4 in hippocampus, but not in 
cortex. Although this data was obtained from a limited sample set, the differences in 
expression of α4 in the hippocampus point to the possibility of sub-normal levels of α4 
being responsible for the reduced response to RY023 on motor ataxia. The lack of 
differences in KO mice on the same behavior is likely the result of compensation. 
Interestingly, the sedating effect of RY023 was maintained in WT and HET mice but not in 
KO. It is possible that the ablation of α4-containing receptors in the KO was sufficient to 
decrease response to the sedating effects of RY023 but a reduction in α4-containing 
receptors (as evidenced in the HET) may not have been sufficient to change response to 
RY023. Lastly, ethanol antagonistic effects of RY023 were maintained in all three 
genotypes indicating that reversal of ethanol-induced LORR by RY023 does not require 
α4-containing receptors.  
These results are in contrast to those obtained with the ethanol antagonist Ro15-
4513 which suggested a role for α4-containing receptors in ethanol antagonism. In a 
previous study, Ro15-4513 antagonism of ethanol-induced motor ataxia and LORR was 
dramatically reduced in the α4 KO, indicating that actions of Ro15-4513 are primarily 
mediated through α4-containing receptors [341]. Since RY023 is a structural analog of 
Ro15-4513, it was proposed that RY023 antagonism of ethanol effects would be mediated 
through α4-containing receptors [262]. However, this was not the case. RY023 antagonism 
of ethanol-induced LORR was maintained in all three genotypes. This suggests a different 
mechanism of action for  the ethanol antagonistic effects of RY023 compared to Ro15-
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 4513. These results are contradictory to the proposed theory of α4δ-containing receptors as 
the common target for ethanol antagonistic actions of these drugs. 
The electrophysiological effects of RY023 have been tested only on limited 
combinations of receptors, namely α1β3γ2, α2β3γ2, α4β3γ2, α5β3γ2 and α6β3γ2 [253, 
255]. Since αβδ receptor combinations are key in alcohol behaviors, characterization of 
responses of RY023 on δ-containing receptor combinations may help explain the 
differences observed here. Differences in electrophysiological profiles of both Ro15-4513 
and RY023 in multiple brain regions will also provide more information about functional 
differences between both drugs in WT, HETS and KO.   
Results obtained here with the HET mice have provided some clues about the 
effects of sub-normal levels of α4-containing receptors. This experience suggests that the 
inclusion of HET mice in behavioral assays, where possible, may help uncover the role of 
the target under study.  
5.4 α4 GABA A receptors, chronic ethanol withdrawal and taurine: 
  
 α4 KO mice were used to study chronic ethanol withdrawal effects and the ability 
of taurine to alleviate chronic ethanol withdrawal behavior. HIC, anxiety and locomotion, 
and tolerance to ethanol were assessed in WT, HET and KO mice that received chronic 
ethanol treatment with or without taurine. Ethanol withdrawal behaviors did not differ on 
saline-treated WT, HET and KO mice. This suggests that α4-containing receptors are not 
required for the withdrawal effects. However, an effect of taurine was also not apparent on 
most withdrawal behaviors studied in this assay except protracted tolerance. As a result of 
this, the role of α4-containing receptors in the actions of taurine during chronic ethanol 
withdrawal remains unanswered. 
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 α4-containing receptors undergo increases in expression and changes in localization 
following ethanol withdrawal [345]. These changes in α4 expression have been linked to a 
variety of behavioral alterations in the aftermath of ethanol exposure. The hallmarks of 
withdrawal include seizure susceptibility, anxiety, insomnia and tolerance to typical 
benzodiazepines among other effects [3]. Chronic ethanol withdrawal increases α4 and γ2 
subunit levels on the one hand and decreases α1 and δ subunit levels on the other [178]. 
Although α4 levels are increased, its combination with γ2 subunits instead of δ results in 
decreased total charge transfer and thus reduces the level of inhibition  [178]. A decrease in 
current potentiated by benzodiazepines and ethanol, correlating with decreases in α1 and δ 
subunits were seen during withdrawal [180]. Concurrent increases in binding of α4-specific 
drugs such as Ro15-4513 and THIP were also observed [181]. Hence, it was proposed that 
adminstration of drugs that specifically modulate α4-containing receptors and increase the 
current mediated through them will be of use during ethanol withdrawal.  
Taurine is one such agent linked to ethanol antagonism and alleviation of ethanol 
withdrawal. Although multiple groups have studied the effects of taurine on ethanol, a 
resolution about its mechanism of action has not been reached. Recent work by Jia and 
collegues showed that this amino acid was a potent agonist at α4-containing GABA A 
receptors and increased tonic current potentiation through them [234]. One group showed 
that taurine alleviated chronic ethanol withdrawal-induced seizures in mice [233]. To test if 
taurine acted through α4-containing receptors, α4 KO and WT mice were subjected to 
chronic intermittent ethanol treatment with and without taurine and subsequent withdrawal 
behaviors were assessed. Contrary to my expectations, a positive effect of taurine on 
withdrawal was not noted on any of the behaviors studied. It is possible that differences in 
assay design and strain of mice used may have contributed to this result. However, it is 
164
 surprising that a fairly high dose of taurine (500 mg/kg) given over three successive days 
failed to elicit any effect in contrast to a single dose (500 mg/kg) of taurine used in the 
previous study [233]. Due to these discrepancies, the role of α4 in actions of taurine could 
not be tested conclusively in these assays. 
The fact that behavioral responses to acute [186] and chronic ethanol exposure were 
maintained in the α4 KO imply that α4-containing receptors are not be necessary for 
mediating these effects of ethanol. It is important to note that acute effects of motor ataxia, 
sedation and hypnosis represent moderate levels of alcohol intoxication. It is possible that 
lower doses of ethanol do depend upon α4-containing receptors for their effects. However, 
these have not been assessed as yet by an assay sensitive to the low dose impairment by 
ethanol. The low dose assay developed by Moore et al to assess cognition-impairing effects 
of ethanol should be useful in this regard [383].  
It is also possible that the extent of compensation observed in the α4 KO may be 
responsible for masking the true role of α4-containing receptors. In fact, Liang et al 
demonstrated changed synaptic receptor dynamics in the α4 KO mice that had increased 
sensitivity to ethanol [340]. Behavioral responses to acute ethanol were also unchanged in 
α4 KO mice. Hence, although the results obtained from chronic ethanol studies in α4 KO 
do not elicit a role for α4 in ethanol withdrawal behaviors, this merits a closer scrutiny.  
It is not known currently how the synaptic changes occuring in α4 KO affect 
current kinetics during ethanol withdrawal. It is possible that these synaptic changes rescue 
deficits in the α4 KO and prevent an apparent role for α4-containing receptors in ethanol 
withdrawal. Given the lack of behavioral changes in ethanol withdrawn KO, it would be 
particularly interesting to understand how changes in subunit composition and GABA A 
receptor-mediated current during ethanol withdrawal are modulated in the α4 KO. 
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 Studying these parameters will illuminate our understanding of the other receptor 
combinations that may be sensitive to ethanol.  
Conditional knockout of α4-containing receptors could be used to elucidate its role 
in ethanol behaviors. For example, a conditional mutant in which α4 subunit expression 
can be turned off in adult mice a few days or weeks prior to studying ethanol withdrawal 
behavior will help exlude compensatory effects that may have arisen due to developmental 
deficit of α4 in the global KO. In fact, Rewal et al [333] showed that reduction of the α4 
subunit-containing receptors in adult rats influenced ethanol drinking behavior markedly. 
Knockdown of α4 mRNA specifically in the nucleus accumbens was achieved by means of 
siRNA technique. This study showed that a 75% reduction of α4 expression in the nucleus 
accumbens did not alter the expression of other subunits such as γ2, α1, β2 and δ [333]. 
Thus, transient reductions in α4 protein expression did not produce compensatory changes 
as evidenced in the global KO mice. This study elucidated that reduction in α4-containing 
receptors was responsible for reduced preference for ethanol [333]. Similar studies could be 
embarked upon to understand the role for α4-containing receptors in acute and chronic 
ethanol actions. If conditional mutants of the α4 subunit  are created in future, a side by 
side comparison of global and conditional knockout mice may be instrumental in resolving 
the results obtained here.  
As for taurine, the contradictory lines of evidence and possible strain differences 
relating to ethanol behavior confound the resolution of its role. Yet, the overwhelming 
evidence for effectiveness of acamprosate, a close analog of taurine, and its hitherto 
unknown mechanism of action, underscore the importance of studying these agents. 
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 5.5 Compensation and its significance: 
 
 Global α4 KO mice show evidence of compensation that needs to be taken into 
account while interpretating behavioral changes in these mice. A prominent decrease in δ 
subunits was observed in thalamic nuclei [349]. In addition, an upregulation of α1 and α2 
subunits was noted [350]. These increases were greatest in regions of δ subunit expression. 
A subtle increase in γ2 subunits was also seen possibly as a result of decreased δ subunit 
expression [350]. Ultrastructural studies also revealed that the δ subunit was localized 
within the cytoplasm, specifically in the endoplasmic reticulum and the Golgi complex 
[349]. This suggested that lack of α4 subunits affected the trafficking of δ subunits to the 
surface. A reduction in tonic current was observed in the hippocampus and dentate gyrus of 
these mice, consistent with a loss of α4-containing receptors [16]. Deletion of α4-
containing receptors did not affect the charge transfer during synaptic current potentiation 
[340]. However, marked slowing of the rise and early decay of mIPSC was noted in the α4 
KO mice [339]. Further characterization of changes in α4 KO mice is underway.  
It is necessary to take these changes into consideration while understanding changes 
that may be observed in response to drugs in the α4 KO mice. Compensatory changes may 
also mask the isolated role of the α4-containing receptors. As stated in the relevant 
chapters, novel combinations of α1 and α2 subunits with δ subunits may be responsible for 
masking the effects of neurosteroids. In addition, increased populations of α1 and α2 
subunits with γ2 subunits may also be responsible for maintaining responses to some 
anesthetics and intrinsic effects of RY023.  
To assess the contribution of novel receptor combinations and increased population 
of certain receptor subtypes to drug responses, several approaches can be used. The α4 KO 
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 mice were created from mice that possessed a floxed allele of the α4 gene by crossing with 
a global Cre-deleter strain of mice [16]. It is possible to create conditional mutant mice by 
crossing the floxed mice to tissue specific Cre-deleter strains where expression of the 
enzyme Cre-recombinase is under the control of a tissue specific promoter. In this way, α4 
expression can be deleted in specific brain tissues. It is also likely that region-specific 
deletion of α4-containing receptors will limit extensive compenstion. Creating region-
specific KO mice where α4 expression is ablated in the cortex, straitum, hippocampus 
and/or thalamus will give us information about the specific behaviors controlled by these 
receptors in different brain regions. In addition, temporal α4 expression could be achieved 
by breeding floxed α4 mice to inducible Cre-recombinase expressing mice. By turning on 
Cre-recombinase a few days before behvioural testing will likely reduce the possibility of 
compensatory responses (These possibilities have already been discussed, see [426]) 
Electrophysiological characterization for specific brain regions could be performed 
with a variety of agonists and antagonists to delineate the contribution of specific receptor 
subtypes to current modulation. The limited availability and the reduced specificity of 
GABA A receptor subtype-specific ligands allows identification of receptor subtypes only 
to a moderate degree of accuracy. This problem is especially confounded in the presence of 
hitherto unknown receptor combinations. Hence, multiple agonists and antagonists at 
varying concentrations are used to determine the identity and characteristics of currents 
modulated by specific brain regions.  
For example, to understand if α1γ2-containing receptors are compensating for α4 
loss and contributing to current modulation and subsequently to behavior linked to a 
specific brain region, one could apply an α1 preferring agonist such as zolipidem. 
Zolpidem shows high affinity for α1 containing receptors [427]. Native and recombinant 
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 receptors containing α1γ2 combinations have been studied extensively and hence their 
characteristics are known [428-431]. By comparing mIPSC characteristics of zolpidem-
induced current in the same brain region from an α4 KO, α4 WT, conditional α4 KO and 
conditional α4 WT, one could hope to understand the relative contributions of native and 
compensatory α1γ2-containing receptors to current modulation in a specific brain region. 
Several such agonists and antagonists could be used for a detailed characterization. Finally, 
studying behavior in the an α4 KO, α4 WT, conditional α4 KO and conditional α4 WT 
mice will allow comparison of whether changes observed at the cellular level (if any) 
translate to behavioral differences.    
Similar studies could be performed with regions that express α1δ receptor 
combinations. It is important to note that the native α1δ receptor combination has been 
recently identified in one brain region, namely, the hippocampus [320]. As yet, this 
receptor combination has been assessed for tonic current contribution and responses to 
ethanol [320]. However, a thorough characterization of responses of such receptors to 
neurosteroids, α1-specific (zolpidem) and δ-specific (gaboxadol, neurosteroids) drugs is 
required. Hence, understanding the contribution of an increased population of such α1δ 
receptors to compensatory responses in the α4 KO will require the characterization of 
native α1δ-containing receptors first.  
While this method is complicated, it is a sound approach to determine how changes 
at the cellular level may mask or unmask responses at the behavioral level. Take the case of 
ethanol responses in the α4 KO and WT mice at the cellular level – hippocampal dentate 
gyrus neurons were evaluated for current modulation by different concentrations of ethanol 
[340]. Tonic currents in response to 10-100mM of ethanol were detected in α4 WT neurons 
[340]. However, tonic current potentiation in response to ethanol was not observed in the 
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 α4 KO mice with the above concentration range [340]. Synaptic current potentiation in the 
presence of ethanol was also recorded. In WT dentate gyrus granule neurons, mIPSC were 
slightly potentiated with 10-100mM of ethanol [340]. However, KO showed a large 
potentiating effect of ethanol on mIPSC recorded from the same region [340]. This 
suggested that deletion of α4 containing receptors had ablated tonic current potentiation by 
ethanol but at the same time produced changes in the synaptic machinery that conferred 
increased sensitivity to ethanol. When studied for behavioral responses at moderate doses 
of ethanol, no differences were observed between WT and KO suggesting that the changed 
synaptic sensitivity to ethanol retained behavioral effects of ethanol in the KO [186].  
Although it is entirely possible that the increased sensitvity of synaptic receptors to 
ethanol rescues any behavioral differences to ethanol in the α4 KO, this explanation does 
not take into account other compensatory mechanisms that may be at play to restore the 
behavioral responses of ethanol. Compensatory responses can extend beyond the GABA A 
receptor system as well. For example, α6 KO mice showed an increase in the voltage-
independent K+ leak conductance in the cerebellar granule cells which allowed 
maintenance of normal granule cell excitability [422]. Similarly, knockout of HCN1 
channels (responsible for hyperpolarization-activated mixed cationic currents) led to the 
compensatory upregulation of GABA A α5 subunit-containing receptors in the cortex 
[432]. This allowed the normal synaptic excitability control in the KO mice [432]. These 
examples imply that compensatory responses to deletion of particular targets involve 
system-wide changes encompassing multiple neurotransmitter- receptor families. Hence, 
analysis of compensation in the α4 KO must also extend to other neurotransmitter-receptor 
families. A gene array of WT and KO mouse brain tissue is one step in resolving this issue. 
In addition to this, functional changes at the cellular level, changes in receptor trafficking 
170
 and channel desensitization characteristics should also be taken into consideration to 
interpret the changes observed in the α4 KO mice.  
Although compensation definitely confounds our ability to interpret the role of the 
the ablated target accurately, such data also gives us some information about built in 
fallback mechanisms. Study of compensatory pathways will elucidate the inter-
dependencies of different receptor systems and how these are regulated. From a more 
global perspective, this kind of information can be extended to potential gene therapy 
applications as well where compensatory patterns may be predicted with greater accuracy 
owing to models developed in mice. In addition, given our limited knowledge about 
receptor dynamics such as densensitization, assembly and trafficking, genetically 
engineered models may be used to study changes in these processes. Overall, the results 
obtained with α4 KO with anesthetics, neurosteroids, ethanol and ethanol antagonists 
challenge our understanding of the mechanism of actions of these drugs. Already, 
biochemical techniques coupled with microscopic characterization have aided our 
understanding of compensatory changes in the α4 KO [349, 350]. Similarly, microarray of 
the global knockout will help anticipate potential candidates for compensation, thus 
facilitating a more accurate interpretation of behavioral data. In addition, the creation of 
conditional α4 knockouts, region-specific or temporal-specific mutations will be useful to 
bypass compensatory responses and allow for a better understanding of the role of α4.  
5.6 Success stories of gene-targeted mice: 
 While genetically engineered mice have long faced criticism due to compensatory 
effects that confound interpretation, the knowledge gained from gene-targeted mice make 
the disadvantages of this technique a small price to pay. Knockout models while being 
expensive and time-consuming to create, have successfully elucidated the physiological 
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 and pharmacological effects of specific targets. Understanding the compensatory 
mechanisms or lack thereof provides information about the significance of deleted or 
modified targets. Dramatic results with some of these knockout models provides answers 
about the functions of certain targets.  
While these benefits are not immediately apparent, the long term study of these 
models yield interesting results. Take the case of δ KO mice- these mice were generated in 
the late 1990's. Ten years after their creation, these mice continue to provide answers and 
elucidate the role of these δ containing receptors in physiological and pathophysiological 
functions of neurosteroids. Thanks to this model, we now know the implications of lack of 
δ-containing receptors in processes such as learning during puberty, premenstrual 
syndrome, pregnancy and post partum depression [286, 288, 290, 311]. Similarly, the β3 
KO mice that were generated in 1997 had severe deficits such as cleft palate, seizures and 
hypersensitivity [388]. Studies on these KO mice have revealed that apart from a role in 
anesthetic sensitivity to etomidate and midazolam [80, 125], the β3-subunit containing 
receptors are involved in epilepsy and autism spectrum disorders [433-436].  
 Advances in the field of genetic engineering have led to newer methods of assessing 
the contributions of specific receptor subtypes to drug actions. Site-specific mutations that 
change response to certain drugs have been identified leading to the creation of knockin 
mutant mice. These knockin mutant mice have the advantage of maintaining normal 
responsiveness to endogenous modulators and altered responses only to specific drugs. 
Normal responsiveness to endogenous ligands allows normal development of these mice 
and reduces the incidence of compensation. This technqiue has been particularly useful in 
delineating the mechanism of actions of benzodiazepines. Knockin mutations in the α1, α2, 
α3 and α5 subunits of the GABA A receptor have successfully outlined the role of these 
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 receptors in the actions of benzodiazepines. α1 KI mice implicated α1-containing GABA 
A receptors in the sedative, amnesic and anti-convulsant (partly) effects of diazepam [437, 
438]. The myorelaxant effects of diazepam were found to be mediated by α2, α3 and α5-
containing receptors  whereas the anxiolytic effects of the same required α2-containing 
receptors [118, 439, 440]. α5 KI mice showed an overall reduction in the abundance of α5-
receptors in the hippocampus and not surprisingly, an improvement in baseline memory on 
hippocampal dependent tasks was observed [118]. In addition, β3 KI mice were also 
critical in delineating the hypnotic and immobilizing effects of etomidate [15].  
 The above mentioned successes are limited to key studies of the GABA A receptor 
system. Similar studies have been pioneered with glycine and NMDA receptors and it is 
hoped that, as with GABA A receptors, these studies will elucidate the physiological and 
pharmacological roles of glycine and NMDA receptors. In conclusion, although genetically 
engineered mice present some disadvantages in terms of confounding compensatory 
changes, possible neonatal lethality as well as increased time and costs, the wealth of 
knowledge to be gained from the successful creation of viable genetically engineered 
models far outweighs the risk associated with this technique. Considering that our 
knowledge of the complex functioning of the CNS is evolving, genetically engineered mice 
present a good model by which to understand the in vivo consequences of alterations in the 
nervous system.  
5.7 Summary: 
It is interesting to note that α4-containing receptors are involved specifically in the 
low dose effects volatile anesthetics and neurosteroids. α4-containing receptors are also 
speculated to be important for low dose effects of ethanol. Because α4-containing receptors 
are mediators of tonic current and because tonic current is a critical regulator of neuronal 
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 excitability, the finding that low doses of alcohol, anesthetics and neurosteroids act on 
these receptors has great significance. It is possible that α4-containing receptors might 
serve as the earliest responders for effects of these classes of drugs.  
Behavioral assays that are uniquely sensitive to low dose effects of anxiety, 
disinhibition, euphoria, cogntion-impairment by alcohol and anesthetics are currently 
unavailable. Developing behavioral assays that are more sensitive to low dose effects of 
anesthetics and alcohol will help dissect the role of α4-containing receptors. In fact, Moore 
et al have recently developed such an assay to assess low dose effects of alcohol [383].  
Because α4-containing receptors are involved in regulating memory [346] as well 
as learning during puberty [290], these receptors may have special significance in 
anesthetic effects in young children and in adolescents. The side effects of anesthetics such 
as post-operative cognitive deficits, anesthetic awareness and the trauma associated with 
these occurances make understanding the mechanism of effects of anesthetics a very 
important goal. In addition to these side effects, very little is known about how anesthetics 
mediate the desirable effects of unconsciousness, amnesia and immobility. Genetically 
engineered models have enabled the study of specific targets thought to be involved in 
anesthetic effects. The GABA A receptor α4 KO model has helped understand better the 
mechanism of actions of inhaled anesthetic-induced amnestic effects. This model could be 
used to evaluate the effects of other anesthetics as well.  
Although some behavioral effects of anesthetics have been studied with the α4 KO, 
the full spectrum of its effects are yet to be understood. The fact that the novel sedative 
gaboxadol, requires α4-containing receptors for its actions suggests that α4-containing 
receptors can be harnessed to produced sedative, hypnotic and analgesic effect. This 
provides some clues for rational drug discovery of novel sedative-hypnotic drugs that have 
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 fewer side effects. Should the structure of α4-containing receptors be elucidated, drugs 
specific to it (like gaboxadol) can be developed resulting in safer, more specific effects. 
Neurosteroids have been implicated in an array of effects from mood disturbances, 
premenstrual syndrome, epilepsy, postpartum depression, ethanol drinking behavior and 
recently, learning during puberty [288, 290, 296, 299, 308, 311, 329, 424, 425]. 
Endogenous neurosteroid levels undergo fluctuations according to hormonal cycles. GABA 
A α4δ-containing receptors have been identified as a major target for neurosteroid effects 
and dysregulation of GABA A receptors are thought to result in the above-mentioned 
syndromes [282, 283, 295, 307, 315]. Studies with the δ KO [17, 286, 311] and the α4 KO 
have been successful in elucidating the relative involvement of each of these targets in 
neurosteroid actions. Hence, these receptors provide a potential therapeutic target for 
alleviating disorders resulting from hormonal disturbances.  
The pursuit of a magic drug that would eliminate the ill-effects of ethanol has kept 
researchers busy for over three decades now. Yet we only have a handful of putative 
ethanol antagonists to date. Finding a specific ethanol antagonist has only been as difficult 
as delineating the mechanism of action of ethanol. A clear understanding of the ethanol-
antagonistic properties of Ro15-4513 has eluded scientists for two decades now and finally, 
the α4 KO mice have proven to be instrumental in elucidating its site of action for 
behavioral ethanol antagonistic effects. Structural analogs of Ro15-4513, namely the RY 
series of drugs have also been shown to act as ethanol antagonists. Recent work by 
Hanchar et al, suggested that these drugs may be acting through the same GABA A 
receptor subtype, i.e., α4δ-containing receptors [262]. My work here with α4 KO mice 
indicates that while some intrinsic effects of the representative drug RY023 are mediated 
through α4-containing receptors, the ethanol antagonistic effects of RY023 are not.  
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 The renewed focus on these drugs will hopefully lead to a better understanding of 
the mechanism of actions of these drugs. It is hoped that such knowledge will enable the 
development of a second generation of better, safer and with a good bit of luck, clinically 
viable ethanol antagonist. Should such drugs be developed, they will have widespread 
applications in the reversal of intoxicating ethanol effects, treatment of acute ethanol 
toxicity and possibly in prevention of ethanol addiction and dependence.  
Because of the addicting potential of ethanol and the tremendous toll that alcohol 
dependence indirectly takes on immediate family as well as society, drugs that enable 
treatment of ethanol addiction and management of ethanol withdrawal are sorely needed. 
Understanding the molecular changes that result in ethanol withdrawal are key to achieving 
this goal. Although studies with the α4 KO have not shed much light on ethanol 
withdrawal effects, they cannot be excluded as important players in ethanol withdrawal 
effects just yet. The overwhelming evidence linking changes in α4 to ethanol withdrawal 
warrant a second look at the role of these receptors. Use of conditional mutants or 
knockdown models of α4-containing receptors may enable the study of α4 containing 
receptors without the complications of compensatory mechanisms.  
Even with the caveat that accompanies a global knockout model, α4 KO mice have 
furthered our understanding of physiological regulation of memory and the actions of 
gaboxadol, isoflurane, alphaxalone and Ro15-4513. In addition, this model has helped 
challenge notions about involvement of α4-containing receptors in actions of etomidate, 
propofol and RY023. Thus, the global knockout strategy, although imperfect, continues to 
provide a wealth of information and advance our understanding about neurotransmitter-
receptor functions. 
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 List of Abbreviations 
 
AWS – Alcohol withdrawal syndrome 
 
BEC – Blood ethanol concentration 
 
CIE – Chronic intermittent ethanol 
 
CNS – Central nervous system 
 
EC50 – Half maximal effective concentration 
 
GABA A – γ aminobutyric acid type A  
 
GABA – γ aminobutyric acid 
 
HET – Heterozygous 
 
i.p. – Intraperitoneal 
 
KI – Knockin 
 
KO – Knockout 
 
LORR – Loss of righting reflex 
 
MAC – Minimum alveolar concentration 
 
mIPSC – Miniature inhibitory postsynaptic current 
  
mRNA – Messenger ribonucleic acid 
 
r.o. – Retro-orbital 
 
RORR – Recovery of righting reflex 
 
Ro15-4513 – ethyl 8-azido-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-α)BZ-3-   
                      carboxylate  
 
RY023 – tert-butyl 8-[trimethylsilyl] acetylene-5,6-dihydro-5-methyl-6- oxo-4H-imidazo   
                [1,5a] [1,4] benzodiazepine-3-carboxylate 
 
THIP – Gaboxadol             
 
WT – Wildtype 
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